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ABSTRACT 
 
MODULATION OF DENDRITIC CELLS WITH THE INTERLEUKIN-10 GENE ON 
POLYCATION-MODIFIED POLYMERIC PARTICLES 
 
 
 
By 
Liang Jia 
December 2009 
 
Dissertation supervised by Wilson S. Meng 
Gene therapy has emerged as a field to modulate cell functions by introducing 
genes of interest to target cells. An emerging focus in this field is to employ non-viral 
vectors to deliver immunosuppressive cytokines to dendritic cells (DCs) to attenuate 
damaging immune responses. DCs serve as potential targets for suppression of T cell 
responses. In this work, we investigated the ability of polycation-modified polymeric 
particles complexed with interleukin-10 (IL-10) gene to modulate DCs. The delivery 
systems (designated as PSO10H6 and PLGAO10H6) were formed by coating cationic peptide 
O10H6 (O: ornithine; H: histidine) on the polystyrene (PS) and poly (lactic-co-glycolic 
acid) (PLGA) particulates. A mouse IL-10 encoding plasmid (pIL-10) was loaded on the 
surface of PSO10H6 and PLGAO10H6 via ionic interactions. Physical characterization of 
these particles revealed stable colloidal dispersions (diameters: 297.2±14nm in 
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PLGAO10H6-pIL-10 and 126.0±8nm in PSO10H6-pIL-10). DNA molecules carried by 
PSO10H6 and PLGAO10H6 were protected from serum digestion. Results from in vitro gene 
transfection studies showed two-fold enhancement of IL-10 expression in bone marrow-
derived DCs transfected with PSO10H6-pIL-10 and PLGAO10H6-pIL-10 compared to 
untransfected DCs. Their suppressive functions were evaluated in an in vitro mixed 
lymphocyte model. Results indicated that PSO10H6-pIL-10 and PLGAO10H6-pIL-10 
modified DCs elicited weakest proliferation of allogeneic bulk T cells as well as CD4 and 
CD8 T cells among all the delivery modes. Using cell-embedded Matrigel as a surrogate 
graft, we showed that IL-10 gene-modified DCs suppressed host cell infiltration in vivo. 
These data suggested PSO10H6-pIL-10 and PLGAO10H6-pIL-10 deliver an overriding 
suppressive signal to T cells. Further studies revealed T cells stimulated by the IL-10 
gene-modified DCs exhibited characteristics of regulatory T (Treg) cells, as evident by 
up-regulation of a Treg cell marker forkhead-type transcription factor 3 (Foxp3).  This 
result was concomitant with an increase in of transforming growth factor β  (TGF-β) 
production.  
 
Taken together, this work demonstrated that PSO10H6 and PLGAO10H6 are effective 
in delivering pIL-10 to modulate DCs to suppress T cell responses.  Collectively, the 
results raise the prospects of using PSO10H6 and PLGAO10H6 as vectors to deliver 
immunosuppressive genes to modulate T cell responses in vivo.  
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CHAPTER 1  
INTRODUCTION 
Statement of problem  
The major function of mammalian immune system is to protect the host from a 
broad range of pathogenic microorganisms including viruses, bacteria, and other 
pathogens. However, excessive immune responses towards auto- and alloantigens can 
lead to host tissue damages, causing inflammation, autoimmune diseases, and transplant 
rejections. Anti-inflammatory and immunosuppressive agents (e.g. tacrolimus, 
cyclosporine, rapamycin, glucocorticoids) that can systematically suppress T cell 
responses have been used. But these drugs are associated with systemic suppression of 
normal immune functions, resulting in malignant and infectious diseases after years of 
administration. The toxicity and the life-threatening side effects associated with these 
agents demand the development of safe and effective therapeutic modalities that can 
attenuate damaging immune responses.  
 
Dendritic cells are highly specialized antigen presenting cells that interact with T 
lymphocytes to trigger adaptive immune responses and suppression. DC’s ability to 
induce immune suppression is currently being investigated. These DCs often constitute 
tolerogenic properties including lower level of co-stimulatory B7 molecules (e.g. CD80, 
CD86) and/or higher tendency to expand CD4+ Treg cells in animal models 
(Bellinghausen, Brand et al. 2001; Muller, Muller et al. 2002; Steinbrink, Graulich et al. 
2002). Treg cells are identified by their capacity of suppressing proliferation and 
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cytotoxic activities of effector T cells. They are marked by their constitutive expression 
of Interleukin-2 (IL-2) receptor α chain (CD25) and Foxp3 (a member of the 
forkhead/winged-helix family of transcription regulators). Because Treg cells play an 
important role in damping excessive immune responses towards auto- and alloantigens, 
the capacity of DCs to induce or expand Treg cells becomes a key measurement of their 
tolerogenic properties. 
 
A variety of studies suggest that immunosuppressive cytokines including IL-10 
and TGF-β render DCs into tolerogenic phenotype. IL-10 is a pleiotropic, anti-
inflammatory cytokine that acts on a variety of immune cells, including T cells, natural 
killer (NK) cells, and antigen presenting cells (APCs). Owning to its exclusive role in 
initiating adaptive immune responses and tolerance via the interaction with naïve T cells, 
DC is believed to be the primary mediator for IL-10 suppressive functions. Thus, IL-10 
conditioned DCs have been extensively studied as therapeutic modalities to suppress 
harmful immune actions toward auto- and alloantigens.  
 
IL-10 directly injected in vivo demonstrated disadvantages such as short half-life 
and instabilities. Therefore, efforts have been made to genetically engineer DCs to 
produce IL-10 in such suppressive signals that might dominate in locale where 
lymphocytes are programmed. A major approach in advancing this strategy is to develop 
effective vehicles to deliver IL-10 plasmid to DCs. Recombinant viral vectors have been 
used to achieve high gene transfection efficiency in vivo. However, the potential systemic 
toxicity of viral vectors and the viral-specific immune elimination by host cells hamper 
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their use in clinical applications.  
 
Specific aims  
 
Synthetic non-viral vectors fabricated from non-lipid polymers have gained 
substantial interests in recent years due to their noninflammatory nature and the relative 
ease in controlling surface functionalities. Among these vectors, submicron polymeric 
particulates are believed to be most favorable for delivery tasks targeted to DCs because 
of the fact that DCs constantly take up particulates in the surrounding tissue through 
phagocytosis and endocytosis due to their role as an immune sentinel. 
 
Polycation-modified polymeric particles have been developed in our lab to deliver 
plasmid DNA molecules to DCs. O10H6, an ornithine-histidine peptide that binds and 
condenses plasmid DNA molecules through ionic interactions is adsorpted on the surface 
of polymeric particles. The objective of this work was to investigate the performance of 
the polycation-modified polymeric particles loaded with a murine IL-10 gene to modulate 
DC functions. In particular, submicron particles fabricated from two polymeric materials 
(a schematic diagram of the construct is shown in Figure 1.1), PLGA and polystyrene 
have been investigated. The former is biodegradable and thus suitable for in vivo or ex 
vivo gene transfer. The latter can be used for ex vivo transfection of graft DCs, which 
does not require repeat in vivo administrations. With respect to macromolecule delivery, 
the majority of studies within the literature employ PLGA and polystyrene in the context 
of vaccination and immune stimulation (O'Hagan, Singh et al. 2004). Whether these 
polymers are suitable delivery platforms for immunosuppressive cytokines has rarely 
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been investigated.  
 
Hypothesis 
The central hypothesis of this work is that the particulate systems (designated as 
PLGAO10H6 and PSO10H6) can effectively deliver pIL-10 to DCs to induce suppression of 
T cell responses via the expansion of Treg cells.  The underling mechanisms are 
described in the following two aspects. First, the O10H6 modified polymeric particles 
can bind and stabilize DNA molecules on the surface of the delivery vectors, therefore 
facilitating their uptakes by DCs. Second, the forced expression of IL-10 in the 
transfected DCs can induce expansion of Treg cells, thus triggering the suppression of 
effector T cell responses. Ultimately, this work may raise the prospect of using 
PLGAO10H6 and PSO10H6 to deliver suppressive genes to induce immune tolerance in vivo. 
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Figure 1.1: Schematic depiction of PLGAO10H6 and PSO10H6 particles loaded with DNA 
condensates on the surface. 
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CHAPTER 2  
LITERATURE REVIEW 
Dendritic cells 
Origin and differentiation of dendritic cells 
DCs were first discovered as Langerhans cells (LCs) in skin in 1868. 
Nevertheless, characterization of DCs began only 35 years ago when Steinman and Cohn 
identified a population of spleen cells having a distinct antigen (Ag) presenting function 
and morphological features with dendrites, and named these cells dendritic cells.  
 
DCs differentiate from hematopoietic progenitors in the bone marrow and home 
to blood as well as peripheral non-lymphoid/lymphoid tissues and thymus via a broad 
pattern of chemokine receptors and adhesion molecules on their surfaces. Depending on 
their functionality and surface markers, DCs can be classified into mature and immature 
state. 
 
Immature DCs are characterized by their highly endocytic and phagocytic 
activities permitting Ag capture, low secretion of pro-inflammatory cytokines, and poor 
antigen presentation capacities. These DCs lack major histocompatibility complex 
(MHC) molecules and the requisite accessory markers for antigen presentation and T-cell 
activation, such as CD40, CD54, CD80 and CD86, but are extremely well equipped with 
antigen-capturing receptors such as macrophage mannose receptor 7, DEC-205, and Fc 
receptors to capture antigens (Jiang, Swiggard et al. 1995). DCs in non-lymphoid 
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peripheral tissues such as skin (e.g. Langerhans cells and dermal DCs), lung, liver, 
kidney, heart, and mucosa of the digest and respiratory tract (mucosal surface-associated 
DCs) exist in immature state and provide a sentinel system at the front line of pathogen 
entry (Banchereau, Briere et al. 2000). Following a microbial infection and tissue 
damage, immature DCs migrate to infection or damage regions to capture antigens in 
response to the chemokines released from these tissues. 
 
Mature DCs are characterized by several properties such as loss of endocytic and 
phagocytic capacities (Garrett, Chen et al. 2000), high expression level of MHC class II 
molecules on the cell surface and increased expression of co-stimulatory molecules such 
as CD80 and CD86, which correlate with the ability to induce the activation of the Ag-
specific or allogeneic T cells. Additionally, mature DCs reprogram their responsiveness 
to chemokines by modifying expression of chemokine receptors, including down-
regulation or desensitization of CCR1, CCR5, and CCR6 to decrease their responsiveness 
to inflammatory cytokines (e.g. CCL3, CCL5, and CCL20), and up-regulation of CCR7 
to improve their responsiveness to homeostatic chemokines such as CCL19 and CCL21. 
These changes in DC’s characteristics down-regulate their capacity to take up antigens 
but advance their antigen presenting ability and stimulatory activity towards T cells. 
Consequently, after antigen sampling, DCs will migrate from periphery to the draining 
lymph nodes, where they present antigens to specific T cells and induce their activation 
and differentiation into effector cells to initiate primary immune responses (Banchereau, 
Briere et al. 2000). 
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Figure 2.1: The life cycle of dendritic cells. 
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Dendritic cell subsets 
Multiple DC subsets have been defined based on their phenotypes and functions. 
CD8, which is expressed in the form of an αα-homodimer on DCs, has been used to 
define DCs subsets, in which CD8α+ DCs have been referred to as “lymphoid DCs” and 
CD8α− DCs as “myeloid DCs”. Combining CD8 with the other four markers, including 
CD4, CD11b (the integrin-αM chain of macrophage receptor 1 [Mac-1]), CD11c (the 
integrin-αx chain of Mac-1), and CD205, five DC subsets are found in the lymphoid 
tissue of mice (Shortman and Liu 2002). Spleen contains three of these subsets, including 
CD4−CD8α+ (20% of spleen DCs), CD4+CD8α− (40% of spleen DCs), and 
CD4−CD8α- (15% of spleen DCs). Among thymic DCs, the CD4−CD8αhigh CD11b− 
CD205+DC is the dominant subtype. Lymph nodes (LNs) contain two extra DC subtypes 
that are not normally found in spleen, which have apparently arrived in the LNs through 
the lymphatic system (Iwasaki and Kelsall 2000). Between them, 
CD4−CD8α−CD11b+CD205+ DC represents the mature form of interstitial tissue DCs. 
CD4−CD8αlowCD11b+CD205high DC, found only in skin draining LNs, is believed to be 
the mature form of Langerhans cells (Iwasaki and Kelsall 2000).  
 
The CD8α− DC subset is efficient stimulators of CD4+ and CD8+ T cells in vitro, 
and can direct immune response in vivo (Yasumi, Katamura et al. 2004). Both mature 
interstitial tissue DCs and mature LCs appear to be fully activated and efficient 
stimulators of naïve CD4+ T cells.  
 
DCs subsets including CD4−CD8αhighCD11b−CD205+ lymphoid DCs and B220+ 
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DCs can promote T-cell tolerance. It has been shown that 
CD4−CD8αhighCD11b−CD205+ DCs have a regulatory effect on T cells, in which they 
can induce apoptosis in CD4+ T cells and a limited CD8+ T cell response (Anjuere, 
Martin et al. 1999; Vremec, Pooley et al. 2000). DCs that express B220, a CD45 isoform 
in mice, can be found in all lymphoid organs of mouse. It has been proposed that B220+ 
DCs are involved in the maintenance of T-cell tolerance by promoting T regulatory cell 
differentiation (Martin, Del Hoyo et al. 2002).   
 -
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-
 
  
Table 2.1. Lymphoid tissue distribution of mouse dendritic cell subtypes. 
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Dendritic cells in antigen presentation 
Dendritic cells reside in most peripheral tissues, particularly at sites of interface 
with the environment (skin and mucosae) (Banchereau and Steinman 1998; Banchereau, 
Briere et al. 2000), where they take up self and non-self antigens from pathogens, 
infected cells, dead cells, or their derived products. Internalized antigens are then 
processed into proteolytic peptides, and these peptides are loaded onto MHC class I and 
II molecules. This process of antigen endocytosis, degradation, and loading is called 
antigen presentation. 
 
There are at least four endocytic pathways exist distinguished based on the size of 
the cargo internalized and the mechanism of internalization: macropinocytosis, 
phagocytosis, and receptor mediated endocytosis (including clathrin-mediated 
endocytosis and caveolae-mediated endocytosis) (Trombetta and Mellman 2005).   
 
Macropinocytosis is characterized by the bulk fluid uptake of soluble antigens 
through the actin skeleton by DCs and macrophages (Norbury 2006). This form of 
endocytosis is down-regulated in DCs upon maturation.   
 
Phagocytosis, which is believed to be the first pathway associated with host 
defense, involves engulfment of large particulates (> 1 µm in diameter) derived from 
both pathogen and endogenous antigens. Immature DCs can phagocyte a broad range of 
particulates, including microbes, apoptotic cells, inert particles, and liposomes. 
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Langherans cells and bone marrow-derived dendritic cells at an early stage of their 
development are shown to internalize particulate antigens by phagocytosis (Steinman and 
Swanson 1995). DC’s endocytic receptors including Fcγ receptors, Scavenger receptors 
(SRs), complement receptors, and a variety of lectins contribute to phagocytic process 
due to their ability to signal actin assembly and drives pseudopod extension and particle 
engulfment after binding to their ligands. Additionally, some microbes can promote their 
own entry into cells by shedding vesicles that may be internalized with the absence of 
endocytic receptors (Cossart and Sansonetti 2004). 
 
Endocytosis is characterized by the uptakes of antigens, smaller vesicles or 
particulates (less than 1 µm) through clathrin-coated vesicles or by caveolin-containing 
invaginations. These antigens will be processed and presented in DCs through a sequence 
of events in clathrin-mediated or caveolae-mediated endocytic pathway, starting with 
transporting the antigen to an acidic endosomal/lysosomal compartments within the cell 
that allows antigen degradation into peptides fragments. Alternatively, a fraction of 
caveolae may fuse with the endoplasmic reticulum (ER) following internalization. From 
the ER, antigens can gain access to endosomal compartments by normal recycling or by 
fusion of ER with endosomal or phagosomal membrane (Tsai, Ye et al. 2002).  
 
As antigens are partially degraded into peptides fragments, vesicles coated with 
nascent MHC class II molecules fuse with the lysosome. Peptides that have high affinity 
for the binding site located within the MHC class II heterodimer will displace the peptide 
on MHC class II molecules. The resulting MHC/Ag-derived peptide complexes are then 
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transported to the DC cell membrane, where they will be presented to Ag-specific CD4+ 
T cells (Figure 2.2; (Virella 2007). 
 
One thing that needs to be pointed out is the maturation of DC down-regulates 
macropinocytosis and phagocytosis, but it seems to have little effect on clathrin-mediated 
endocytosis pathway (Garrett, Chen et al. 2000). Thus, antigen or particulates can still be 
internalized in mature DCs. 
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Figure 2.2: Schematic representation of the general steps in antigen processing. 
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Dendritic cells in T cell activation 
The interaction between MHC class II/Ag-derived peptide complex on DCs and 
the complementary T cell receptor (TCR) on CD4+ T cells (signal 1, Figure 2.3) is the 
initial step to trigger a coordinated sequence of signals that induce T cell activation. In an 
acute transplant model, the miss match between MHC class I molecules on graft DCs and 
TCR on host CD8+ T cells will trigger T cell activation. Additionally, co-stimulatory 
pathways are required to deliver secondary signals to activate T cells. These pathways are 
mediated by interaction between CD28 on T cells and its correspondent B7 molecules 
(e.g. CD80, CD86) on DCs (signal 2, Figure 2.3). Mature DCs up-regulate co-stimulatory 
molecules, which will improve DC’s T cell priming ability.  
 
MHC class I and MHC class II molecules interact exclusively with CD8+ 
cytotoxic T cells (CTLs) and CD4+ helper T cells, respectively. The engagement between 
MHC class II complex and CD4+ helper T cells induces downstream signals to activate 
and translocate transcription factors, such as the nuclear factor-kappa B (NF–κB) and the 
nuclear factor of activated T cells (NFAT). Once entering the nucleus, these factors 
trigger expression of IL-2, IL-2 receptor, and the release of pro-inflammatory cytokines 
[e.g. interleukin-12 (IL-12), interferon-gamma (IFN-γ) and tumor necrosis factor-alpha 
(TNF-α)]. These changes will stimulate T cells proliferation and activation into effector T 
cells, which in turn orchestrate cell-mediated immunity and promote inflammation. CTLs 
will undergo clonal expansion with the presence of IL-2 (Bennett, Carbone et al. 1997). 
While exposed to antigen-specific somatic cells, CTLs will release perforin and 
granzyme, or up-regulate Fas ligand to kill target cells. Specifically, perforin forms pores 
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in the plasma membrane of target cells that allows granzyme, a serine protease, to enter 
the cytoplasm of these cells, which in turn leads to a caspase cascade that induces their 
apoptosis  (program cell death). Fas ligand expressed on activated CTLs can bind to Fas 
receptor on target cells to induce apoptosis. 
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Figure 2.3. T-cell activation by antigen presenting cells. Reprinted by permission from 
Macmillan Publishers Ltd: Journal of Investigative Dermatology (2006) 126, 32–41, 
copyright 2006. 
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Dendritic cells in cell-mediated and humoral immunity 
Antigens and lymphocytes had long been focused in the study of immunity in past 
decades. It was found that immune actions do not always been triggered by the simple 
presence of those two parties. APCs, especially DCs play a very significant role in 
initiating and modulating immune functions, including controlling T-cell and B cell 
immunities, and developing immune tolerance to self-antigen. 
 
DCs are efficient in triggering cell-mediated immunity, in which target cells with 
specific antigens are recognized and killed by T cells that circulate in the blood stream. 
This type of T cell response is typically challenged by the small amount (typically one 
hundred or less per cell) of antigen presented on target cells (e.g. tumor, infection cells), 
and the rare Ag-specific T-cell clones (typically at a frequency of 1/100,000 or less) in 
the host. DCs provide a means of solving these challenges by capturing, internalizing and 
processing these antigens, and displaying them at their surface, along with up-regulation 
of co-stimulatory surface markers. DCs then migrate to lymphoid organs including spleen 
and drain lymph nodes, where they deliver activating signals to engage T cells in antigen 
recognition, leading to the clonal expansion and activation of Ag-specific T cells. More 
importantly, DCs are very effective in stimulating Ag-specific T cells: one DC is capable 
of turning 100 to 3,000 T cells into active T cells.  
 
Besides their effects on cell-mediated immune response, DCs are also known to 
stimulate humoral immunity by presenting antigen peptides to specific T-helper cells and 
orchestrating them into Type 2 helper T cells (Th2). Th2 secrete cytokines such as 
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interleukin-4 (IL-4) and interleukin-5 (IL-5), and stimulate the proliferation and 
activation of specific B cells. Activated B cells subsequently produce antibodies that 
inhibit pathogens. Additionally, DCs in interstitial tissues can directly interact with B 
cells to stimulate the production of antibodies including immunoglobulin A2 (IgA2) 
(Banchereau, Briere et al. 2000).  
 
Dendritic cells in immune tolerance 
DCs play a key role in orchestrating cell-mediated and humoral immunity. 
Additionally, there is emerging evidence that DCs induce Ag-specific tolerance by taking 
up antigens in peripheral tissues and presenting antigens in the context of MHC 
molecules to T cell. (Morelli and Thomson 2003; Steinman, Hawiger et al. 2003). An 
addition study demonstrated that effective deletion of auto-reactive thymocytes was 
found in developing thymus injected with Ag-bearing DCs, but not with other APCs, 
including macrophages (Zal, Volkmann et al. 1994). In peripheral tissues, DCs can 
capture and present self-antigens that are exclusive to thymus to T cells in draining lymph 
nodes to induce tolerance as a result of T-cell anergy or deletion. There is also evidence 
that DCs contribute to the expansion and differentiation of regulatory T cells.  
 
The control of immunity requires that DCs undergo differentiation or maturation 
in response to stimuli. In mature DCs, phenotypic changes such as increased expression 
of MHC-peptide complexes, co-stimulatory molecules and IL-2 contribute to their 
abilities to process antigens and activate T cells. Immature DCs, which express low level 
of MHC and co-stimulatory molecules, capture and present antigens to targeting naïve T 
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cells and induce their tolerance (Steinman, Turley et al. 2000; Roelen, Schuurhuis et al. 
2003). One strategy that delivers defined antigens to specific populations of immature 
DCs to induce T cell tolerance in vivo has been explored (Jonuleit, Schmitt et al. 2000; 
Hawiger, Inaba et al. 2001; Barrat, Cua et al. 2002; Liu, Iyoda et al. 2002). 
 
Interestingly, it has been demonstrated that some population of mature DCs can 
promote T cell tolerance both in vitro and in vivo (Albert, Jegathesan et al. 2001; Menges, 
Rossner et al. 2002; Verhasselt, Vosters et al. 2004). Therefore, DC maturation is no 
longer a distinguishing feature of immunogenic activity. Literature data suggested that 
both immature and mature DCs can expand Treg cells in vitro and in vivo under certain 
conditions, which is associated with the suppressive property of these DCs (Yamazaki, 
Iyoda et al. 2003; Tomasoni, Aiello et al. 2005). Specifically, DCs that express 
immunoglobulin like transcript 3 (ILT3) contribute to the induction of Treg cells. Studies 
also showed that IL-10 producing DCs isolated from lung or gut mucosal–associated 
lymphoid tissue suppress immune responses, as IL-10 enhances the formation of mouse 
(Barrat, Cua et al. 2002) and human (Levings, Sangregorio et al. 2002) Treg cells. 
Administration of IL-10 producing pulmonary DCs can suppress immunity following 
adoptive transfer of hyporesponsive antigen into mice (Akbari, DeKruyff et al. 2001). 
 
It has been suggested that autoimmunity, certain inflammatory diseases, and 
transplant rejection can be influenced by the Ag-specific tolerogenic role of DCs. Two 
major approaches that use DCs to induce immune tolerance are under investigation: 1) 
use of immature DCs or control of DC maturation, and 2) engineering DCs using 
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immunosuppressive cytokines. In the first approach, clinical use of immature DCs may 
be limited by the graduate maturation of those cells under inflammatory conditions. In the 
second approach, immunosuppressive cytokines such as IL-10 can induce DCs into 
suppressive phenotype and expand the population of Treg cells. A strategy that utilizes 
this approach is to genetically modify therapeutic DCs ex vivo and re-infuse them to the 
host tissue or organ, where they can down-regulate immunity and expand regulatory T 
cells. Therefore, development of genetically modified DCs expressing IL-10 could be a 
suitable method for the induction of immune tolerance.  
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Interleukin-10  
IL-10 was originally recognized as cytokine-synthesis-inhibiting factor (CSIF) 
when it was discovered in 1989 because of its ability to suppress the production of pro-
inflammatory cytokines in macrophages and Type 1 helper T cells (Th1). Further studies 
revealed that IL-10 profoundly acts on a variety of immune cells to block the expression 
of pro-inflammatory cytokines and co-stimulatory molecules, leading to the suppression 
of T cell activation during an immune response.  
 
Structure and biological activities of human and mouse Interleukin-10 
The primary structures of human IL-10 (hIL-10) and mouse IL-10 (mIL-10) were 
determined by cloning cDNAs encoding the cytokines (Vieira, de Waal-Malefyt et al. 
1991). Nucleotide sequence of mIL-10 has a significant degree (more than 80%) of 
homology with hIL-10 throughout their entire length (Howard and O'Garra 1992). The 
major difference between the two sequences is the insertion of a human Alu repetitive 
sequence element in the 3’-untranslated region of the hIL-10 cDNA clone. hIL-10, which 
contains 160 amino acid residues, has a primary structure comprising of an 18.5 kDa 
polypeptide that lacks detectable carbohydrate. mIL-10 is N-glycosylated at a site near its 
N-terminus that is missing from hIL-10. This glycosylation is heterogeneous, resulting in 
a mixture of 17, 19, and 21 kDa species (Moore, Vieira et al. 1990). However, the N-
glycosylation of mIL-10 is not required for biological activity since mutants lacking the 
N-linked site are still active. 
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The secondary structure of hIL-10 and mIL-10 comprises of four helices in each 
subunit (Shanafelt, Miyajima et al. 1991). Disulfide bonds between cysteine (cys) residue 
1, 3 and cys 2, 4 maintain helical structures of the subunit and subsequently the biological 
integrity of IL-10. The tertiary structure of hIL-10 is a V-shaped homodimer with six 
helices (four derived from one subunit and two from the other) in each half (Syto, 
Murgolo et al. 1998), while the structure of mIL-10 is a monomer with four helices. 
 
It has been demonstrated that hIL-10 is active on mice. However, mIL-10 has not 
yet been found to cross-react significantly on human. Recombinant mlL-10 and hIL-10 
have been expressed in cells from different species, including COS7 cells, mouse 
myeloma cells, Chinese hamster ovary (CHO) cells, baculovirus expression systems, and 
E. coli. The biological activities of these recombinant IL-10 proteins are so far 
indistinguishable. 
 
Regulation of IL-10 by immune cells 
IL-10 was originally described as a product of Th2 cells. It was soon discovered 
that many other T cell types (e.g. Th1 cells, Treg cells) and non–T cell hematopoietic 
cells (e.g. DCs, natural killer cells, monocytes, and macrophages) also produce IL-10. 
Currently, immunoregulators responsible for the generation of IL-10 have not been 
completely characterized and the mechanism by which these agents stimulate the 
production of IL-10 in a variety of cell types are under investigation. It is shown that 
different cells respond differently to IL-10 stimulus, and the response can depend on the 
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microenvironment of the cell.  For example, IL-12 has been described to induce the 
generation of Th1 cell clones that produce large amounts of IFN-γ and IL-10. 
Lipopolysaccharide (LPS) has been reported to stimulate IL-10 production by human 
monocytes and alveolar macrophages concomitant with activation of p38 and Jun N-
terminal (JNK) mitogen-activated protein (MAP) kinases, which involve in cell 
differentiation and apoptosis (Chanteux, Guisset et al. 2007). In addition, Interferon alpha 
(IFN-α) and interferon beta (IFN-β) have been demonstrated to increase IL-10 
production by monocytes and CD4+ T cells (Porrini, Gambi et al. 1995); (Ho, Kaufman 
et al. 1996; Schandene, Del Prete et al. 1996; Platzer, Docke et al. 2000). Systemic 
release of TNF-α also induces IL-10 through a negative feedback using NF-κB 
dependent pathway (Barsig, Kusters et al. 1995). Literature data also suggested that TGF-
β up-regulates IL-10 mRNA in Lewis rat with experimentally induced uveitis (Li, Sun et 
al. 1996). Interleukin-22 (IL-22), a cytokine produced by activated T cells, has been 
shown to increase IL-10 production by colon epithelial cells via the activation of signal 
transducer and activator of transcription 3 (STAT3) pathway (Nagalakshmi, Rascle et al. 
2004). Studies also suggested that IL-2 enhances IL-10 production by CD4+CD25+ Treg 
cells or NK cells through STAT5 or STAT4 activation, respectively (Grant, Yao et al. 
2008; Tsuji-Takayama, Suzuki et al. 2008).  
 
Other cytokines including IL-4, interleukin-13 (IL-13) and interleukin-27 (IL-27) 
have been shown to down-regulate IL-10 production by monocytes via STAT1 pathway 
(Chomarat, Rissoan et al. 1993; de Waal Malefyt, Figdor et al. 1993). In addition, I kappa 
B (I-κB) family member Bcl-3, a regulatory protein for NF-κB pathway, has been 
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demonstrated to inhibit IL-10 expression in macrophages (Riemann, Endres et al. 2005). 
Also, IL-10 can down-regulate IL-10 mRNA production in a negative feedback manner 
(de Waal Malefyt, Abrams et al. 1991). 
 
IL-10 signal transduction 
It has been elucidated that IL-10 exerts its biological functions through the 
activation of IL-10 receptor complex on target cell surface. The IL-10 receptor complex 
comprises of a high affinity (dissociation constant [Kd]~35–200 pM) IL-10 receptor 1 
(IL-10R1) that binds ligands and a low affinity IL-10 receptor 2 (IL-10R2) that initiates 
signal transduction (Liu, Wei et al. 1994).  Consistent with IL-10’s role as an immune 
inhibitor, down-regulation of IL-10R1 expression is associated with T cell activation 
(Liu, Wei et al. 1994). However, no evidence for regulation of IL-10R2 expression has 
been found in associated with immune cell activation (Gibbs and Pennica 1997).  
 
As of now, limited knowledge is available regarding the IL-10 intracellular 
signaling transduction pathway. The best-characterized IL-10 signaling pathway is the 
Janus tyrosine kinase (JAK)/STAT system. In details, the difference of the affinity 
between IL-10R1 and IL-10R2 triggers a sequential binding mechanism, by which IL-10 
first binds to IL-10R1 and subsequently engages IL-10R2 (Walter 2002). This interaction 
induces cross-phosphorylation of two tyrosine residues on the intracellular domain of IL-
10R1 and subsequently engages the JAK family tyrosine kinases 2 (TYK2), which are 
constitutively associated with IL-10R1 and IL-10R2, respectively (Finbloom and 
Winestock 1995). The activated tyrosine kinase mediates the direct interaction between 
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STAT3 and IL-10 receptor complex, and subsequently phosphorylates latent transcription 
factors STAT1, STAT5 in cytoplasma with the formation of different DNA binding 
complexes (Weber-Nordt, Riley et al. 1996; Wehinger, Gouilleux et al. 1996). These 
complexes translocate into nucleus, bind to specific sites on DNA and trigger the 
activation/regulation of specific genes. Among genes activated by IL-10 are suppressors 
of cytokine synthesis (SOCS)-1 and SOCS-3, which play key roles in the inhibitory 
effects of IL-10 on immune cell activation (Cassatella, Gasperini et al. 1999; Berlato, 
Cassatella et al. 2002). It has been shown that SOCS-1 silences signaling by binding to 
the activation loop of JAK and physically occluding the kinase active site, preventing it 
from phosphorylating its substrates (Morse, Bidwell et al. 1999).  
 
Both in vitro and in vivo studies in gene-deficient mice have linked the biological 
function of IL-10 to JAK/STAT signaling pathways. It was demonstrated that 
macrophages from JAK1 knockout mice do not respond to IL-10 (Rodig, Meraz et al. 
1998), which indicates that JAK1 plays a key role in IL-10 response. In this pathway, 
STAT3 is served as an obligatory mediator of IL-10 signaling. STAT3 is recruited 
directly to the IL-10/IL-10R complex via tyrosine residues in the IL-10R1 cytoplasmic 
domain and phosphorylated in response to IL-10 (Weber-Nordt, Riley et al. 1996). Study 
showed that mice, in which STAT3 is abolished in macrophages and neutrophils, develop 
chronic enterocholitis, and their macrophages are completely resistant to the effects of 
IL-10 (Riley, Takeda et al. 1999).  
 
In addition to JAK/STAT pathway, a number of studies demonstrated that IL-10 
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inhibits NF-κB pathway, which controls the synthesis of pro-inflammatory cytokines 
(Clarke, Hales et al. 1998; Ehrlich, Hu et al. 1998; Schottelius, Mayo et al. 1999). Further 
mechanistic studies revealed two different mechanisms: 1) IL-10 blocks NF-κB 
translocation in monocytes and macrophages by inhibiting IKK, a I-κB kinase, thus 
inhibiting degradation of I-κB, a NF-κB inhibitor; and 2) IL-10 inhibits DNA binding of 
NF-κB present in the nucleus. It was also shown that IL-10 inhibits the synthesis of 
interleukin-1 (IL-1), interleukin-6 (IL-6) and TNF-α by promoting the degradation of 
their mRNA (Wang, Wu et al. 1995). IL-10 can also stimulate phosphatidyl inositol-3 
and p70 S6 kinases, which play important roles in promoting the expression of IL-10 
(Crawley, Williams et al. 1996).  
 
Immunosuppressive functions of IL-10 
Literature data revealed that IL-10 suppresses immune action in damaging 
immune responses. It was demonstrated that both IL-10 monoclonal antibody (mAb) 
treated and IL-10 gene knockout mice developed exaggerated inflammatory responses to 
peritonitis or endotoxemea (van der Poll, Marchant et al. 1995; Lang, Rutschman et al. 
2002). 
 
The immunosuppressive action of IL-10 can be achieved both directly and 
indirectly on a number of immune cells. IL-10 acts on monocytes and macrophages to 
inhibit the synthesis of a number of cytokines that stimulate T cell responses, such as IL-
1α, IL-1β, IL-6, IL-2, IL-12, IFN-γ, TNF-α GM-CSF, G-CSF, and M-CSF (Pestka, 
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Krause et al. 2004). Among them, IL-1 and IFN-γ are crucial for inflammatory activities 
due to their synergistic effect on inflammatory pathway. IL-10 also inhibits chemokines 
secreted by activated monocytes, including MCP-1, MIP-1, MIP-2, Rantes, MDC and IP-
10 (Kopydlowski, Salkowski et al. 1999). These chemokines are implicated in the 
recruitment of monocytes, dendritic cells, neutrophils, and T cells in immune responses. 
Moreover, IL-10 enhances expression of natural antagonists of these cytokines. For 
instant, IL-10 enhanced production of IL-1 receptor antagonist (IL-1RA) and soluble p55 
and p75 TNFR, which inhibit expression of IL-1RI and IL-1RII (Dickensheets and 
Donnelly 1997) of monocytes.  
 
More importantly, IL-10 can modulate DC phenotypes and functions to suppress 
T cell activation and proliferation. Earlier studies showed that IL-10 down-regulates 
surface expression of MHC class II and co-stimulatory B7 molecules (e.g. CD80 and 
CD86) as well as IL-12 production by various types of DCs (Kubin, Kamoun et al. 1994; 
Willems, Marchant et al. 1994; Tong, Toshiaki et al. 2005). Addition of IL-10 during the 
culture of bone marrow derived DCs in vitro with GM-CSF and IL-4 inhibits co-
stimulatory molecule and IL-12 elevation of these DCs by LPS and CD40 ligand 
(Fortsch, Rollinghoff et al. 2000). Moreover, observations in recent decades have shown 
that IL-10 treated DCs, including fully matured DCs (B7high), can expand Treg cells or 
induce an anergy state in Ag-activated T cells (Takayama, Nishioka et al. 1998; Zeller, 
Panoskaltsis-Mortari et al. 1999; Mahnke and Enk 2005). These effects will lead to the 
suppression of T cell responses. Additional study demonstrated that treatment of DCs 
with glucocorticosteroids, vitamin D3, and prostaglandins in T cell co-cultures resulted in 
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IL-10-producing regulatory T cells (Penna and Adorini 2000). In general, the effects of 
IL-10 on DCs are consistent with inhibition of Th1 immune response and can be achieved 
by inhibitory effects on DCs, or by induction of T cell anergy or regulatory T cell 
expansion. 
 
Besides its regulatory effects on DCs, IL-10 is capable of inhibiting cytokine 
production and proliferation of CD4+ T cells by directly affecting their functions. It has 
been shown that IL-10 suppressed anti-CD3 mAb stimulated T cell proliferation via 
inhibition of IL-2 production as well as IL-5 secretion by T cells (de Waal Malefyt, Yssel 
et al. 1993; Schandene, Alonso-Vega et al. 1994). Other studies showed that IL-10 
inhibited CD28 tyrosine phosphorylation and abrogated CD28 downstream signaling to 
down-regulate co-stimulatory pathway and promote T cell anergy (Akdis, Joss et al. 
2000; Joss, Akdis et al. 2000; Yang, Li et al. 2006). Additionally, study has demonstrated 
that naïve T cells that exposed to IL-10 in vitro developed into Treg cells (Levings, 
Sangregorio et al. 2001).  
 
Owing to the suppressive function of IL-10, it has been used to hamper damaging 
immune responses that are prone to be found in autoimmunity, inflammation, as well as 
transplantations. Recent studies showed that administration of IL-10 to cardiac or cornea 
allograft models in rats or rabbits can prolong their survival after transplantation 
(Furukawa, Oshima et al. 2005; Yang, Li et al. 2006; Gong, Pleyer et al. 2007). 
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Regulatory T cells 
T cells that can suppress immune response were first reported in the 1970s: when 
animals were injected with high doses of immunogen, a tolerant T cell population that is 
specific to that immunogen was developed (Chatenoud, Salomon et al. 2001). It was not 
until the 1990s that the concept of regulatory T cells was introduced. Treg cells are a 
subset of T lymphocytes involved in the maintenance of immune tolerance to auto- and 
alloantigens. Disordering in the development and function of Treg cells is related to the 
occurrence of autoimmune and inflammatory diseases in humans and animals. Emerging 
data suggests that adaptive immune response involves the recruitment of both effector 
cells and Treg cells. The balance between the two populations is critical for the 
establishment of tolerance to self- and non-self-antigens. Conversely, the literature has 
demonstrated that the immunosuppressive potential of Treg cells can be utilized 
therapeutically to treat autoimmune diseases and facilitate transplantation tolerance 
(Hawiger, Inaba et al. 2001). It was shown that Treg cells (CD25+CD4+) enriched from 
normal mice suppress allergy, establish tolerance to organ grafts, and prevent graft-
versus-host diseases after bone marrow transplantation (Sakaguchi 2005). 
 
Natural and adaptive regulatory T cells 
Regulatory T cells are classified into naturally occurring and adaptive Treg cells. 
Naturally occurring Treg cells are generated within the thymus and exit to the peripheral 
tissue with fully functional suppressive phenotype. These Treg cells are CD4+ and 
express high affinity IL-2 receptor α chain (CD25) on the cell membrane surface. They 
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constitute approximately 5-10% of peripheral CD4+ T cell population. Naturally 
occurring Treg cell’s function of maintaining self-tolerance has been demonstrated in 
many in vitro and in vivo experiments (Takahashi, Kuniyasu et al. 1998; Belkaid, 
Piccirillo et al. 2002; Nishimura, Sakihama et al. 2004). For instance, depletion of 
naturally occurring Treg cells by thymectomy in both neonatal and adult mice results in 
the appearance of tissue-specific auto antibodies in blood circulation and autoimmune 
damage in various organs (e.g. stomach, thyroid, ovaries, islets, or testes) (Sakaguchi 
2000). Additionally, direct depletion of naturally occurring Treg cells results in excessive 
immune response to non-self-antigens, leading to inflammatory diseases such as bowel 
syndromes (Singh, Read et al. 2001).  
 
Unlike naturally occurring Treg cells, adaptive Treg cells are developed in the 
periphery. They can be generated or expanded by CD4+CD25+ naturally Treg cells or by 
altering the activity of CD4+CD25- T cells in the presence of a number of suppressive 
cytokines, such as TGF-β, IL-10 and IL-35 (Groux, O'Garra et al. 1997; Chen, Jin et al. 
2003; Kretschmer, Apostolou et al. 2005). These cytokines can transfer naïve T cells into 
different Treg cell subtypes including Foxp3+ Treg cells, IL-10 secreting Tr1 regulatory 
T cell (Tr1) (Chen, Kuchroo et al. 1994; Groux, O'Garra et al. 1997), and TGF-β 
secreting T cells (Th3) cells. Those adaptive Treg cells demonstrate the same immune 
suppressive function as naturally occurring Treg cells in many in vitro and in vivo studies 
(Groux, O'Garra et al. 1997; Zheng, Wang et al. 2004); (Khattri, Cox et al. 2003; 
Yamazaki, Iyoda et al. 2003; Fehervari and Sakaguchi 2004). 
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Regulatory T cell markers 
An optimal approach of characterizing Treg cells is to identify a unique functional 
Treg cell marker. CD5high and CD45RBlow were first identified in the 80’s as surface 
markers of CD4+ T cell with suppressive function (Sakaguchi, Fukuma et al. 1985; 
Morrissey, Charrier et al. 1993). These findings prompted the search for a more specific 
marker in defining such immune suppressive CD4+ T cells.  
 
It was not until 1995 that the discovery of CD25 expressed on a subset of T cells 
with regulatory properties was revealed (Sakaguchi, Sakaguchi et al. 1995). CD25 (the 
IL-2 receptor α-chain) positive T cells, which constitute 5%–10% of peripheral CD4+ T 
cells and less than 1% of peripheral CD8+ T cells in normal naïve mice and humans, are 
contained in the CD5high and CD45RBlow fraction of CD4+ T cells. It was shown that 
when spleen cell suspensions from normal mice were transferred to T cell–deficient mice, 
animals that received suspensions depleted of CD25+ cells developed autoimmune 
diseases consisting of gastritis, oophoritis, thyroiditis, insulitis, and arthritis. Addition of 
purified CD4+CD25+ T cells prior to transfer prevented the autoimmunity. Further 
investigation demonstrated that CD4+CD25+ T cells had dominant suppressive effects on 
conventional CD4+ CD25− T cells in vitro, and their survival and growth relied on IL-2. 
Although these studies were performed in mice, but existence of a similar CD4+CD25+ 
T cell population was subsequently confirmed in humans (Ng, Duggan et al. 2001).  
 
CD25 is a useful marker for obtaining a highly enriched population of Treg cells 
in normal naïve mice (Sakaguchi, Sakaguchi et al. 2001). However, CD25 is not unique 
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to Treg cells owing to the fact that conventional T cells also up-regulate CD25 marker 
when activated through their TCR. Nevertheless, within the CD4+CD25+ T cell 
population there exist cells with potent suppressive capabilities. 
 
Recent discovery of the Treg-specific transcription factor Foxp3 supported the 
identification of Treg cells as a lineage potentially distinct from other T cells. Being a 
master control gene of Treg cells, Foxp3 transcription factor orchestrates a wide range of 
biological processes that are critical for the development, differentiation, and function of 
Treg cells (Fontenot, Gavin et al. 2003; Hori, Nomura et al. 2003; Khattri, Cox et al. 
2003). Therefore, Foxp3 is currently one of the most reliable Treg markers.  
 
Constitutive expression of Foxp3 gene can be used to characterize Treg cells. 
Foxp3 gene was first identified as the defective gene in the mouse strain Scurfy, with an 
X-linked recessive mutant. The mutant male mouse exhibits hyperactivation and 
overproduction of CD4+ T cells, resulting in autoimmune disease and dysregulated T cell 
function that leads to its death within a month after birth (Brunkow, Jeffery et al. 2001). 
A human counter part of Scurfy, which has the mutation of the human FOXP3 gene, was 
also found to develop autoimmune disease (Kim, Rasmussen et al. 2007; Lahl, 
Loddenkemper et al. 2007). Foxp3 transfected T cells exert suppressive function in vitro 
and inhibit the development of autoimmune and inflammatory disease in vivo (Hori, 
Nomura et al. 2003; Khattri, Cox et al. 2003). Literature data indicated that Foxp3 is 
related to CD4+CD25+ Treg cell development, evidenced by studies that Foxp3-deficient 
mice harbor few CD4+CD25+ Treg cells, and transfection of Foxp3 gene in 
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CD4+CD25− T cells can up-regulate expression of CD25 (Fontenot, Gavin et al. 2003). 
Additionally, CD4+CD25+ T cells in both thymocyte and peripheral compartment of 
normal mice express high levels of Foxp3, whereas effector T cells do not (Hori, Nomura 
et al. 2003; Khattri, Cox et al. 2003).  
 
The cellular and molecular mechanisms by which Foxp3 orchestrates Treg cell 
development and function have not been completly understood. It has been proposed that 
Foxp3 interacts with transcription factors that facilitate the activation and differentiation 
of T cells into effectors, overriding their transcription machinery, thus converting them to 
Treg cells. Such transcription factors include NFAT, NF-κB, acute myeloid leukemia-1 
(AML1)/ runt-related transcription factor 1 (Runx1), and the histone acetyl transferase 
(HAT)/histone deacetyl transferase (HDAC) (Schubert, Jeffery et al. 2001; Bettelli, 
Dastrange et al. 2005). For example, NFAT and NF-kB promote the expression of IL-2 
and IFN-γ, thus contribute to the activation of effector T cells (Rao, Luo et al. 1997). 
Interaction between Foxp3 and NFAT could restrain expression of IL-2, and promote 
expression of CD25. Recent studies demonstrate that Foxp3 directly or indirectly controls 
hundreds (~700) of genes (Marson, Kretschmer et al. 2007; Zheng, Josefowicz et al. 
2007) that encode cytokines (e.g. IL-2) and cell-surface molecules (e.g. FasL).  
 
Other Treg cells markers include cytotoxic T cell associated antigen-4 (CTLA-4) 
and glucocorticoid-induced TNF receptor family-related gene/protein (GITR).  It was 
found that regulatory activity detectable in the CD25-CD4+ T cell population in normal 
naive mice was attributed to CTLA-4+ and GITRhigh cells. Depletion of CTLA-4+ and 
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GITRhigh T cells from normal spleen cells produced more severe forms of autoimmune 
diseases in a wider spectrum of organs (M. Ono and S. Sakaguchi, manuscript in 
preparation).  
 
In general, the most specific marker for naturally occurring Treg cells is the 
Foxp3, which is expressed by the majority of CD4+CD25+ T cells and a fraction of 
CD4+CD25- T cells (Figure 2.4) (Sakaguchi 2004).  
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Figure 2.4: Cell surface markers for naturally occurring CD4+ Treg cells. 
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Regulatory T cell functions 
Treg cells suppress proliferation and the cytotoxic activities of effector T cells 
(CD4+ and CD8+), natural killer cells, and DCs. The mechanisms by which Treg cells 
suppress the activity of these effectors remain unclear. Several of them have been 
proposed, including increase of immunosuppressive cytokines production, cell-contact-
dependent suppression, and functional modification of APC by Treg cells (Asseman, 
Mauze et al. 1999; Seddon and Mason 1999).  
 
Early studies reported that secretion of TGF-β or IL-10 by Treg cells could 
contribute to the suppression of effector T cell proliferation (Takahashi, Kuniyasu et al. 
1998; Thornton and Shevach 1998). These cytokines may directly mediate suppression of 
responder T cells, or maintain Foxp3 expression and suppressive activity in Treg cells 
(von Boehmer 2005). IL-10 has a wide range of immunosuppressive effects such as 
decreasing T cell cytokine production, and decreasing antigen presentation and co-
stimulatory molecule expression on DCs. TGF-β is a pleiotropic cytokine that acts on a 
variety of cells and regulates a wide range of biological activities, including wound 
healing, cell adhesion and migration, extracellular matrix formation, cell cycle and cell 
death (Nakamura, Kitani et al. 2001). More importantly, TGF-β plays a key role in 
regulating immune actions, evidenced by the report that TGF-β gene knock out mice 
developed aggressive autoimmune diseases in the first few weeks of life (Nakamura, 
Kitani et al. 2001). It was demonstrated that not only TGF-β is expressed by Treg cells, 
but also contributes to the expansion and differentiation of Treg cells. Local expression of 
TGF-β within the pancreas islets of non-obese diabetic (NOD) mice can inhibit the 
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autoimmune disease by promoting the expansion of the intra-islet CD4+CD25+ T cells 
(Javelaud and Mauviel 2004). Studies also showed that naïve human T cells could be 
differentiated into Foxp3+ regulatory cells when activated in the presence of TGF-β 
(Yamagiwa, Gray et al. 2001; Zheng, Wang et al. 2004). Finally, TGF-β may exert its 
effects indirectly by helping to maintain Foxp3 expression in Treg cells in peripheral 
tissues (Marie, Letterio et al. 2005).  
 
Treg cells also hamper the activations between responder T cells and DCs in a 
cell-to-cell contact dependent manner (Thornton and Shevach 1998). This is supported by 
the finding that separation of CD4+CD25+ T cells and effector T cells with a semi-
permeable membrane in vitro impeded the suppressive effect of Treg cells to effectors 
(Takahashi, Kuniyasu et al. 1998; Thornton and Shevach 1998). A recent study suggested 
that this in vitro suppressive cell contact was related to the delivery of a negative signal 
such as up-regulation of intracellular cyclic AMP to responder T cells (Tang and 
Bluestone 2008).  
 
Treg cells may also hamper or down-modulate DC functions and thereby make 
DCs unable to activate effector T cells. For example, studies showed that Treg cells 
impeded stable contacts between responder T cells and DCs (Tadokoro, Shakhar et al. 
2006; Tang, Adams et al. 2006), leading to anergy/inactivation of responder T cells, 
thereby suppressing immune response. Some studies suggested that CD4+CD25+ T cells 
down-regulated the expression of co-stimulatory molecules on DCs (Cederbom, Hall et 
al. 2000) . 
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Delivery of IL-10 to DCs 
Introduction 
Recombined IL-10 (rIL-10) has been tested in healthy volunteers, organ 
transplant patients, and rheumatoid arthritis patients for its inhibition of pro-inflammatory 
cytokine release (Wissing, Morelon et al. 1997; Keystone, Wherry et al. 1998; Boyer and 
Marcellin 2000; Colombel, Rutgeerts et al. 2001; Moore, de Waal Malefyt et al. 2001; 
Herfarth and Scholmerich 2002). The drug was well tolerated in healthy adults when 
administered intravenously at doses up to 25 µg/kg (Chernoff, Granowitz et al. 1995). 
Pharmacokinetic studies showed that rIL-10 was cleared through the kidney fairly rapidly 
following I.V. administration and yielded a terminal phase with a short half-life (~2 h) 
(Moore, de Waal Malefyt et al. 2001). Thus, in vivo administration of rIL-10 often 
resulted in low IL-10 concentrations in drug action sites, leading to little or no clinical 
improvement (Fedorak, Gangl et al. 2000; Narula 2000; Colombel, Rutgeerts et al. 2001). 
Increasing the dose of systemically administered IL-10 (>25 µg/kg) will cause side 
effects including anemia, headache, and flu-like symptoms (Moore, de Waal Malefyt et 
al. 2001; Herfarth and Scholmerich 2002).  
 
Gene therapy provides a unique approach by introducing genes of interest to 
target tissue or cells. Genetically modifying DCs to express IL-10 becomes an attractive 
strategy to induce immune tolerance. A successful delivery system should protect DNA 
molecules from degradation, facilitate gene uptake and expression in target cells, and 
have minimal potential for inflammatory responses in vivo.   
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Gene delivery barriers 
Delivery of therapeutic genes faces a variety of physical and biological obstacles 
that are categorized into extracellular and intracellular barriers.  
 
Based on the target tissue, extracellular barriers can be extracellular glycocalyx 
barriers, mucus in apical membrane, glycoaminoglycan in tissue interstitum, and 
endothelial barriers as exemplified by the blood brain barrier. Studies also showed that 
DNA or oligonucleotide complexes are degraded by endonuclease in the serum and 
rapidly cleared from blood circulation after I.V. injection (Maurer, Mori et al. 1999). 
Others reported that several serum proteins such as bovine serum albumin (BSA), 
macroglobulin, high-density lipoproteins (HDL) and low-density lipoproteins (LDL) 
interact with cationic lipids in DNA delivery complexes, altering their physicochemical 
properties (Zelphati, Uyechi et al. 1998).  
 
Intracellularly, three major processes, which are endocytosis, endosomal escape 
and nuclear entry, can affect gene delivery efficiency. DNA complexes can enter cells 
through a number of routes, including membrane fusion, phagocytosis, macropinocytosis, 
clathrin-mediated endocytosis, caveolae-mediated endocytosis, and other endocytic 
pathways. The majority of DNA complexes enter target cells by clathrin-mediated 
endocytosis. During this process, DNA complexes bind to surface receptors and trigger 
the formation and accumulation of clathrin-coated vesicles that invaginate near the 
surface of the plasma membrane. The vesicles are delivered rapidly to early endosomes 
(pH 6.0), and then transferred to late endosomes (pH 5-5.5) that become more acidic as 
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ATP-dependent proton pumps transport hydrogen ions into the vesicle lumen.  
Eventually, late endosomes become lysosomes with even lower pH (~5.0), which 
accomplishes intracellular digestion using a variety of hydrolytic enzymes (Schmid, 
Fuchs et al. 1988). Thus, delivery vectors incorporating a mechanism of endosomal 
escape have been developed to avoid lysosomal degradation of carried DNA molecules in 
this cellular entry pathway. Lack of an endolytic feature in delivery vectors usually 
results in low transfection efficiency even when a high cellular uptake is achieved.  
Nuclear entry can be easily achieved in rapidly dividing cells and is often the rate-
limiting step in slow or non-dividing cells. DNA fragments in the cytoplasm can 
accumulate in the nucleus by diffusion through the nuclear pore. The size of the nuclear 
pore complex is about 25 to 30 nm in diameter and allows the passage of molecules with 
a molecular weight lower than 40-60 kDa (Pante and Aebi 1996).  Larger DNA 
molecules enter nucleus either during the process of cell division, or via a mechanism of 
nuclear pore targeting or active nuclear transport, such as nuclear localization sequence 
(NLS) peptides (Imamoto 2000). 
 
Delivery of IL-10 gene by viral vectors 
Currently available DNA delivery systems can be classified into two categories: 
viral and non-viral vectors. Viral vectors (e.g. retroviruses and adenoviruses), which 
utilize viral machinery to express carrying genes in the host cells, are capable of inducing 
highly efficient gene delivery. For instance, replication-deficient adenoviruses have been 
used to successfully deliver IL-10 gene in preclinical studies (Bromberg, Boros et al. 
2002). However, viral vectors including adenoviruses also come with the increased risk 
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of triggering a viral specific immune response and subsequence immune-associated 
pathology in human. This may result in viral vector elimination from the host and a rapid 
immune response with potentially dangerous consequences under extreme circumstances 
(Sen, Hong et al. 2001; Buonocore, Van Meirvenne et al. 2002). Additionally, some viral 
vectors (e.g. retroviruses) are able to randomly integrate into the host cell genome and 
induce mutagenesis, which may be followed by development of cancer, especially upon 
chronic administration. Therefore, non-viral delivery systems become more attractive 
because they are less hazardous in terms of immunogenicity and mutagenesis.  
 
Delivery of plasmid IL-10 gene by direct injection 
A plasmid is a small circular piece of DNA molecule in bacteria that is capable of 
replicating independently of the chromosomal DNA. A DNA fragment that contains a 
gene of interest can be inserted into a plasmid and the resulting vector can be used to 
import DNA into a host cell. Since plasmid DNA is less immunogenic and is generally 
considered to be safer compared to viral vectors currently used, it has been widely used 
as a non-viral gene delivery vector. Direct administration of naked plasmid IL-10 to 
experimental animals was evaluated in the past. Nakagome et al. demonstrated the 
delivery of pIL-10 in mice challenged with ovalbumin (OVA) antigen through I.V. 
injection (Nakagome, Dohi et al. 2005). Experimental data indicated that expression of 
serum IL-10 was increased in mice after pIL-10 injection and antigen-specific immune 
response was suppressed subsequently. The authors further confirmed that suppressive 
effect of IL-10 is induced by attenuation of DC functions, including their antigen-
presenting capacity and cytokine productions. However, naked plasmid DNA is 
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susceptible to endonuclease degradation and is more difficult to cross cell membranes, 
which reduce the quantity of DNA molecules taken up by target cells, thereby limiting 
their efficiency of gene expression. A very high dose of plasmid DNA (>100 mg per 
mouse) is usually required for direct injection to achieve a therapeutic response. 
However, such high dose is not suitable for DNA delivery into small organs that have 
lower capacity, such as mouse thyroids. Moreover, such large amounts may lead to Th1 
cytokine IFN-γ synthesis in response to immunostimulatory sequences present in plasmid 
DNA (Roman, Martin-Orozco et al. 1997), which should be avoid especially when 
immunomodulation is expected.  
 
Delivery of plasmid IL-10 by polymer-based non-viral vectors 
Non-viral vectors have been developed to deliver DNA-based therapeutics. Based 
on the synthetic material used, they can be classified into two major categories: polymer-
based and liposomal delivery systems.  
 
In polymeric delivery systems, natural and synthetic cationic polymers or peptides 
such as chitosan, poly-L-lysine (PLL), polyethyleneimine (PEI) and polymethacrylates 
have been widely used (Nguyen, Green et al. 2008). These materials are usually 
biodegradable and/or biocompatible, and their physicochemical properties can be 
modified for different delivery applications. Cationic polymers can condense anionic 
DNA molecules into positively charged, nano-scaled complexes (polyplexes) via 
electrostatic interaction. The smaller size of cationic polyplexes and the electrostatic 
interaction between the polyplex and the cell membrane facilitate DNA intracellular 
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uptakes. Additionally, polyplexes can protect DNA molecules from endonucleases and 
improve their biological stability in vivo. These polymers can also be modified with 
functional groups that promote DNA release from endosomal compartment into 
cytoplasm.  
 
PEI has been investigated as a prominent cationic polymer for gene delivery due 
to its ability to condense plasmid DNA molecules and protect them from nuclease 
degradation. The amine groups of PEI display proton buffer capacity at endosomal pH 
and act as a proton sponge that disrupt endosomal compartment to allow release of DNA 
into cytoplasm. Lee et al. (Lee, Park et al. 2006) used PEI as a carrier to intravenously 
deliver plasmid IL-10 into 5-week old nonobese diabetic (NOD) mice at a dose of 50 mg 
of DNA per mouse. The self-assembly polymer/DNA complexes were prepared by 
mixing PEI (25,000 Da) with pIL-10 in 5% glucose solution at a 5/1 N/P (nitrogen of 
PEI/phosphate of DNA) ratio. Experimental results showed that mice I.V. injected with 
PEI/pIL-10 complexes had persistent IL-10 gene expression greater than 5 weeks 
compared to PEI injected-only, and noninjected control mice. Assay of serum glucose 
levels showed that PEI/pIL-10 injection prevented Type 1 diabetes in 40% of NOD mice. 
The study demonstrated that PEI could be used to deliver pIL-10 systemically to suppress 
autoimmune response in mice. 
 
Polymethacrylates are vinyl-based polymers that have been evaluated for gene 
delivery. Cationic polymethacrylates are usually engineered with side groups containing 
tertiary amine, pyridine and imidazole groups which display DNA condensing and proton 
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buffering abilities similar to PEI but with less toxicity (Dubruel, Christiaens et al. 2003; 
Dubruel, Christiaens et al. 2004). Basarkar et al. fabricated cationic particles with PLGA 
and methacrylate copolymer (Eudragit E100) to deliver mouse pIL-10 in vitro and in 
vivo (Basarkar and Singh 2008). Blended with cationic surfactant cetyl trimethl 
ammonium bromide (CTAB), the prepared particles displayed a positive zeta potential 
and were capable of loading DNA on the surface. PLGA/E100 copolymer showed 
increased buffering ability at endosomal pH in the presence of E100. In vitro transfection 
study indicated that pIL-10 loaded PLGA/E100 particles have greater IL-10 expression in 
HEK293 cells compared to plain PLGA particles. In vivo efficacy study indicated that 
intramuscular injection of pIL-10 loaded PLGA/E100 particles at a dose of 50 µg/mouse 
enhanced IL-10 expression in mice tissue, leading to effective protection against insulitis. 
The study suggested that the cationic polymethacrylates-based particles are feasible for 
IL-10 gene delivery to prevent autoimmune diabetes.  
 
Other biodegradable cationic polymers, such as poly [α-(4-aminobutyl)-L-
glycolic acid] (PAGA) have been synthesized for plasmid DNA delivery. Koh et al. 
(Koh, Ko et al. 2000) reported that PAGA enhanced plasmid IL-10 transfection 
efficiency in vitro. In vivo injection of PAGA/pIL-10 complexes into the tail vein of 
NOD mice (100 µg/mouse) elevated serum level of IL-10 after 5 days and the 
development of severe insulitis on these mice was reduced to 15.7% compared with mice 
injected with naked DNA (34.5%) and non-treated mice (90.9%). The study suggested 
that PAGA is a suitable vector to deliver plasmid IL-10 to suppress the progression of 
insulitis in NOD mice.  
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Delivery of pIL-10 by liposomal delivery systems 
Liposomes are vesicles that consist of an aqueous compartment enclosed in a lipid 
bilayer. They have been used to formulate a wide range of DNA delivery system in recent 
years. Compared to viral vectors, liposomes are generally less immunogenic and easier to 
be scaled-up in production. Additionally, their size range, surface charge, and 
composition can be engineered.  
 
When using liposomes as gene carriers, DNA molecules can be either entrapped 
inside the aqueous core or be carried in the lipid bilayer of the delivery system. Entrapped 
DNAs can enter target cells from liposome through fusion with phospholipid bilayer of 
cell membrane or via endocytic pathway. In the later situation, the mechanism of DNA 
release from cationic liposome/DNA complexes in endosome is driven by interaction 
between liposome and endosomal vesicle, and the subsequence destabilization of 
endocytic membrane that causes disassociation of DNA from the complex and its release 
to cytoplasm.  
 
Liposome formulations usually contain one cationic lipid such as 1,2-dioleoyl-3-
trimethylammonium propane (DOTAP) and dioleyloxy propyl trimethylammonium 
chloride (DOTMA), and one or more neutral helper lipids such as dioleoyl L-
phosphatidylethanolamine (DOPE) and cholesterol. Cationic lipids are used to form 
complexes with negatively charged DNA molecules. The formation of complexes, 
referred to as lipoplexes, will improve vector association with target cells and offer 
protection to carried DNA molecules from endonuclease degradation in vivo. However, 
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excess amount of cationic lipids may hamper DNA release from the formulation, leading 
to low gene expression. Neutral helper lipids function to stabilize cationic bilayers and 
promote endosomal escape. For example, DOPE undergoes hexagonal phase transition in 
acidic conditions, which will result in the rupture of endosome membrane and the release 
of DNA to cytoplasm. Therefore, the ratio and the combination of cationic lipid and 
helper lipid are considered as important factors for DNA expression as well as liposome 
stability.  
 
Liposomal delivery systems have been evaluated for plasmid IL-10 delivery in 
recent years.  Fellows et al. used a cationic liposome to deliver IL-10 gene to mice with 
established collagen induced arthritis (Fellowes, Etheridge et al. 2000). The liposome was 
formulated from a novel cationic lipid cytofectin (ACHx), a polyamine analogue 
dimethlaminoethame carbamoyl cholesterol (DC-Chol), and DOPE. Human pIL-10 was 
constructed with a SV40 promoter and complexed with ACHx/DC-Chol:DOPE 
liposomes in 1:2.4 (w/w) ratio. Liposomes loaded with pIL-10 were intraperitonealy 
(I.P.) injected into mice with established arthritis. Experimental data suggested that 
human IL-10 mRNA was detected in the paws 24 hours after injection and IL-10 protein 
was also detected in several tissues up to 10 days after injection in mice. Additionally, 
attenuation of arthritis was achieved in pIL-10 treated mice for 30 days. The results 
suggested that cationic liposomes can be use to systemic deliver plasmid IL-10. 
 
Kabay et al. used cationic liposomes (DOTAP: Cholesterol [1:1 molar ratio]) to 
I.P. deliver mouse pIL-10 to suppress inflammatory damage triggered by intestinal 
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ischemia (Kabay, Aytekin et al. 2005). The authors found that IL-10 protein expression 
was improved in mice injected with liposome/pIL-10 complexes compared to the one 
without IL-10 treatment. Data also showed that the subsequent expression of IL-10 
resulted in attenuation of leukocyte infiltration locally and reduction of pulmonary tissue 
injury that is normally induced by intestinal ischemia. The study indicated that cationic 
liposomes could be used to deliver IL-10 gene in vivo to modulate damaged immune 
responses.  
 
Furukawa et al. used liposome vectors (N-[3-aminopropyl]-N, N-dimethyl-2,3-
bis[dodecyloxy]-1-propaniminium bromide/DOPE) to ex vivo deliver pIL-10 (50µg) to a 
rabbit cardiac allograft and examined the efficacy and cardiac adverse effects using a 
functional cervical heterotrophic transplant model. The study demonstrated that the 
expression of IL-10 gene was long lasting and localized in the target organ. The mean 
survival of cardiac allograft was prolonged for greater than 100 days. Expression of IL-10 
inhibited the infiltration of T lymphocyte and cytotoxicity in the cardiac allograft and 
modulated pro-inflammatory cytokine production (Furukawa, Oshima et al. 2005). The 
study indicated that liposome could be used to in vivo deliver pIL-10 to suppress 
transplant rejection in rabbit allograft heart transplant model. 
 
Limitations of current polymer-based and liposomal delivery systems 
Although extensive efforts have been made for the development of non-viral gene 
delivery vectors, current systems are not without problems. Non-viral vectors generally 
suffer from low transfection efficiency compared to viral vectors. Additionally, some of 
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the non-viral delivery systems are associated with cytotoxicity and immunogenicity when 
administered in vivo.  
 
It was shown that chitosan administered at high doses can cause 
hypocholesterolemia in humans. Branched PEI that has high cationic potential can be 
extremely cytotoxic due to induction of apoptosis. PLL suffers from toxicity induced by 
its cationic amino acid backbone, which could disrupt cellular membrane structure. PLL 
are also potentially immunogenic, making them unfavorable for long-term treatments 
aiming to suppress immune responses.  Additionally, PLL/DNA complexes may undergo 
nonspecific binding to cell membrane, thus limiting their application in targeting 
delivery.  
 
Clinical use of liposomes is limited by their cytotoxic effects. It has been 
confirmed in various studies that cationic lipids cause cytotoxicity and pulmonary 
toxicity to varying degrees. Those effects are caused by lipid incorporation in the plasma 
membrane facilitated by lipid fusion or mixing (Stamatatos, Leventis et al. 1988; Zelphati 
and Szoka 1996), which inhibits protein kinase C activity (Farhood, Bottega et al. 1992).  
 
In addition to the safety and immunogenicity concerns, non-viral vectors 
including chitosan, PLL-DNA polyplexes and cationic lipoplexes usually have a high 
degree of polydispersity, making it difficult to characterize and control the 
physicochemical properties of the drug products, which may lead to less reproducible 
efficacy.    
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Characterization of non-viral vectors 
In order to achieve efficient gene delivery using non-viral vectors, it is important 
to understand the relationship between the physicochemical properties of the delivery 
systems and their transfection activities. Studies have revealed that the physicochemical 
properties have an impact on stability of non-viral vectors and carried DNAs, as well as 
biological processes such as association with target cells, intracellular uptake and 
trafficking.  
 
Since DNA complexes are usually formed by the electrostatic interaction between 
the cationic charged vectors and anionic charged DNA molecules, the mixing ratio of the 
two components can be adjusted to produce delivery complexes with different 
characteristics, such as particles size and zeta potential. 
 
Particle size of non-viral vectors plays a critical role in gene delivery to target 
cells. For in vivo delivery, particle size needs to be well defined to govern critical factors 
including biodistribution, toxicity, and transfection efficiency based on the target sites. 
For example, the optimum particle size for pulmonary delivery generally is in the range 
of 1-5 microns because particles larger than 5 microns deposit primarily in the upper 
airways. Submicron particles with diameters less than 400 nm are prefer candidates for 
tumor-targeted delivery because the particles are small enough to extravasate through the 
leaky capillaries (pore size ~400 nm) in the tumor without excessive distribtion to normal 
tissues. Additionally, particle size of non-viral vectors should be optimized to achieve 
effective entries to target cells and avoid being taken up by macrophages from the 
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reticuloendothelial (RES) system.  
 
Zeta potential is an essential property for gene delivery vectors because positive 
zeta potential facilitate non-specific uptake of DNA complexes via the interaction of the 
excess positive charge of the complex to the negative charge cell membrane. 
Additionally, particles and complexes can be stabilized in storage condition by their 
excess zeta potential. Therefore, optimization of zeta potential is necessary in order to 
yield efficient transfection rate in target cells and prevent aggregation of DNA 
complexes.  
 
Binding between DNA molecules and non-viral vectors stabilizes DNA 
complexes from denaturation during both extracellular and intracellular transit (Prevette, 
Lynch et al. 2008). However, excess binding between DNA and cationic vectors may 
hamper the release of DNA from its carrier, causing low gene expression. Binding 
strength of DNA complexes can be explored by titrating the complex with anionic 
molecules such as low molecular weight heparin and dextran sulfate. The released DNA 
can be quantified using gel electrophoresis or Picogreen® assay. In addition, 
thermodynamic approaches including UV melting curve measurement, differential 
scanning calorimetry (DSC), and isothermal titration calorimetry (ITC) are used to 
examine the stability of DNA/cationic carrier complexes.  
 
 DNA UV melting curve analysis has been employed to characterize binding 
stability of DNA/carrier complexes. Melting of DNA is conveniently monitored by an 
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increase in UV absorbance at 260 nm that results from the disruption of base stacking in 
DNA duplex due to the breakage of hydrogen bonds. DNA base pairs complexed with 
cationic polymers or lipids are more stable than free, unbound base pairs. Therefore, 
melting of free DNA molecules occurs at a lower temperature, while melting of DNA 
complexes occurs at a higher temperature. When a stoichiometric stable complex is 
formed between DNA and cationic condensate, only the transition due to the denaturation 
of the complexed DNA will be observed at higher temperature. However, when an 
unstable complex is formed between cationic condensate and DNA, disassociation of the 
constituent molecules may have occurred in the complex, resulting in shift of transition 
temperature of the melting curve (Mandel and Fasman 1976).  
 
 DSC method has been employed to characterize the interaction between DNA and 
cationic condensate. The principal of the DSC approach is that denaturation of DNA 
molecules induces heat adsorption peaks in a thermogram, and any increase in the 
stability of DNA complex due to interaction with cationic condensate will be directly 
reflected in the change of temperature and enthalpy of the endotherm in a DSC profile. 
Compared to free DNAs, the endothermic peaks of DNA complex is presented at a higher 
temperature range in DSC curves owing to the increase of stability in the system.  
Additional methods such as ITC have been used to directly quantify thermodynamic 
parameters of DNA/carrier complexes, including binding affinity (Ka), enthalpy changes 
(∆H), and binding stoichiometry (n) for the evaluation of interactions between cationic 
condensate and DNA.  
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Polystyrene and PLGA polymeric particulates for DNA delivery to DCs 
Recently, nanoparticles (size ≤ 100 nm) or submicron particles (10-1000 nm) 
have become attractive tools for drug delivery applications due to the reasons shown as 
follows. First, nano or submicron particles are able to adsorb, bind and stabilize 
molecules such as DNA and proteins on the surface. Second, the relatively large surface 
to volume ratio of these particles make them capable of carrying more drugs on the 
surface compared to other systems. Third, compared with other larger particulates (> 
1000 nm), the smaller size of these particles allows them to penetrate deeper tissues and 
to be taken up relatively easily by different types of cells. DCs pick up particles more 
efficiently than soluble antigen because their dimensions are comparable to 
microorganisms. It has been found that particles larger than 1000 nm are internalized 
through phagocytosis by APCs including both macrophages and DCs, while nano and 
submicron particles are taken up via endocytosis preferentially by DCs (Vidard, 
Kovacsovics-Bankowski et al. 1996; O'Hagan, Singh et al. 2004). Therefore, these types 
of particles are more advantageous in passive targeting delivery of plasmid DNA to DCs.  
 
Submicron particles fabricated from polymers including polystyrene and PLGA 
have been investigated in drug delivery applications. Polystyrene (Figure 2.5A) consists 
of a long hydrocarbon chain with every other carbon connected to a phenyl group. The 
material can easily adsorb proteins and peptides owing to its hydrophobic surface. 
Polystyrene particles can stabilize DNA molecules by providing DNA absorption and 
protection sites on their surface. Polystyrene is classified as a biocompatible material by 
the Food and Drug Administration (FDA), and has been approved, including particulate 
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form, for administration to human via the oral route. It is also a component of specific 
types of bone cement used in humans. Synthetic polymeric particles fabricated from 
polystyrene have been tested as vaccine carriers in mice and sheep (Fifis, Gamvrellis et 
al. 2004; Scheerlinck, Gloster et al. 2006). Minigo et al. have developed formulations 
made of PLL-coated polystyrene nanoparticles, which condense and deliver DNA 
vaccines to C57BL/6 mice (Minigo, Scholzen et al. 2007).  
 
Polystyrene is generally safe for in vivo use. Thermal and photo-oxidative 
degradation of polystyrene can occur in vitro but produces only carbon dioxide and water 
residue. An independent study that evaluated the safety profile of polystyrene particles 
demonstrated that subcutaneous/intradermal administration of the material in the Sprague 
Dawley rat did not induce pathology changes in the tissue or organs tested (including 
draining lymph nodes, liver, kidneys, spleen, heart, adrenals, lungs, brain) over 28–56 
days (Minigo, Scholzen et al. 2007). Additionally, in vivo clearance studies in the mouse 
after intradermal injection indicated that polystyrene particles are being slowly cleared 
via the RES system.  
 
 
Because polystyrene is a non-degradable polymer, it may be suitable for making 
particles that are for short-term treatments (e.g. ex vivo gene delivery). Repeat injection 
of non-degradable particles may cause accumulation of the polymer material in the cells 
and tissues, which could lead to potential toxicity. Therefore, a particle delivery system 
based on a biodegradable polymer is more suitable for applications that require long-term 
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administration.   
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Figure 2.5: Structure of polystyrene (A) and poly (lactic-co-glycolic acid) (B). 
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 PLGA (Figure 2.5B) refers to biodegradable copolymers consisting of various 
ratios of two monomers: glycolic acid and lactic acid. Glycolic acid is achiral and the 
lactic acid used is a racemic mixture (d and l). PLGA is a commercially available, GMP 
grade material that has been approved by the FDA for medical applications because of its 
biocompatibility and biodegradability. The co-polymer is amorphous rather than 
crystalline and shows a glass transition temperature in the range of 40-60 °C. PLGA 
degrades by hydrolysis of its ester linkages in the presence of water. It has been 
demonstrated that the time required for PLGA degradation is related to its monomer 
ratio: the higher the content of glycolide units, the lower the time required for 
degradation. An exception to this rule is the co-polymer with 50:50 monomer ratio 
exhibits a faster degradation (~ 2 months) (Astete and Sabliov 2006). In the body, 
hydrolysis of ester links of PLGA produces the original monomers, lactic acid and 
glycolic acid. The two monomers are by-products of various metabolic pathways in the 
body. Thus, PLGA is biodegradable and there is very minimal systemic toxicity 
associated with it. PLGA has long been used in cosmetic and orthopedic applications, and 
in other therapeutic devices (e.g. implants, internal sutures) in humans, as well as a 
delivery system for peptide and protein drugs (Athanasiou, Niederauer et al. 1996; 
Temenoff and Mikos 2000). Additionally, it was reported that PLGA facilitates the 
escape from endosome into cytoplasm due to a change in surface charge from negative to 
positive at endosome pH (Panyam, Zhou et al. 2002). Therefore, PLGA is attractive to 
many researcher involved in DNA delivery.  
 
In most of the previous studies, DNA or protein drugs are encapsulated in PLGA 
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polymer matrices during fabrication processes that use double emulsion (water–oil–
water), solvent evaporation technique. An emulsion containing a two-phase system is 
prepared by combining two immiscible liquids, in which droplets of one phase are 
dispersed uniformly through the other phase (Troy 2005). During the preparation of 
emulsions, emulsifying agents such as polyvinyl alcohol (PVA) are added to the system 
to reduce the surface energy between the hydrophilic phase and hydrophobic phase, 
therefore stabilizing the emulsion system. In the preparation of double or multiple 
emulsions (e.g. water-oil-water) system, a two-stage emulsification procedure is 
employed, including forming the primary emulsion (e.g. water-oil) and adding it to the 
second phase (e.g. water-oil-water). The preparation of emulsions also requires a certain 
amount of energy to form the interface between the two phases on the droplet. Certain 
processes including sonication, homogenizing and milling are required for providing 
energy to the system.  
 
The advantage of a DNA encapsulation approach in particle preparation is that the 
polymer matrix should protect embedded DNA from endonuclease degradation. 
Additionally, sustained expression of plasmid DNA could be achieved by the prolong 
release of the embedded DNA on the order of weeks (Cohen, Levy et al. 2000). However, 
there are several drawbacks in this system for DNA delivery. First, because of the large 
size and hydrophilic character of plasmid DNA, encapsulation of a high amount of DNA 
molecules in hydrophobic PLGA particles is a challenge. Second, DNA may be 
inactivated during the encapsulation process by sonication. The shear force in energy-
driven particle size reduction (e.g. sonication) during PLGA particle fabrication can 
 - 60 - 
severely affect the tertiary structure of plasmid DNA (Levy, Collins et al. 1999). The 
interaction of shear with air-liquid interfaces shows the highest potential for damaging 
plasmid DNA during sonication. The extent of damage is also found to be dependent on 
plasmid size and ionic strength of the environment. Third, it is well known that 
hydrolysis of PLGA may substantially decrease the pH environment in PLGA particles, 
potentially resulting in degradation of DNA (Walter, Moelling et al. 1999; Wang, 
Robinson et al. 1999). Fourth, due to the fact that plasmid DNA has to diffuse through 
the polymer matrices, the rate of release is often too slow (release lasts for several 
days/weeks) (Walter, Moelling et al. 1999; Tinsley-Bown, Fretwell et al. 2000; Zhu, 
Mallery et al. 2000; Luten, van Steenis et al. 2003). The slow release of DNA molecules 
may result in less optimal gene expression because of the following reasons: 1) the 
amount of plasmid DNA immediately available after cellular uptake by APCs is too 
limited, and 2) plasmid DNA released after days/weeks from the particles may be 
significantly damaged due to the acid microenvironment in PLGA particles.  
 
Alternatively, plasmid DNAs can be loaded on polymeric particle surface 
associated with cationic agents, rather than entrapping them in the particle matrices. The 
cationic surface of particles is capable of binding plasmid DNA through electrostatic 
interaction, and upon entering cytoplasm intracellular glutathione can facilitate DNA 
release from bound particles (Zugates, Anderson et al. 2006).  
 
Cationic peptides and polymers such as PLL and PEI can be used as DNA 
condensing agents to improve delivery efficiency and to protect DNA from enzymatic 
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degradation (Pack, Hoffman et al. 2005). However, PLL is not considered as an effective 
polymeric vector presumably because of the lack of an efficient mechanism for 
endosomal escape. Endosomolytic agents such as chloroquine are required to achieve 
DNA release to the cytoplasm when using PLL, but this is not applicable for in vivo use. 
PEI can condense DNA with its high cationic charge potential (Boussif, Lezoualc'h et al. 
1995). It also provides endosomal escape through the ‘‘proton sponge’’ mechanism 
(Sonawane, Szoka et al. 2003). However, PEI is not an ideal gene delivery agent by itself 
because the polymer causes cell necrosis and apoptosis (Moghimi, Symonds et al. 2005).  
 
O10H6, a cationic peptide of 10 ornithine and 6 histidine residues, has been 
shown in our lab to have more efficient uptake by DCs and is less toxic than other PLL 
containing cationic peptides (K16 and K10H6) (Chamarthy, Kovacs et al. 2003). 
Ornithine, a non-natural amino acid with a basic side chain (-CH2-CH2-NH2), provides 
most of the positive charges at physiological pH. The positive charge of the peptide 
contributes to DNA condensation that can increase DNA uptake and protect DNA from 
nucleases (Albert, Jegathesan et al. 2001; Meng and Butterfield 2005). The later is crucial 
for in vivo gene delivery where DNA is susceptible to serum digestion. To achieve 
successful transfection, DNA must escape from the endosome and enter the nucleus after 
it is taken up by host cells. Histidine, which has a near-neutral pKa group (pKa = 6) in the 
imidazole group on the side chain, can buffer the acidic environment of the endosome, 
causing water uptake by a pH pump in order to maintain lower pH (5-6) inside and 
induce endosome membrane rupture (Putnam, Gentry et al. 2001). Additionally, physical 
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properties of particles such as surface potentials can be adjusted by varying the amount of 
cationic peptides. 
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CHAPTER 3  
 
PHYSICAL CHARACTERIZATION OF POLYCATION-MODIFIED 
POLYMERIC PARTICLES LOADED WITH PLASMID IL-10 
 
Introduction 
Polymeric submicron particles have become versatile tools for macromolecular 
drug delivery (Vasir and Labhasetwar 2006). Macromolecules such as DNA, RNA and 
protein can be either encapsulated within the matrix of polymer particles, or loaded on 
the particle surface. In the second situation, the submicron size gives the particle large 
surface area to volume ratio (4л × radius2/1.33л × radius3) (Rotello 2003), making them 
capable of carrying more drugs compared to micron scale particles (Faraji and Wipf 
2009). Moreover, experimental data showed particles smaller than 500 nm are taken up 
preferentially by DCs via endocytosis (Vidard, Kovacsovics-Bankowski et al. 1996; 
O'Hagan, Singh et al. 2004). Therefore, surface loaded submicron particles are chosen as 
vectors for passive targeting delivery to DCs.  
 
Polystyrene is stable in vivo and is classified as a biocompatible material by the 
FDA for diagnostic uses in humans. Particles fabricated from polystyrene have been used 
for passive targeting delivery of DNA vaccines to DCs (Minigo, Scholzen et al. 2007). A 
recent study demonstrated that polystyrene particles within optimal size range (100-500 
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nm) can be taken up efficiently by a large portion of DC population within 4 hours of 
incubation in vitro (Foged, Brodin et al. 2005). When modified with negatively charged 
carboxylated functional groups, polystyrene particles can adsorb cationic peptides on the 
surface, making them capable of binding and condensing plasmid DNA molecules via 
electrostatic interactions. Such types of polycation-modified carboxylated polystyrene 
particles have been used in our lab to successfully deliver oligonucleotides and DNA to 
DCs. However, polystyrene is a non-biodegradable polymer that can accumulate slowly 
in the spleen and liver after repeated injections.  Therefore, delivery vectors formulated 
with biodegradable polymers would be more suitable for clinical applications that require 
long-term administration.  
 
PLGA has been approved by the FDA for drug and protein delivery due to its 
good biocompatibility and biodegradability (Panyam and Labhasetwar 2003; Bala, 
Hariharan et al. 2004). PLGA has been used as a copolymer for the fabrication of nucleic 
acids carriers because of its capacity to encase macromolecules in matrices (Panyam and 
Labhasetwar 2003). In this research work, we chose to load plasmid DNA on the 
polymeric particle surface rather than entrapping in the particle matrice in order to reduce 
degradation of encapsulated DNA during particle fabrication and drug release (Walter, 
Moelling et al. 1999; Wang, Robinson et al. 1999). It has been reported in our lab that the 
cationic peptide O10H6 can be adsorbed on both PS and PLGA particle surfaces, 
providing a positive surface capable of loading and condensing DNA molecules (Zheng, 
Kovacs et al. 2006). Compared to other PLL containing cationic peptides (K16 and 
K10H6), O10H6 has been shown to have more efficient uptake by DCs with less 
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cytotoxicity (Chamarthy, Kovacs et al. 2003). Another purposed advantage of PSO10H6 
and PLGAO10H6 particles is their physical properties such as surface potential which can 
be controlled by varying the amount of the cationic peptide O10H6. These properties 
have an impact on their stability as well as biological processes such as target cell 
association of these particles.  
 
In the work presented in this chapter, physical properties (e.g. particle size 
distribution and zeta potential) of PSO10H6 and PLGAO10H6 particles loaded with plasmid 
DNA were evaluated. Their ability to condense and stabilize DNA molecules from serum 
endonuclease was also determined. These characteristics have a great impact on the 
stability of gene delivery vectors, as well as critical biological processes during gene 
transfer.  The objective is to evaluate the physical characteristics of PSO10H6 and 
PLGAO10H6 particles, and determine the suitability of these particles to deliver plasmid 
DNA to DCs.  
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Methods 
O10H6 peptide and plasmid DNAs 
The cationic peptide, O10H6 ((MW = 2250) (Figure 3.1 A) was custom 
synthesized by Sigma-Genosys (Houston, TX). Crude peptides were purified by HPLC 
(>90%) and their identities were confirmed by liquid chromatography-mass spectrometry. 
Peptides were aliquoted in sterile distilled water and stored at -80°C until use. Plasmids 
encoding murine IL-10 (Figure 3.1B, pUMVC3-mIL10; 4563 bp), Green Fluorescent 
Protein (pUMVC3-GFP) and Luciferase (pUMVC3-Luc) were obtained from Aldevron 
(Fargo, ND), aliquot in distilled water, and stored in -80°C until use. The transgenes in 
these vectors are driven by the cytomegalovirus (CMV) promoter/enhancer with trimmed 
intron A and a rabbit β-globin polyadenylation (poly A) signal.  
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Figure 3.1: Chemical structure of O10H6 cationic peptide (in acidic environment) 
(A); mammalian expression vector for mouse IL-10 (B). 
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Preparation of PSO10H6-pIL-10 and PLGAO10H6-pIL-10 particles 
The vectors for plasmid IL-10 delivery were carboxylated polystyrene 
(Polysciences Inc, Warrington, PA) and PLGA (50:50, M.W. 12,000-16,500, 
Polysciences Inc, Warrington, PA) particles coated with O10H6.  
 
The plain polystyrene particle has an average diameter of 100 nm with less than 
10% variance. The polystyrene vector was formulated as follow: 3 µL (75 µg) of PS 
particles (2.5% w/v; 4.55×1011 particles.mL-1) were first coated with 200 µg of O10H6 in 
300 µL of deionized-distilled water (ddH2O). To assure sufficient binding of O10H6 to 
the particles, the components were equilibrated in a 1.5mL Eppendorf tube with gentle 
shaking for 2 h at room temperature on a mini shaker at a setting that is equivalent to the 
second lowest speed. The resulting positively charged particles were then equilibrated 
with the plasmid DNA (15 µg) for an additional 30 min with gentle shaking at room 
temperature. The N: P ratio for PSO10H6-pDNA particle was estimated to be 9-18:1. The 
final particle had plasmid DNA (e.g. pIL-10) condensed by O10H6 associated with 
polystyrene particle surface and was referred to as PSO10H6–pDNA (e.g. PSO10H6-pIL-10, 
PSO10H6-pLuc and PSO10H6-pGFP).  
 
PLGA particles were prepared in our lab using a double emulsion (w/o/w) solvent 
evaporation technique described previously (Wang, Robinson et al. 1999; Jain 2000). 200 
µL of aqueous solution and 6 mL of a solution of methylene chloride (MeCl2) and PLGA 
(3%, w/v) were emulsified by sonication. A Fisher model 100 sonic microprobe was used 
to introduce 24 W of energy (over 2 min) to form this water-in-oil emulsion mixtures 
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were sonicated on ice. This primary emulsion was added drop wise into 20 mL of 
aqueous solution of poly (vinyl alcohol) (0.5%, w/v) to form a water-in-oil-in-water 
emulsion. PVA, a non-mutagenic polymer with low acute oral toxicity (LD50 = 15–20 
g/kg), has been commonly used as an emulsion stabilizer in the preparation of PLGA 
particles. The resulting double emulsion was stirred for 4 hours in chemical fume hood to 
allow the MeCl2 to evaporate. Particles were recovered by ultracentrifugation and washed 
twice with ddH2O before lyophilization to remove excess PVA and un-trapped DNA.  
 
The PLGA particles used in the experiments were either lyophilized or freshly 
prepared prior to each analysis. Our lab data showed that freeze-dried PLGAO10H6 loaded 
with oligonucleotide retains 90% of its physical characteristics (particle size and zeta 
potential) upon reconstitution (Zheng, Kovacs et al. 2006). The PLGA delivery vector 
presented in this chapter was formulated as follows: 60 µg of lyophilized PLGA was first 
coated with 200 µg of O10H6 in 300 µL of ddH2O. To assure sufficient binding of 
O10H6 to the particles, the components were equilibrated in a 1.5 mL Eppendorf tube 
with gentle shaking for 2 hours at room temperature on a mini shaker at a setting that is 
equivalent to the second lowest speed. The resulting positively charged particles (denoted 
as PLGAO10H6) were then equilibrated with the plasmid DNA (15 µg) for an additional 30 
min with gentle shaking at room temperature. The N: P ratio for the PLGAO10H6-pDNA 
particle was estimated to be 9-18:1. The final particle had plasmid DNA condensed by 
O10H6 associated with the PLGA particle surface and was referred to as PLGAO10H6–
pDNA (e.g. PLGAO10H6-pIL-10, PLGAO10H6-pLuc and PLGAO10H6-pGFP).  
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Particle size and zeta potential analysis 
A Nicomp 380 ZLS analyzer (Particle Sizing Systems, Santa Barbara) was used 
to determine the zeta potential of PSO10H6-pIL-10 and PLGAO10H6-pIL-10 particles. The 
instrument operates on the dynamic light scattering (DLS) principle, capable of detecting 
particles size diameter ranging 1–5000 nm.The mean particle size was measured using 
suspensions (3 mL) of fresh polystyrene or PLGA particles, and particles modified with 
O10H6 and pIL-10, diluted 10 times with ddH2O in 4 mL disposable glass tubes. Radius 
was calculated using the Stokes–Einstein equation based on diffusion coefficient of the 
particles in the medium. Data were integrated over 10 min in duplicate experiments and 
were test fit for Gaussian and non-Gaussian functions.  
 
Zeta potential measurements were performed with samples diluted 30 times with 
ddH2O (pH = 7.4) in 3 mL disposable glass tubes. Data were integrated over 10 min in 
duplicate experiments. The measurement is based on electrophoretic mobility of the 
sample particles when subjected to an electric field.  
 
Gel electrophoresis 
In order to confirm the binding of pDNA onto the surface of PLGAO10H6 and 
PSO10H6 particles, the electrophoretic mobility of naked plasmid or the respective DNA 
complexes (O10H6-pIL-10, PLGAO10H6–pDNA, and PSO10H6–pDNA) was evaluated by 
agarose gel electrophoresis. Samples were analyzed in 1% agarose gel (MP Biomedicals, 
Solon, Ohio) with or without the addition of low molecular weight heparin sodium 
(Eikins-Sinn, Inc., Cherry Hill, NJ) (50 U/mL) that can release charge-bound DNA. DNA 
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was visualized by ethidium bromide staining. The binding of DNA on the particles is 
determined based on the ability of each complex to prevent the migration of negatively 
charged pDNA toward the anode of the electric field of the agarose gel.  
 
To assess the stability of pDNA against nuclease, naked plasmid or the respective 
DNA complexes (O10H6-pIL-10, PLGAO10H6–pDNA, and PSO10H6–pDNA) were 
incubated with 10% fetal bovine serum (FBS) at 37 °C for overnight. Following 
incubation samples were analyzed in agarose gel. Low molecular weight heparin sodium  
(50 U/mL) was added to samples to release charge-bound DNA in 1% agarose gel. DNA 
was visualized by ethidium bromide staining. Percentage of DNA recovery was 
calculated by dividing the band intensity of DNA recovered with the intensity of DNA 
loaded (multiple by 100). 
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Results 
Physical characterization of PSO10H6-pIL-10 and PLGAO10H6-pIL-10 particles 
as colloidal dispersions 
Particle sizes and zeta potentials of unmodified particles (PS and PLGA), O10H6 
coated particles (PSO10H6 and PLGAO10H6), and DNA loaded particles (PSO10H6-pIL-10 and 
PLGAO10H6-pIL-10) were measured using Nicomp 380 ZLS analyzer. Particle size data 
from three independent experiments indicated that addition of O10H6 and pIL-10 slightly 
increased the size of the complex relative to unmodified particles (Figure 3.2, Table 3.1). 
Carboxylated polystyrene particles had an average hydrodynamic size of 104 ± 0.8 nm 
whereas sizes of PSO10H6 and PSO10H6-pIL-10 were found to be 121.7± 28.4 nm and 126 ± 
8.3 nm, respectively. Modifying the surface of PLGA particles (259 ± 3 nm) with O10H6 
and pIL-10 generated slightly larger particles with 277.9± 5.9 nm (PLGAO10H6) and 297 ± 
14.1 nm (PLGAO10H6-pIL-10) in diameter. This change in size is consistent with 
association of O10H6 and DNA on the particles. The particle size deviation of the 
complex became slightly larger after addition of O10H6 and pIL-10 (Table 3.1), but the 
relative standard deviation in PSO10H6-pIL-10 and PLGAO10H6-pIL-10 remained to be 
6.6% and 4.6%, respectively. 
 
Data also showed that both PSO10H6-pIL-10 and PLGAO10H6-pIL-10 displayed 
unimodal (Gaussian) distributions (Figure 3.2) in the submicron range (Chi-squared [χ2] 
= 0.76). This result indicated that both systems exist as uniform stable colloidal 
dispersions, which is a prerequisite in parenteral administration. It also implied that the 
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three-component particle (PSO10H6-pIL-10 or PLGAO10H6-pIL-10) is the dominant specie 
in the dispersion. Because both systems remained below 500 nm in diameters, PSO10H6-
pIL-10 and PLGAO10H6-pIL-10 particles are suitable for passive targeting delivery into 
DCs (Cohen, Levy et al. 2000; Panyam, Dali et al. 2003).  
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Figure 3.2: Mean diameter (left) of PS and PLGA particles.  Histogram (right) 
represents data fit to Gaussian function (χ2 = 0.76) and non-Gaussian fit also yielded 
a single peak. 
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Table 3.1: Summary of particle size analysis of PS and PLGA particles. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Particle Mean diameter 
 (nm) 
Standard Deviation 
(nm) 
PS 104.0 ±0.8 
PSO10H6 121.7 ±28.4 
PSO10H6-pIL-10 126.0 ±8.3 
PLGA 258.6 ±3.4 
PLGAO10H6 277.9 ±5.9 
PLGAO10H6-pIL-10 297.2 ±14.1 
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The surface repulsive force of colloidal particles is associated with the stability of 
colloidal dispersion. This property can be evaluated by the surface electrostatic potential 
(zeta potential) of the particle. Figure 3.3 and Table 3.2 are the results of zeta potential 
analysis from three independent experiments. The average surface potential of 
unmodified PS particle is -36.31±5.26 mv. This negative potential is due to the presence 
of carboxylate groups on the surface of PS particles. The average zeta potential of 
unmodified PLGA particle is slightly negative (-12.3±0.21 mv), which is due to the 
presence of PVA molecules (mainly hydroxyl groups) on the surface. The negative 
surface of both unmodified particles is capable of absorbing cationic peptide O10H6 via 
electrostatic interaction. As shown in Figure 3.3 and Table 3.2, addition of O10H6 
reverses the surface potential of both unmodified PS and PLGA particles from negative 
to positive. Modifying the surface of PS particles with O10H6 changed their zeta 
potential to 30.61±3.05 mv. Likewise, altering the surface of PLGA particles with O10H6 
changed their surface potential to 5.2 mv. The reversal of the zeta potential is the result of 
absorption of O10H6 peptide on the particle surface and the protonation of excess 
amount of polycation O10H6 at neutral pH. This positive potential provides a tunable 
binding surface for plasmid DNA. After addition of pIL-10, the surface potential of both 
particles was not changed dramatically. As shown in Figure 3.3 and Table 3.2, the zeta 
potential of PSO10H6-pIL-10 and PSO10H6-pIL-10 particles are 31.26±2.46 mv and 4.7 ±0.5 
mv, respectively. This positive surface potential stabilizes PSO10H6-pIL-10 and 
PLGAO10H6-pIL-10 particle dispersion.  
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Figure 3.3: Zeta potentials of PS and PLGA particles. 
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Particle Zeta potential (milli-volt) 
Standard Deviation 
(milli-volt) 
Plain PS -36.31 ±5.26 
PSO10H6 30.61 ±3.05 
PSO10H6-pIL-10 31.26 ±2.46 
Plain PLGA -12.30 ±0.21 
PLGAO10H6 5.2  
PLGAO10H6-pIL-10 4.65 ±0.53 
Table 3.2: Summary of zeta potential analysis of PS and PLGA particles. 
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Complexation of plasmid IL-10 on PLGAO10H6 particles 
Particle size distribution and zeta potential data suggested that cationic peptide 
O10H6 was associated on the surface of PSO10H6 and PLGAO10H6 particles. The ability of 
polycation O10H6 coated particles to bind and condense DNA molecules was further 
confirmed using gel electrophoretic analysis. As shown in Figure 3.4b, pIL-10 was 
immobilized on PLGAO10H6 particles after running the gel at 90 volts for 50 min when 
free pIL-10 was shifted to anode (on the right) in the same electric field. The lack of 
DNA migration in samples suggested plasmid molecules were associated with 
PLGAO10H6. Further electrophoretic analysis after the addition of excessive amount of low 
molecular weight heparin sodium (an anionic polymer that competes the electrostatic 
binding between cationic peptide and DNA) showed that free pIL-10 was released from 
PLGAO10H6 particles (Figure 3.4a). The immobilization and release of pIL-10 on 
PLGAO10H6 particles before and after heparin addition was consistent with an O10H6-
pIL-10 complex, indicating that the binding between PLGAO10H6 and plasmid DNA is 
mainly via strong electrostatic interactions. By comparing the band intensity of DNA 
released by heparin from PLGAO10H6 particles with the control well loaded with the same 
amount of free pIL-10 (Figure 3.4a) using ImageJ software, we estimated that 87% 
(percent recovery) of pIL-10 on PLGAO10H6 was associated with O10H6 through ionic 
interactions. Taken together, these data suggested that a PLGA particle presents an 
electrostatic surface conducive for O10H6 binding and DNA condensation. 
 - 80 - 
 
 
 
Figure 3.4: Complexation of pIL-10 with PLGAO10H6. Samples of free plasmid IL-10, 
O10H6-pIL-10 complex and PLGAO10H6-pIL-10 particle were loaded in 1% agarose gel 
and mobilized in an electric field (anode on the right, 90 volt) for 50 min (b). Low 
molecular weight heparin sodium was then added to samples to release charge-bound 
DNA in 1% agarose gel which was mobilized in the same electrophoresis condition (a). 
DNA was visualized by ethidium bromide staining.  
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Serum stability of plasmid DNA carried by PSO10H6 and PLGAO10H6 
At in vivo conditions, DNA molecules are susceptible to degradation by serum 
endonuclease. Cationic peptides including O10H6 are capable of protecting these 
molecules from nuclease by forming complexes with them. To evaluate the ability of 
PSO10H6 and PLGAO10H6 particles to protect plasmid DNA from serum destabilization, free 
plasmid DNA, O10H6-DNA complexes, PSO10H6-pIL-10 and PLGAO10H6-pIL-10 particles 
were incubated with 10% FBS at 37 ˚C for up to 48 hours.  An excess of low molecular 
weight heparin sodium was added to samples after incubation to release charge-bound 
DNA from the complexes prior to electrophoresis in 1% agarose gel. Unbound DNA 
molecules were mobilized in an electric field (anode on the right, 90 volt) for 50 min and 
DNA was visualized by ethidium bromide staining. The results (Figure 3.5) demonstrated 
that DNA molecules carried by PSO10H6 particles had highest amount of DNA remaining 
among all the groups after extended incubation with FBS. In contrast, naked DNA and 
DNA incubated with PS only (without O10H6) were completely degraded after serum 
incubation. DNA complexed with O10H6 (without PS) also resulted in some DNA 
degradation after incubation with FBS, as evidenced by the lower DNA recovery 
compared to PSO10H6-pIL-10 particles. These data suggested that PSO10H6 particles 
protected DNA molecules from serum degradation. DNA directly incubated with PS 
particles was not protected in serum because no complex was formed between the two. 
The association of cationic peptide O10H6 on the particle provides a binding surface for 
plasmid DNA, improving the stability of O10H6-pIL-10 complexes against serum 
degradation.  
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Likewise, PLGAO10H6 also confers plasmid DNA protection in serum. Complexed 
or free plasmids (pLuc) were incubated in the presence or absence of 10% fetal bovine 
serum at 37 °C for 48 hours and heparin was added to each incubated sample. DNA was 
analyzed in 1% agarose gel electrophoresis and visualized by staining with ethidium 
bromide. Percent DNA recovery was calculated using pLuc released without serum 
incubation as the control. As shown in Figure 3.6, greater than 50% of pLuc loaded onto 
PLGAO10H6 was recovered after incubation. Conversely, free plasmids were completely 
degraded after serum incubation. This result indicated that condensation of plasmid DNA 
on PLGAO10H6 surface protects DNA from serum digestion. Although O10H6 bound the 
plasmid molecules, in the absence of PLGA, the DNA was completely degraded by 
serum incubation over 48 hours, while more than 50% of DNA still bound to the 
PLGAO10H6 particle after the incubation. This result demonstrated that PLGA particle 
improved stability of O10H6-DNA complexes in serum. Presumably, the polymer 
backbone may provide an anchorage for O10H6-DNA complexes, rendering extra 
protection mechanism against serum endonucleases.  
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Figure 3.5: PSO10H6-pIL-10 particles protect plasmid IL-10 from serum digestion. Naked 
plasmid DNA or the respective DNA complexes were incubated with 10% FBS at 37°C 
for overnight. Low molecular weight heparin sodium was added to samples to release 
charge-bound DNA in 1% agarose gel. DNA was visualized by ethidium bromide 
staining. A representative of three experiments is shown. 
 
 
 
 
 
PSO10H6-plL-10 
 
 
O10H6-plL-10 
 
PS-plL-10 
 
Naked plL-10 
 - 84 - 
 
 
 
Figure 3.6: PLGAO10H6-pIL-10 particles protect plasmid IL-10 from serum digestion. 
Complexed or free pLuc were analyzed in 1% agarose gel with or without incubation 
with 10% fetal bovine serum (37 °C, 48 hours). DNA in wells was released by heparin 
(50 U/mL) and visualized by staining with ethidium bromide. Percent recovery was 
calculated using pLuc released without serum incubation as the control. DNA in control 
‘‘pLuc’’ lanes (with and without serum) was allowed to migrate before the addition of 
heparin to other groups. A representative of three independent experiments is shown. 
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Discussion 
The results presented in this chapter demonstrated that PSO10H6 and PLGAO10H6 
particles are suitable carriers for DNA delivery to DCs.  
 
The goal of particle formulation is to form a stable, colloidal dispersion that 
retains both monodispersity and particle size in an effort to achieve consistent efficacy. A 
colloidal system consists of particles (usually ranging in size from 1nm to 1µm) 
distributed evenly throughout a dispersion medium. In pharmaceutical applications, 
colloids such as liposomes, micelles or submicron particles have been used as drug 
delivery systems for therapeutics in parenteral administration.  
 
Particle size distribution of PSO10H6 and PLGAO10H6 was measured by dynamic 
light scattering with a Nicomp 380 particle analyzer. DLS is a technique measuring the 
particles suspended in a liquid in the submicron region. The principle of this method is 
briefly described as follows. Particles in a colloidal system are in the state of random 
movement caused by Brownian motion, and this motion causes the intensity of scattered 
light to fluctuate as a function of time. The speed of given particles is inversely 
proportional to its size and smaller particles move faster than their larger counter parts. 
Diffusion coefficient of the particles can be measured by analyzing the fluctuation rate of 
scattered laser light in the system, which is obtained from the correlation function of 
signal decays. Thus, size of spherical particles will be calculated using the Stokes–
Einstein equation based on diffusion coefficient of the particles in the medium. 
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The unimodal distribution of PSO10H6-pIL-10 and PLGAO10H6-pIL-10 particles 
indicated that both systems exist as uniform stable colloidal dispersions, and the three-
component particle (PSO10H6-pIL-10 or PLGAO10H6-pIL-10) is the dominant specie in the 
dispersion, given that their mean diameters are 126 ± 8.3 nm for PSO10H6-pIL-10, and 297 
± 14.1 nm for PLGAO10H6-pIL-10 (Chi-squared [χ2] = 0.76). These results also indicated 
that particle sizes of PSO10H6-pIL-10 and PLGAO10H6-pIL-10 remain below 500 nm, which 
is preferred for DC uptakes.  
 
Zeta potential is a measurement of the electric charge acquired by a particle, 
which is a good indication of how stable the system is. Colloidal dispersion is governed 
by both the repulsive force from the electric double layer of particles and the attractive 
Van Der Waals force that particles experience as they approach one another. When the 
particles collide as a result of Brownian motion, they can adhere and form aggregates. 
The electric repulsive force of the particle, on the other hand, presents an energy barrier 
to overcome the attractive Van Der Waals force, and thereby stabilizes the system.  
 
Particles with positive or negative zeta potential will repulse each other and 
remain in a stable, monodisperse form. However, excessive high surface potential could 
increase the toxicity of particles by disrupting the structure of negatively charged cellular 
membranes.  The positive zeta potential stabilizes PSO10H6-pIL-10 (31.3 mv) and PLGA 
O10H6-pIL-10 (4.3 mv) particles as colloidal dispersions without increasing their toxicities. 
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Our data also showed that both plain PS and PLGA particles have negative zeta 
potentials, owing to the presence of carboxylate and PVA groups on PS and PLGA 
particles, respectively. The display of PVA molecules on the exterior of PLGA particles 
was confirmed in our lab using an IR spectrometer, which is consistent with the result 
reported previously by Sahoo et al. (Sahoo, Panyam et al. 2002). The carboxylate and 
PVA groups on PS and PLGA particles serve as conduits for polyelectrolyte-adsorption 
of polycation O10H6.  Successful coating of O10H6 on both particles was confirmed by 
the reversal of zeta potential upon addition of O10H6 peptide. The binding of the peptide 
was also indirectly verified by the slight increase of particle size of PSO10H6 and 
PLGAO10H6 particles compared with the plain particles.  
 
The principle role of O10H6 is to exert a tunable DNA binding surface so that 
DNA can be loaded and protected on the particle, considering that the ionic interaction 
between the DNA and O10H6 peptide is strong enough to bind DNA. Previous data in 
our lab showed that short oligonucleotides bind to O10H6 on polystyrene particles and 
that the half-maximal concentration of O10H6 required for DNA immobilization is 0.5 
mg/mL. Gel electrophoresis data presented in this chapter demonstrated that pIL-10 was 
condensed on PLGAO10H6 particle via electrostatic interaction, as evidenced by the 
release behavior after the addition of excessive amount of low molecular weight heparin. 
The binding of pIL-10 on PLGAO10H6 particles was indirectly confirmed by the slightly 
increase of particle size of PSO10H6-pIL-10 and PLGAO10H6-pIL-10 particles compare with 
PSO10H6 and PLGAO10H6 particles. 
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One of the important features of cationic peptide /DNA complex is its ability to 
condense and protect DNA against serum endonuclease, which is critical for in vivo 
delivery.  Our data confirmed that O10H6 peptide alone protected DNA in serum for up 
to 24 hours. Moreover, data from gel electrophoretic analysis showed that polycation 
particles PSO10H6-DNA and PLGAO10H6-DNA have greater DNA retention compared to 
O10H6-DNA complexes after 48 hours incubation in serum. The result indicated that 
coating of polycation on particles improved its protective effect on DNA against serum 
endonuclease. Presumably, the polymer structure of polystyrene and PLGA provided 
anchorages for the cationic peptide/DNA complexes, and thus rendered additional 
protection mechanism against nuclease in serum.  
 
In summary, PSO10H6 and PLGAO10H6 particles existed as a colloidal dispersion 
with a preferential size range for DC uptake. The O10H6 coated surface on these 
particles is capable of binding and protecting plasmid DNA from serum endonuclease. 
Thus, PSO10H6 and PLGAO10H6 particles are suitable for DNA delivery to DCs and these 
vectors might serve as a non-inflammatory alternative to lipid and viral vectors. 
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CHAPTER 4  
O10H6 MODIFIED POLYSTYRENE AND POLY (LACTIC-CO-
GLYCOLIC ACID) PARTICLES ENHANCE GENE TRANSFER INTO 
DENDRITIC CELLS 
 
Introduction 
Gene therapy has emerged as a field with the goal to modulate cell functions by 
introducing gene of interest to target cells. Efficient delivery of DNA-based therapeutics 
is challenged by physicochemical and biological barriers presented in blood circulation, 
tissues, and cells. Major delivery barriers include degradation of DNA in the extracellular 
space by nuclease, internalization of DNA into target cells, escape of DNA from 
endosome into the cytoplasm, and transfer of DNA into the nucleus. Development of 
vectors to overcome these barriers is important to achieve efficient gene delivery. 
 
The objective of the work in this chapter is to evaluate the performance of PSO10H6 
and PLGAO10H6 particles as vectors to deliver plasmid DNA to DCs in vitro. The 
hypothesis is that the polycation surface-modified polymeric particles could facilitate in 
vitro gene transfer to DCs for three reasons. First, coating of cationic peptide O10H6 on 
polymeric particle improves its ability to condense DNAs and stabilize these molecules 
against endonuclease in serum (Albert, Jegathesan et al. 2001; Meng and Butterfield 
2005). Data presented in the previous chapter demonstrated that PSO10H6 and PLGAO10H6 
particles increased the stability of loaded DNA in serum. Second, submicron range 
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particles have been used in passive targeting DNA delivery to DCs, because these 
particles can be taken up preferentially by DCs through the endocytic pathway. Third, the 
histidine cluster in O10H6 peptide functions as an acid-buffering agent to assist DNA 
escape from the endosomal compartment to the cytosol (Midoux, Kichler et al. 1998; 
Putnam, Gentry et al. 2001).  In this chapter, the in vitro transfection efficiency of 
PSO10H6 and PLGAO10H6 particles was investigated in pGFP, a reporter gene plasmid and 
pIL-10, a therapeutic gene plasmid.  
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Methods 
Generation of primary DCs 
Six to eight weeks old female certified virus free C57BL/6 (H-2b) and BALB/c 
(H-2d) mice were purchased from Hilltop Lab Animals, Inc. (Scottdale, PA) and housed 
in the Duquesne University Animal Care Facility. All experimentations were handled in 
accordance with the institutional animal care policy. 
 
The method of generating primary DCs was adapted from the Inaba protocol with 
modifications (Inaba, Inaba et al. 1992; Meng, Butterfield et al. 2001). Harvested bone 
marrow progenitors from femurs were cultured overnight in serum free Roswell Park 
Memorial Institute (RPMI) medium (Life technologies, Gaithersburg, MD).  Nonadherent 
cells were then re-plated at 106 cells/mL in 6-well tissue culture plates (Costar, 
Cambridge, MA, USA) in RPMI containing 10% heat-inactivated fetal bovine serum, 50 
µM 2-mercaptoethanol, antibiotics (penicillin/streptomycin/fungizone), all from Life 
Technologies (Gaithersburg, MD), and cytokines (5 ng/mL of murine GM-CSF and 5 
ng/ml of murine IL-4; R&D Systems, Minneapolis, MN) and maintained at 37 °C in 5% 
CO2. On day 4, nonadherent cells were removed by aspirating 80–90% of the media and 
adherent cells were re-fed with culture medium (1 mL/106 cells) containing murine GM-
CSF and IL-4. 
In vitro IL-10 gene transfection 
On day 6 of primary DC culture, culture medium was removed and cells were 
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washed two times with 1 mL of 1× sterile PBS at room temperature, followed by 
complete removal of PBS from each well and addition of 1.2 mL of sterile serum reduced 
Opti-MEM media (Invitrogen). DCs were transfected with a plasmid reporter gene 
encoding green fluorescent protein (pGFP, 5.3 kb, Fargo, ND) and pIL-10 using PSO10H6-
pIL-10 and PLGAO10H6-pIL-10 particles. Free plasmids were used as the control. 75 µg of 
PS or 60 µg of PLGA particles coated with 200 µg of O10H6 and 15 µg 300 µL of DNA 
in 200 µL of ddH2O were then added to each well and incubated for 4 h at 37 °C in 5% 
CO2. Upon completion Opti-MEM was then removed and DCs were washed with 1 mL 
of 1× sterile PBS. Fresh RPMI 1640 media containing 10% FBS and GM-CSF/IL-4 was 
added to each well and DCs were cultured in for an additional 24–48 h at 37 °C in 5% 
CO2. Expression of pGFP or pIL-10 after the transfection was analyzed using confocal 
imaging or reverse transcriptase polymerase chain reaction (RT-PCR) analysis, 
respectively.  
 
Confocal imaging analysis of pGFP expression 
Bone marrow-derived primary DCs were allowed to adhere to coverglasses, 
washed with PBS, and exposed to 300 µL of PLGAO10H6-pGFP particles in 1.2 mL Opti-
MEM media for 4 h 37 °C in 5% CO2. Upon completion of transfection, DCs were 
washed and cultured in RPMI medium containing 10% FBS and GM-CSF/IL-4 for an 
additional 48 h. After the incubation period, cells were washed in PBS twice and fixed in 
4% paraformaldehyde for 15 min at 4 °C before mounting on slides with MOWIOL4-88 
anti-fade media (CalBiochem, Darmstadt, Germany). Images were collected using a 
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Leica TCS SP-2 spectral microscope (Leica Microsystems AG, Wetzlar, Germany) with 
an argon/helium laser and FITC filter.  
 
IL-10 RT-PCR analysis of IL-10 gene expression 
Total RNA of transfected DCs was isolated using a SV total RNA isolation kit 
(Promega, Madison, WI). 0.1-0.5 mg of RNA sample was amplified using One-Step 
Eppendorf Master RTplus PCR kit (Eppendorf, Hamburg, Germany) in an Eppendorf 
MasterCycler. 2 µL of primer pairs (7.5 pmoles/μL) specific for IL-10 and β-actin 
(R&D Systems, Minneapolis, MN) were added to 0.1-0.5 µg of RNA sample in a reverse 
transcription (50 °C for 50 min) step, followed by denaturation (94 °C for 4 min). The 
amplification steps consisted of 35 cycles of template denaturation (94 °C for 45 s), 
primer annealing (55 °C for 45 s) and primer elongation (68 °C for 45 s). 20 µL of PCR 
products were loaded in 2% agarose gel and run at 90 volts for 50 minutes and DNA was 
visualized by 0.5 µg/mL of ethidium bromide in agarose gel. 
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Results 
To evaluate the gene transfer efficiency, bone marrow derived DCs (BMDCs) 
were transfected in vitro with PSO10H6 and PLGAO10H6 particles carrying a reporter gene 
pGFP. Free pGFP was used as a control vector to investigate whether the O10H6-
modified polymeric particles can facilitate in vitro gene transfer to DCs. Reporter genes 
are common tools for evaluating gene transfer efficiency of a delivery vector. Expression 
of pGFP will result in the synthesis and accumulation of green fluorescence protein in 
cytoplasm, which has a major excitation peak at a wavelength of 498 nm and an emission 
peak at 509 nm in the lower green portion of the visible spectrum. Thus, pGFP 
expression can be evaluated by confocal imaging analysis using an inverted Leica TCS 
SP-2 spectral microscope with an argon/helium laser and a FITC filter cube as the 
excitation source.  
 
The confocal images shown in Figure 4.1 are cells expressing green fluorescence 
protein after transfection with PSO10H6-pGFP (a), PLGAO10H6-pGFP (b), and free pGFP(c) 
using a 63X oil immersion objective. The green fluorescence in the images was emitted 
by the green fluorescence protein and the average intensity in each image was quantified 
using ImageJ software. Analysis of the images showed that DCs transfected with 
PSO10H6-pGFP resulted in 77% increase in fluorescence intensity compared to those 
transfected with free pGFP (Figure 4.1a and c), while DCs transfected with PLGAO10H6-
pGFP showed 72% of enhancement of pGFP intensity over cells treated with free pGFP 
(Figure. 4.1b and c). The increased intensity of green fluorescence in cells came from the 
more efficient expression of pGFP, indicating that both PSO10H6 and PLGAO10H6 particles 
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can effectively facilitate gene delivery to DCs, leading to increased transgene expression 
over free plasmid DNA.  
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Figure 4.1: Transgene expression in DCs transfected by complexed or free pGFP. 
Confocal images of cells expressing (GFP) after transfection with PSO10H6-pGFP (a), 
PLGAO10H6-pGFP (b), and free pGFP (c). Slides were prepared by adhering DCs 
incubated with the respective complexes for 2 h at 37 °C. Images were captured using a 
Leica confocal microscope at 63× magnification. 
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Our results showed that PSO10H6 and PLGAO10H6 particles can effectively facilitate 
plasmid reporter gene delivery to DCs. The next step is to investigate whether these 
particles can increase therapeutic gene (e.g. pIL-10) expression in DCs. To test this, 
BMDCs from C57/BL6 mice were in vitro transfected with pIL-10 loaded on PSO10H6 and 
PLGAO10H6 particles. DCs transfected with free pIL-10 alone were designed as a control 
to evaluate the efficiency of IL-10 gene transfer using PSO10H6-pIL-10 and PLGAO10H6-
pIL-10 particles. IL-10 expression in DCs was evaluated by isolating total RNA of 
transfected DCs in each delivery mode and semi-quantifying levels of mIL-10 using RT-
PCR analysis. RT-PCR is a highly sensitive technique that has been used to measure the 
expression of a defined gene. The specific RNA strand is first reverse transcribed into its 
DNA complement, followed by amplification of the resulting DNA using PCR. The final 
PCR products were analyzed in 2% agarose gel and DNA was visualized by ethidium 
bromide staining. Expression of β-actin, a housekeeping gene in cells, was measured in 
the same sample for semi-quantification purpose.  
 
Figure 4.2 and table 4.1 are the results of IL-10 gene expression in cells 
transfected with PSO10H6-pIL-10, PLGAO10H6-pIl-10, and free pIL-10. Bands shown in 
Figure 5.2a matched predicted PCR products of IL-10 (235 bp) and β-actin (302 bp), 
respectively. The intensity of the band indicates the level of mRNA. Consistent with the 
result from reporter gene transfer, IL-10 mRNA expressions were enhanced in PSO10H6-
pIL-10 and PLGAO10H6-pIL-10 transfected DCs compared to DCs transfected with free 
pIL-10, as evidenced by the increased intensity of IL-10 band shown in Figure 4.1a.  
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The results of IL-10 gene expression from two independent experiments were also 
semi-quantitatively analyzed by normalizing the intensity of IL-10 against the 
corresponding β-actin band (Figure 4.2b, Table 4.1). The result demonstrated a 2.8-fold 
and three-fold increase of IL-10 expression in DCs transfected with PSO10H6-pIL-10 and 
PLGAO10H6-pIL-10 (p<0.05, student’s t-test one-tailed, equal variance) relative to DCs 
transfected with free pIL-10, respectively. These results indicate that PSO10H6 and 
PLGAO10H6 can facilitate pIL-10 entering the nuclear compartment in DCs, resulting in 
higher expression of the IL-10 gene in target DCs compared to free plasmid IL-10. 
Therefore, PSO10H6 and PLGAO10H6 can be used as vectors to achieve increased pIL-10 
transfer to DCs in vitro. 
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Figure 4.2: Up-regulation of IL-10 in transfected DCs. (a): IL-10 mRNA was 
determined using RT-PCR in cells transfected with the respective complexes. (b): 
Expression was normalized against β-actin mRNA. RNA was extracted from bone 
marrow-derived DCs and amplified using murine IL-10 specific primers. Bands 
identified were consistent with predicted PCR products of IL-10 and β-actin with 235 
and 302 bp, respectively. 
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IL-10/ β-actin mRNA 
 Mean SEM 
PSO10H6pIL-10 
Transfected DCs 1.14* 0.27 
PLGAO10H6-pIL-10 
Transfected DCs 1.25** 0.28 
Control DCs 0.41 0.04 
 
Table 4.1: IL-10 mRNA expression in transfected and control (untransfected) DCs. Data 
were normalized against β-actin mRNA from two independent experiments. (*p=0.05; 
**p<0.05. Student’s t-test, one-tailed compared to control. ) 
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Discussion 
Previous data from our lab showed that PSO10H6 particles are efficient carriers of 
oligonucleotides, capable of introducing NF-κB decoy molecules into greater than 50% 
of primary DCs in vitro.  Results from the research presented in this chapter 
demonstrated that O10H6-modified polymeric particles PSO10H6 and PLGAO10H6 can 
effectively deliver plasmid DNA to DCs. This is confirmed by the successful delivery of 
both reporter gene pGFP and therapeutic gene pIL-10 in vitro.  
 
Delivery of free plasmid DNA is challenged by physicochemical and biological 
barriers presented in blood circulation, tissues, and cells. Those barriers cause low gene 
transfection when free plasmid DNA is used. Development of vectors to overcome these 
barriers is important to achieve efficient gene delivery. 
 
The enhanced DNA transfection by PSO10H6 and PLGAO10H6 particles over free 
plasmid DNA was most likely influenced by four factors. First, DCs take up particulates 
efficiently due to active and responsive cytoskeletal remodeling mechanisms (Mellman 
2005), thereby particle systems can facilitate the internalization of carried DNA 
molecules into DCs. Previous data from our lab demonstrated that PSO10H6 particles 
significantly increase oligonucleotide uptake in DCs by five-fold compared to free 
oligonucleotide (Kovacs, Zheng et al. 2005). Likewise, oligonucleotide encapsulated in 
PLGA particles is taken up by DCs efficiently (two-fold increase compared to free DNA 
transfection) (Zheng, Kovacs et al. 2006).  
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Second, the amine group (pKa = 6) on the imidazole ring of the histidine cluster 
in O10H6 functions as an acid-buffering agent to assist DNA escape from endosome. 
DCs are equipped with robust endo-lysosomal machinery (Wakkach, Fournier et al. 
2003), resulting in the accumulation of relatively minor fractions of exogenous materials 
in the cytosol. Data from our lab show that accumulation of plasmid DNA in cytosol can 
be mediated by O10H6 coated polymeric particles through an endosome escape 
mechanism., We used confocal microscopy with  a FITC-labeled short oligonucleotide 
(ODN) as a probe to observe enhanced DNA escape within 30 min and accumulation 
outside of acidic compartments in DCs (stained with a pH-sensitive LysoTracker dye) 
exposed to PSO10H6-ODN (Jia, Kovacs et al. 2008). Conversely, in cells exposed to free 
ODN, few DNA clusters were found outside of lysosomes compartment.  It is worth to 
point out that PLGA also facilitates the escape of therapeutic agents from endosome into 
cytoplasm, owing to a change in surface charge of the polymer from negative to positive 
(Panyam, Zhou et al. 2002; Bala, Hariharan et al. 2004). Given that carboxylated 
polystyrene particles do not confer acid-buffering effect as PLGA does, escape of DNA 
was most likely mediated by O10H6.  
 
Third, surface loading of nucleic acids allows DNA to be released inside cells 
without having to diffuse through acidic matrices, thereby increasing DNA transfection 
efficiency. Upon hydration lactic and glycolic acids (polymer byproducts) accumulate 
within the matrix of PLGA polymer (Ding and Schwendeman 2004). These byproducts 
will drop the interior pH value of submicron PLGA particles below 3, which is harmful to 
the integrity of embedded DNA molecules.  Consistent with this theory is that Kasturi et 
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al. (Kasturi, Sachaphibulkij et al. 2005) have reported superior transfection efficiency 
when plasmid DNA is carried on the exterior of PLGA particles compared to that 
encapsulated within.  
 
Fourth, submicron particles have a very large surface-to-volume ratio compared 
to larger particles. Thus, even small quantities of particles present extremely large surface 
areas available for DNA binding, allowing a large dose of plasmid DNA to translocate 
across the plasma membrane with each particle entry, and transfer from cytoplasm to 
nucleus. Additionally, rapid accumulation of plasmid DNA in the cytosol resulting from 
large surface-to-volume ratio and the endosomal escape mechanism of PSO10H6 and 
PLGAO10H6 particles provides sufficient copies of plasmid DNA to enter the nucleus 
during mitosis. This is an important factor for gene delivery because primary DCs divide 
relatively slowly in vitro.  
 
In summary, we reported in this chapter that the polycation O10H6 modified 
polymeric submicron particles (PSO10H6-pIL-10 and PLGAO10H6-pIL-10) are capable of 
facilitating plasmid DNA transfer into dendritic cells. Thus, these vectors should be 
further investigated as a means of genetically modifying DCs to suppress T cell 
responses. One of the potential advantages of these particulate vectors is they can be 
adjusted to achieve different payloads of DNA by changing the amount of O10H6 
peptide added to the particles during fabrication. Increasing amounts of O10H6 coated on 
the particles will likely to increase amount of positive charge available for DNA binding, 
thereby increasing DNA loading per particle.  
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CHAPTER 5  
SUPPRESSIVE EFFECTS OF PSO10H6-pIL-10 AND PLGAO10H6-pIL-10 
MODIFIED DENDRITIC CELLS ON T CELL RESPONSES 
 
Introduction 
IL-10 is an important cytokine with a central role in preventing damaging immune 
responses in healthy individuals. Because dendritic cells have exclusive privilege to 
initiate naïve T cell activation, induction of adaptive immune tolerance through IL-10 is 
believed to be primarily mediated by DCs (Mahnke, Johnson et al. 2007). Literature data 
suggested that IL-10 can modulate DCs to trigger T cell suppression by altering the 
expression of MHC class II and co-stimulatory molecules (Kubin, Kamoun et al. 1994; 
Willems, Marchant et al. 1994; Tong, Toshiaki et al. 2005) and modifying the release of 
pro-inflammatory cytokines from DCs (Fortsch, Rollinghoff et al. 2000). Additionally, 
IL-10 modified DCs can induce regulatory T cell expansion in allogeneic or Ag-activated 
T lymphocytes (Takayama, Nishioka et al. 1998; Zeller, Panoskaltsis-Mortari et al. 1999; 
Mahnke and Enk 2005). IL-10 secreted by DCs could also directly act on T cells and 
other APCs to induce their suppressive functions. 
 
Owing to the above reasons, IL-10 has been used to render DCs into a suppressive 
phenotype to attenuate damaging immune responses in autoimmunity, inflammation, and 
transplant rejection. Efforts have been taken to genetically modify DCs with the IL-10 
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gene to render suppressive signals in local microenvironment.  
 
We have shown in previous chapters that PSO10H6-pIL-10 and PLGAO10H6-pIL-10 
particles are effective vectors to deliver plasmid IL-10 to DCs. In this chapter, we 
evaluated the suppressive effects of PSO10H6-pIL-10 and PLGAO10H6-pIL-10 modified 
DCs on T cell responses. An in vitro mixed lymphocyte reaction (MLR) model that used 
two mouse strains (C57BL/6 and BALB/c) with mismatched class II MHC (H-2b and H-
2d) was employed to evaluate the ability of these IL-10 gene-modified DCs to stimulate 
allogeneic T cells. Additionally, an ex vivo Matrigel implant system embedded with DCs 
was used to study the ability of IL-10 gene-modified DCs to alter allogeneic immune 
responses in vivo. The hypothesis is that DCs treated with PSO10H6-pIL-10 and 
PLGAO10H6-pIL-10 particles will attenuate allogeneic T cell response in vitro and in vivo. 
The rationale is that delivery of  the IL-10 gene to DCs will increase IL-10 expression in 
the local microenvironment and alter the functionality of these DCs. Specifically, DC’s 
ability to present Ag or stimulate allogeneic T cells, as well as their characteristics of 
cytokine production could be affected. Moreover, IL-10 modified-DCs could expand 
regulatory T cells in the local microenvironment to suppress T cell responses. 
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Methods 
Enrichment of primary DCs 
DCs of C57/BL6 mice (H-2b) were generated from mouse bone marrow 
progenitors as described in the previous chapter. Cells were harvested from cultures on 
day 6, washed, and stained with anti-CD11c magnetic beads in PBS containing 2 mM 
EDTA (Figure 5.1). Stained cells were washed with separation buffer (PBS, 2 mM 
EDTA, 0.5% bovine serum albumin) and passed through MiniMACS (Miltenyi Biotec) 
columns or separated by the IMagTM system (BD Bioscience). Greater than 80% of the 
eluted population were CD11c+ cells.  
 
Mixed leukocytes cultures for T cell proliferation 
CD11c+ DCs were transfected with DNA complexes using the method described 
in the previous chapter, and cultured with fresh RPMI 1640 media containing 10% fetal 
bovine serum and GM-CSF/IL-4 (R&D Systems, Minneapolis, MN) for an additional 48 
hours. Control and transfected DCs (H-2b) were cultured with splenocytes of mismatched 
BALB/c mice (H-2d) in AIM V liquid medium (Invitrogen/Gibco) containing 10% fetal 
bovine serum and GM-CSF/IL-4 (R&D Systems, Minneapolis, MN) for 5 days at 37°C 
5% CO2. The splenocytes were passed through nylon mesh (70 micron pores) prior to the 
mixing. T cells were seeded with DC at a stimulator to responder ratio of 1:5 in 24-well 
or 96-well tissue culture plates (Costar, Cambridge, MA). T cell proliferations were 
analyzed using bulk T cell proliferation studies, and flow cytometry in CD4 and CD8 T 
cell subset proliferation studies (Figure 5.2).  
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Figure 5.1: Schematic diagram of primary DC enrichment. 
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Figure 5.2: Schematic diagram of mixed lymphocyte reaction model. 
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MTT and flow cytometry assays for T cell proliferation analysis 
In bulk T cell proliferation studies, the tetrazolium salt 3-(4,5-Dimethylthiazol-2-
yl)-2,5-diphenyl tetrazolium bromide (MTT; Cell Titers 96 kit, Promega, Madison, WI), 
which is cleaved into formazan in metabolically active cells, was added to each well and 
equilibrated for 4–6 h at 37 °C in a 5% CO2 environment. Proliferation was determined 
by colorimetric changes based on optical density measured at 590 nm using a Perkin 
Elmer microplate reader. One-way ANOVA was used to calculate statistical significance 
and pairwise comparison was determined by the Tukey–Karmer test.  
 
To quantify CD4 and CD8 subset proliferation, T cells were first stained with 1.5 
µM of carboxy-fluorescein diacetate succinimidyl ester (CFSE) (Invitrogen/Molecular 
Probes, Eugene, OR) for 8 min at room temperature followed by quenching with 50% 
fetal bovine serum. Stained cells were washed extensively with PBS containing 2% fetal 
bovine serum prior to mixing with DC. On day 5, T cells were harvested, pre-treated with 
purified Fcγ III/II receptor (BD Pharmingen, San Diego, CA) for 10 min at room 
temperature, and stained with PE-Cy5 conjugated anti-mouse CD8α and PE conjugated 
anti-mouse CD4 antibody (BD Pharmingen, San Diego, CA) and analyzed by a Beckman 
Coulter EPICS XL flow cytometer gated on live cells. Student’s t-test was used to 
evaluate statistical significance. 
 
Grafting of Matrigel seeded with allogeneic DCs 
 
Matrigel (BD Bioscience, Bedford, MA) was mixed with IL-10 transfected or 
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control DCs (0.5-1.5×106 cells) derived from BALB/c (H-2d) mice, and injected 
(subcutaneous) into C57BL/6 (H-2b) mice (Figure 5.3). Volume of injection was 
maintained at 0.4 mL in all experiments. The cell-matrix was kept on ice prior to 
injection to prevent gel from solidifying at temperature above 10 °C. Solid plugs were 
formed in the host upon injection. Matrigel plugs were retrieved 7 days post-implantation 
and cell infiltration was analyzed either by flow cytometry or live-cell confocal 
microscopy in phase contrast mode. In flow cytometry analysis, cells in Matrigel plugs 
were recovered in 1 mL recovery solution (BD Bioscience) at 4 °C for 2 hours and 
washed with PBS to remove matrix components. Single cell suspensions were analyzed 
using a Beckman Coulter EPIC XL flow cytometer. In microscopy analysis, Matrigel 
plugs were observed using the phase contrast mode of a confocal microscope with a 10× 
objective. Photos were taken at the same location of the gel in each sample, and total cell 
numbers were counted using ImageJ software.  
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Figure 5.3: Schematic diagram of DC- embedded Matrigel injection allogeneic to host 
mouse. 
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Results 
DCs modified with PSO10H6-pIL-10 elicit weak allogeneic bulk T cell 
proliferation 
We have shown that PSO10H6 and PLGAO10H6 particles successfully delivered pIL-
10 into DCs. The ability of these IL-10 gene-modified DCs to suppress T cell responses 
was further evaluated using a MLR model (Schwarz 1968), in which DCs are mixed with 
allogeneic T cells in vitro. The mismatch between MHC class II of donor DCs (H-2b) and 
TCR of recipient T cells (H-2d) will trigger T cell activation and proliferation to induce T 
cell responses. Herein we hypothesize that IL-10 gene-modified DCs is tolerogenic and 
can weaken allogeneic T-cell proliferation in vitro. In this experiment, CD11c (a marker 
of DCs)-enriched DCs from C57BL/6 mice were transfected with equal quantity of pIL-
10 using different delivery modes including free pIL-10, O10H6-pIL-10 complexes, and 
PSO10H6-pIL-10 particles. DCs exposed to PSO10H6 particles alone and left untreated 
served as control groups. After the transfection, DCs were mixed with BALB/c (H-2d) T 
cells at a stimulator to responder ratio of 1:5 (DC: T cell) and bulk T cell proliferation 
was analyzed using a tetrazolium salt MTT assay. Proliferation was quantified by 
measuring colorimetric changes in absorbance at 590 nm.  
 
Data collected from four independent experiments showed that DCs transfected 
with PSO10H6-pIL-10 particles induced significant weak allogeneic T cell proliferative 
response (58±6% of control) compared to untreated control DCs (Figure 5.4, Table 5.1), 
as shown in a one-way analysis of variance data (F = 0:0016) and Tukey–Kramer 
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pairwise comparison between PSO10H6-pIL-10 and the control group (p<0.05). 
Proliferation of T cells stimulated with DCs exposed to PSO10H6 particles alone was 
neither significantly increased nor reduced compared to untreated control DCs (106±11% 
vs. 100±8%, respectively, p>0.05). This result showed that the delivery system itself does 
not affect the functionality of DCs, and thereby the suppressive effect of PSO10H6-pIL-10 
modified DCs on T cell proliferation was not due to potential toxicities of the PSO10H6 
particle. DCs transfected with naked plasmid IL-10 and O10H6-pIL-10 showed minor 
reduction of T cell proliferation (90±6% and 81±7% of control, respectively), and the 
proliferation of T cells stimulated with O10H6-pIL-10 transfected DCs is slightly lower 
than those treated with plasmid IL-10 transfected DCs. However no statistically 
significent difference from the control group was observed in either transfection mode (p 
>0.05). PSO10H6-pIL-10 treated DCs showed lowest bulk T cell proliferation among all the 
delivery modes and is the only group that was significantly different from control DCs. 
These results support the notion that PSO10H6 particles are more efficient at gene delivery 
into DCs compared to free plasmid and other vectors such as O10H6-DNA complexes. 
The delivery of IL-10 genes into DCs by PSO10H6 elicits the weakest bulk T cell responses 
between all the delivery modes. These data suggeste that O10H6 modified polymeric 
particles were effective in transferring pIL-10 into DCs to induce suppression of immune 
responses, particularly in allogeneic T cells.   
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Figure 5.4: Proliferation of bulk T cells in response of allogeneic DCs.  DCs transfected 
with PSO10H6-pIL-10 elicit weak allogeneic T cell response. Data were averaged from 
four independent replicate experiments (n = 20-30) and error bars indicate standard error 
of mean. One-way analysis of variance data in groups was significantly different (F = 
0:0016). Pairwise comparison was performed using Tukey–Kramer method (* indicates 
p<0.05). 
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Percentage Proliferation of Bulk T cells 
 Mean SEM 
Control 100 8.05 
O10H6-pIL-10 81.17 6.27 
pIL-10 90.47 7.41 
PSO10H6 106.81 11.49 
PSO10H6-pIL-10 58.17 6.34 
 
Table 5.1: Data summary of proliferation of bulk T cells in response of allogeneic DCs. 
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DCs modified with PSO10H6-pIL-10 elicit weak proliferation in CD4 and CD8 
T cell subsets 
We have demonstrated that PSO10H6-pIL-10 modified DCs can suppress allogeneic 
bulk T cell proliferation. Effector T cells such as CD8+ and CD4+ T cells can be directly 
stimulated by allogeneic DCs driven by the interaction between MHC class II on DCs 
and mismatched TCR on T cells. Upon activation, CD4+ T cells will release pro-
inflammatory cytokine INF-γ to trigger CD8+ T cell expansion. To further evaluate the 
effect of IL-10 gene-modified DCs on these effector T cells, proliferation of CD4+ and 
CD8+ T cell subsets in the mixed lymphocyte culture was analyzed using flow cytometry 
with carboxyfluorescein succinimid ester (CFSE) staining. CFSE, an intracellular 
fluorescent dye, is transported into T cell cytoplasm during incubation and binds 
covalently to cytoplasm proteins to become membrane impermeable without adversely 
affecting cellular function. Analysis of cell division can be determined by its intensity 
when measured by flow cytometry. With each round of cell division, the fluorescent 
intensity per cell division is reduced by 50%, thus providing a measure of the mitotic 
activity within a specific population of cells. 
 
In this experiment, allogeneic T cells were mixed with CD11+ DCs that were 
transfected with an equal quantity of pIL-10 using different delivery modes including 
PSO10H6pIL-10 particles, O10H6-pIL-10 complexes and free pIL-10. Untreated DCs 
served as the control group. Results of CD8+ T cell proliferation in mixed lymphocyte 
culture are shown in Figure 5.5 and Table 5.2. The CD8+ T cell (PE-Cy5 positive) 
population was selected from the upper-left region of the PE-Cy5 vs PE dot-plot for 
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analysis (Figure 5.5A). The distribution of CFSE intensity in CD8+ T cells was displayed 
with a histogram and the population of proliferated CD8+ T cells (CFSElow) was 
determined based on the distribution of unstimulated CFSE-stained T cells in the 
histogram (Figure 5.5A).  
 
Results from three independent experiments (Figure 5.5, Table 5.2) indicated that 
DCs transfected with PSO10H6-pIL-10 particles induced significant weak proliferation of 
allogeneic CD8+ T cells compared to untreated control DCs (percentage of proliferated 
CD8+ T cells: 18.00±1.20% and 44.17±5.17%, respectively; p < 0.05 in Tukey–Kramer 
pairwise comparison). In a representative experiment (Figure 5.5A), BALB/c (H-2d) 
CD8+ T cells proliferation decreased from 41% in control (cells stimulated with 
untreated DCs) to 15% in PSO10H6-pIL-10 modified DCs. DCs exposed to O10H6-pIL-10 
and pIL-10 alone exhibited slightly lower CD8+ T cell proliferation (26% and 35%, 
respectively) in the representative experiment compared to control DCs. However, data 
combined from three independent experiments indicated no significant difference of 
CD8+ T cell proliferation from the control group in both transfection modes (Figure 5.5, 
Table 5.2, p<0.05). PSO10H6-pIL-10 treated DCs showed lowest CD8+ T cell proliferation 
among all the delivery modes and is the only group that was significantly different from 
control DCs. 
 
Results of CD4+ T cell proliferation in mixed lymphocyte culture are shown in 
Figure 5.6 and Table 5.3. The CD4+ T cell (PE positive) population was selected from 
the upper-right region of the PE-Cy5 vs. PE dot-plot for analysis (Figure 5.6A). 
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Distribution of CFSE intensity in CD4+ T cells was plotted in a histogram and the 
population of proliferated CD4+ T cells (CFSElow) was determined based on the 
distribution of unstimulated CFSE-stained T cells in the histogram (Figure 5.6B). 
Similarly, data from three independent experiments (Figure 5.6, Table 5.3) indicated that 
DCs transfected with PSO10H6-pIL-10 particles induced a significant weak proliferation of 
allogeneic CD4+ T cells compared to untreated control DCs (percentage of proliferated 
CD4+ T cells: 11.83±5.08% and 22.56±4.05%, respectively; p < 0.05 in Tukey–Kramer 
pairwise comparison). In a representative experiment (Figure 6.6), BALB/c (H-2d) CD4+ 
T cell proliferation was almost eliminated falling from 13.8% in controls (cells stimulated 
with untreated DC) to 3.8% in PSO10H6-pIL-10 transfected DCs. DCs exposed to pIL-10 
alone and O10H6-pIL-10 exhibited almost the same or slightly lower CD4+ T cell 
proliferation (13.0% and 6.5%, respectively) in the representative experiment compared 
to control DCs. However, combined data from three independent experiments showed no 
significant difference of CD4+ T cell proliferation from the control group in both 
transfection modes (Figure 5.6, Table 5.3, p>0.05). Likewise, PSO10H6-pIL-10 treated DCs 
showed the lowest CD4+ T cell proliferation among all the delivery modes and is the 
only group that was significantly different from control DCs. 
 
Again, these results support the notion that PSO10H6-pIL-10 particles are effective 
vehicles in delivering pIL-10 into DCs. The expression of IL-10 in PSO10H6-pIL-10 
modified DCs induced the suppression of allogeneic effector T cells such as CD4+ and 
CD8+ T cells. These T cell subsets play important roles in triggering T cell activation and 
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cell-mediated immune response. Thus, PSO10H6-pIL-10 modified DCs are effective in 
suppress T cell responses. 
 
We have shown that cationic peptide coated polymeric particles are more efficient 
in gene transfer to BMDCs compared to peptide-DNA complexes (Chamarthy, Jia et al., 
2004). The enhanced expression of IL-10 in PSO10H6-pIL-10 transfected DCs contributes 
to the higher T cell suppression over DCs transfected with O10H6-pIL-10. The 
submicron polymeric particles are preferentially taken up by DCs, and the backbone of 
polymeric materials provide an anchorage to further stabilize O10H6-DNA complexes on 
the particle surface.  These factors may contribute to the enhanced IL-10 expression and 
T cell suppression in polycation O10H6 modified polymeric particles compared to other 
non-particulate vectors. 
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Figure 5.5: Response of CD8+ T cell subset to DC. T cells were first stained with CSFE 
prior to mixing with CD11c-enriched DC. Cells were stained with anti-CD8 and 
analyzed using flow cytometry. Data shown represent typical proliferation profiles of T 
cells gated on CD8 positive region (A). Bar graphs depict collective analysis of three 
independent experiments (B). *p<0.05 compared to control, pIL-10, and O10H6-pIL-10 
DC. 
A 
B 
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Percentage of proliferated 
CD8+ T cells 
Relative proliferation of 
CD8+ cells Experimental 
Groups 
Mean SEM Mean SEM 
Control 44.17 5.17 1 0.12 
O10H6-pIL-10 40.69 7.12 0.92 0.16 
pIL-10 49.57 5.88 1.12 0.13 
PSO10H6-pIL-10 18.00* 1.20 0.41* 0.03 
 
Table 5.2: Data summary of the response of the CD8+ T cell subset in response of 
allogeneic DCs. *p<0.05 compared to control, pIL-10, and O10H6-pIL-10 DCs. 
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B 
A 
Figure 5.6: Response of CD4+ T cell subset to DC. T cells were first stained with CSFE 
prior to mixing with CD11c-enriched DC. Cells were stained with anti-CD4 and 
analyzed using flow cytometry. Data shown represent typical proliferation profiles of T 
cells gated on CD8 positive region (A). Bar graphs depict collective analysis of three 
independent experiments (B). *p<0.05 compared to control, pIL-10, and O10H6-pIL-10 
DC. 
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Percentage of proliferated 
CD4+ T cells 
Relative proliferation of 
CD4+ cells Experimental 
Groups 
Mean SEM Mean SEM 
Control 22.56 4.50 1 0.21 
O10H6-pIL-10 25.79 12.48 1.14 0.55 
pIL-10 27.96 7.45 1.24 0.33 
PSO10H6-pIL-
10 11.83* 5.08 0.52* 0.03 
 
Table 5.3: Data summary of the response of the CD4+ T cell subset in response of 
allogeneic DCs. *p < 0.05 compared to control, pIL-10, and O10H6-pIL-10 DC. 
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 Ex vivo IL-10 gene-modified DCs suppress host cell infiltration  
We have shown that PSO10H6-pIL-10 transfected DCs suppressed responses in 
both bulk allogeneic T cells and CD4+, CD8+ effector T cells in vitro. It is important to 
know whether a correspondent suppression of T cell responses could be observed in vivo. 
To determine if PSO10H6-pIL-10 modified DCs could alter the immune response in vivo, 
we employed an ex vivo DC transfection model that utilizes Matrigel (BD Bioscience, 
Bedford, MA) as a scaffold to establish a surrogate ‘‘graft’’ in allogeneic mice. Matrigel, 
which solidifies at a temperature above 10 ˚C has been used extensively as a matrix 
scaffold for implanting tissues in vivo (Shih and Towle 1995; Edamura, Ohgawara et al. 
2001; Zimmermann, Didie et al. 2002; Zimmermann, Melnychenko et al. 2004; Bharat, 
Benshoff et al. 2005). Matrigel consists primarily of laminin, collagen IV, and growth 
factors (Kleinman, McGarvey et al. 1982) that can support cell attachment, infiltration 
and differentiation in various lineages. In this dendritic cell transplant study, DCs from 
BALB/c (H-2d) mice were transfected ex vivo with PSO10H6-pIL-10 or PLGAO10H6-pIL-10 
particles and then mixed with Matrigel and injected (subcutaneous) into C57BL/6 (H-2b) 
mice to form a surrogate graft. Seven days after implantation, Matrigel plugs were 
retrieved and host cell infiltration was analyzed using either flow cytometry or 
microscope imaging analysis.  
 
Figure 5.7 is representative of four independent flow cytometry experiments from 
Matrigel plugs embedded with PSO10H6-pIL-10 transfected DCs and untransfected control 
DCs. Data from the dot-plots (“FF”-forward scan and “SS”-side scan) of recovered cells 
coming from Matrigel samples embedded with control DCs (Figure 5.7a, b) indicated that 
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host cells were infiltrated into the plug 7 days after implantation. Approximately 9/10 less 
cells (Figure 5.7c) were detected using flow cytometry in Matrigel samples seeded with 
PSO10H6-pIL-10 modified DCs at day 7 compared to samples seeded with control DCs 
(Figure 5.7b). These data showed that PSO10H6-pIL-10 modified DCs reduced allogeneic 
host cell infiltration into graft tissue in vivo compared to untransfected control DCs.  
 
The same experiment was performed using Matrigel embedded with PLGAO10H6-
pIL-10 modified DCs as the implant plug. Host cell infiltration was evaluated under a 
confocal microscope in phase contrast mode. Figures 5.8 are the microscope images 
taken from the central area of Matrigel implant plugs seeded with untransfected control 
DCs (Figure 5.8a), and PLGAO10H6-pIL-10 modified DCs (Figure 5.8b) under the same 
magnifying power. Numbers of infiltrated host cells were quantified using ImageJ 
software. Consistent with the results from PSO10H6-pIL-10 modified DCs, the PLGAO10H6-
pIL-10 transfected DCs hampered allogeneic host cell infiltration into graft Matrigel in 
vivo: approximately 53% less cells infiltrated in to Matrigel seeded with PLGAO10H6-pIL-
10 modified DCs compared to Matrigel seeded with control DCs 7 days after 
implantation (Figure 5.8).  
 
Taken together, data presented in this section demonstrate that both PSO10H6-pIL-
10 and PLGAO10H6-pIL-10 modified DCs can reduce allogeneic host cell infiltrations in 
an ex vivo Matrigel implant model. The results indicated that a suppress phenotype exists 
in these IL-10 gene-modified DCs with increasing IL-10 expression, which may play a 
critical role in hampering allogeneic host cell infiltration in the local microenvironment. 
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This was in consistence with the data from the in vitro mixed lymphocyte model, in 
which suppressive functionality of IL-10 gene- modified DCs was observed.  
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Figure 5.7: Flow analysis of host cell infiltration into Matrigel. Flow plots from Matrigels 
embedded with untransfected DCs recovered from host 1 day (a) and 7 days (b) after 
injection; Matrigel embedded with PSO10H6 -pIL-10 DCs 7 days after injection. JB6, an 
epithelial cell line, and bone marrow-derived DC, both generated from BALB/c mice (H-
2d) were implant into C57BL/6 mice to elicit host cell infiltration. JB6 and DC, untreated 
(a, b) or transfected with PSO10H6 -pIL-10 (c), were mixed with Matrigel on ice and 
injected into flanks (subcutaneous space) of C57BL/6 (H-2b) host. Matrigel, which 
solidifies at temperature above 10 ºC, forms plugs once injected in the recipient mice. 
Plugs were retrieved from mice 7 days after implantation and associated cells were 
recovered in BD recovery solution on ice with gentle shaking for 2 h. Released cells were 
then washed and analyzed using flow cytometry. Result is a representative of four 
independent experiments. FS: forward scan; SS: side scan. 
 - 128 - 
Figure 5.8: Confocal images of host cell infiltration into Matrigel embedded with 
PLGAO10H6-pIL-10 transfected and control DCs. Bone marrow-derived DC generated 
from BALB/c mice (H-2d) were implant into C57BL/6 mice to elicit host cell 
infiltration. DC, untreated (a) or transfected with PLGAO10H6 -pIL-10 (b), were mixed 
with Matrigel on ice and injected into flanks (subcutaneous space) of C57BL/6 (H-2b) 
host. Matrigel, which solidifies at temperature above 10 ºC, forms plugs once injected 
in the recipient mice. Plugs were retrieved from mice 7 days after implantation and 
gel image were taken under confocal microscope in phase contrast mode. Numbers of 
host cell infiltration were analyzed using ImageJ software (a: 549; b: 259). 
(a) Host cell infiltration in Matrigel 
with control DCs 
(b) Host cell infiltration in Matrigel 
with PLGAO10H6-pIL-10 transfected 
DCs 
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Discussion 
In the research presented in this chapter, we evaluated the immune suppressive 
effects of DCs modified with pIL-10 loaded on O10H6 coated polymeric particles 
(PSO10H6-pIL-10 and PLGAO10H6-pIL-10). IL-10 is a pleiotropic cytokine that has been 
demonstrated to induce adaptive immune tolerance. DCs were chosen as a target for IL-
10 delivery because of their key role in activating T cell responses. Data from previous 
chapters indicated that both PSO10H6 and PLGAO10H6 particles are efficient carriers of 
plasmid DNA, capable of increasing IL-10 gene expression in DCs about two-fold over 
free IL-10 plasmid. Herein we evaluated the ability of PSO10H6-pIL-10 and PLGAO10H6-
pIL-10 modified DCs to suppress T cell responses. An in vitro mixed lymphocyte model 
that uses DCs (C57BL/6) to stimulate T cells from a different strain (BALB/c) was 
chosen to evaluate the suppressive function of IL-10 gene-modified DCs. This is because 
the mismatch between MHC class II on DCs (H-2b) and allogeneic T cell (H-2d) triggers 
T cell proliferation and DCs contributes to a large part of this kind of response (Steinman 
1991). Proliferation of bulk T cells as well as CD8+ and CD4+ subsets was measured as 
the quantitative indicator of T cell activation. The results presented in this chapter 
supported the hypothesis that PSO10H6-pIL-10 and PLGAO10H6-pIL-10 modified DCs can 
attenuate allogeneic T lymphocyte response in vitro and in vivo, indicating that IL-10 
gene modification can modulate DCs into suppressive phenotype. These data also 
suggested that PSO10H6-pIL-10 and PLGAO10H6-pIL-10 are more effective in modulating 
DC functions compared to other non-particulate vectors, indicating that polycation 
O10H6 modified polymeric particles are effective tools for genetically modifying DCs 
with therapeutic genes.    
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In addition, we employed a cell transplant model that utilizes Matrigel seeded 
with ex vivo pIL-10 modified DCs from BALB/c (H-2d) mice as a scaffold to establish 
surrogate ‘‘graft’’ in C57BL/6 (H-2b) mice. The immune response from the recipient was 
evaluated by analyzing host cell infiltration into the graft plug 7 days after implantation. 
Expectedly, Our result confirmed that both PSO10H6-pIL-10 and PLGAO10H6-pIL-10 
modified DCs attenuated allogeneic host cell infiltration into graft plugs in vivo, which is 
in agreement with suppression of T cell proliferation when they are exposed to PSO10H6-
pIL-10 modified DCs in vitro. The effect may result from the following mechanisms: 
First, donor DCs without IL-10 modification will trigger host allogeneic T cell activation 
and secretion of chemokines and pro-inflammatory cytokines including GM-CSF, IL-2, 
IFN-γ, and TNF-α for the recruitment and activation of other effectors (e.g macrophages, 
NK cells, and CD8+ T cells), leading to host cell infiltration. However, PSO10H6-pIL-10 
and PLGAO10H6-pIL-10 modified DC present suppressive phenotype in vivo and may 
suppress allogeneic T-cell recognition and response to deter infiltration of host T cells in 
the local microenvironment (Thomson 2002). Second, IL-10 gene-modified DCs may 
induce and expand regulatory T cells (Wakkach, Fournier et al. 2003) in vivo to suppress 
T cell activation and trafficking into the plug. Third, IL-10 gene-modified DCs may 
traffic to draining lymph nodes to induce the expansion of specific Treg cells. 
Additionally, IL-10 itself has also been shown to prevent APC accumulation (Qin, Noffz 
et al. 1997), thus expression of IL-10 in the local microenvironment may limit host DCs 
and macrophages to elicit indirect recognition mechanisms. 
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The use of polycation O10H6 modified polymeric particles (e.g. PSO10H6 and 
PLGAO10H6) for intracellular delivery of oligonucleotide and plasmid DNA has been 
broadly explored in our lab (Kovacs, Zheng et al. 2005; Jia, Kovacs et al. 2006; Zheng, 
Kovacs et al. 2006; Jia, Kovacs et al. 2008). Potentially, these particulates could be 
administered in vivo to deliver DNA therapeutics (e.g. NF-κB decoy oligonucleotide, 
plasmid IL-10) to DCs to modulate immune functions with the following advantages: 
First, particles can be taken up preferentially by DCs, thereby targeted distribution of 
delivered oligonucleotide and DNA molecules in those cells can be increased; Second, 
because of their particulate nature and the submicron size, those polymeric vectors are 
likely to gain access to draining lymph nodes, where DCs prime Ag-specific T cells. It 
has been reported that particles from 20 nm to 400 nm in diameter are accumulated in 
draining lymph nodes upon injection (Manolova, Flace et al. 2008), suggesting that those 
polymeric particles can directly act on DCs located in these tissues and alter their 
interaction with effector T cells.  
 
Alternatively, these polymeric particles can be used for ex vivo gene transfer to 
DCs. Specifically, ex vivo delivery of plasmid IL-10 loaded on O10H6 modified 
polymeric particles to donor DCs could induce their suppressive functionality, thereby 
reducing the risk of graft rejection from host immune system. It was reported that ex vivo 
transfection of suppressive gene to donor tissue could decrease the risk of transplant 
rejection in a variety of tissue grafts including lung and islet (Yano, Mora et al. 1999; 
Akamaru, Ito et al. 2003). The triggering of transplant rejection involves the recognition 
of MHC-derived antigens on the donor DCs by host T cells designated as direct pathway, 
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and the recognition of donor MHC products by host antigen presenting cells designated 
as indirect pathway. The former plays a role in acute rejection and the later contribute to 
chronic rejection. Thus DCs in donor tissues could be an effective target for gene therapy 
to suppress T cell response in acute transplant rejection. IL-10 has been demonstrated to 
affect chronic allograft changes and systemically administrated IL-10 was studied as a 
treatment for prolonging transplant survivals in different animal models (Hong, Mullen et 
al. 2003; Zhang, Pileggi et al. 2003; Martins, de Perrot et al. 2004; Carter, Ellett et al. 
2005; Chen, Kapturczak et al. 2007). Therefore, ex vivo targeting delivery of IL-10 gene 
to donor DCs could reduce recipient T cell response to donor organs, and subsequently 
reduce the risk of transplant rejection. 
 
In conclusion, the abilities of PSO10H6-pIL-10 and PLGAO10H6-pIL-10 modified 
DCs to attenuate immune response in vitro and in vivo are confirmed in the data 
presented in this chapter. A Matrigel system embedded with ex vivo transfected DCs 
provides an opportune setting for studying alloreactivity of ex vivo-modified DC in vivo. 
An advantage is the number of donor cells in the implant can be controlled, leading to 
reproducible inflammation. These polymeric particulates could be further investigated in 
their ability to suppress excessive immune reactions in autoimmune diseases, 
inflammation, and transplant rejections. 
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CHAPTER 6  
IMMUNOSUPPRESSIVE MECHANISMS OF DENDRITIC CELLS 
MODIFIED WITH PSO10H6-pIL-10 AND PLGAO10H6-pIL-10 PARTICLES 
  
Introduction 
Dendritic cells are being considered as a therapeutic means of attenuating 
damaging immune responses in autoimmune diseases and transplant rejections. Efforts 
have been taken to genetically render DCs into tolerogenic phenotypes with IL-10 gene 
to suppress lymphocyte activation and proliferation in locales where these cells are 
programmed (Kubin, Kamoun et al. 1994; Willems, Marchant et al. 1994; Tong, Toshiaki 
et al. 2005). It was also demonstrated in our lab that DCs modified with synthetic vectors, 
PSO10H6-pIL-10 and PLGAO10H6-pIL-10 suppressed allogeneic T cell response in vitro and 
host cell infiltration in a MHC-mismatched graft model in vivo.  
 
The ability of DCs to induce adaptive immune tolerance have been extensively 
investigated in recent years (Lu and Thomson 2002; Slavin, Tarner et al. 2002; Kubach, 
Becker et al. 2005) and the following mechanisms have been proposed for the 
suppressive effect of IL-10 modified DCs.  First, it was demonstrated in earlier studies 
(Kubin, Kamoun et al. 1994; Willems, Marchant et al. 1994; Tong, Toshiaki et al. 2005) 
that IL-10 suppresses antigen presenting functions of DCs by down-regulating their 
surface expression of B7 co-stimulatory molecules (e.g. CD80 and CD86). However, 
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other studies suggested that depending on the model system employed, expression of 
CD80 and CD86 could also be unchanged or up-regulated in IL-10 modified DCs (Enk, 
Angeloni et al. 1993; Mitra, Judge et al. 1995; Morel, Quaratino et al. 1997; Sharma, 
Stolina et al. 1999; Faulkner, Buchan et al. 2000). Therefore, other mechanisms exist for 
modulating the suppressive functionality of DCs. Second, IL-10 modified DCs could 
regulate the secretion of Th1 cytokines (e.g. IL-12, IFN-γ, and TNF-α) from DCs and T 
cells (Fortsch, Rollinghoff et al. 2000). These cytokines stimulate or synergize the 
activation and proliferation of immune effector T cells. Third, immunosuppression by IL-
10 modified DCs often develops concomitantly with an expansion of CD4+ regulatory T 
cells (Takayama, Nishioka et al. 1998; Zeller, Panoskaltsis-Mortari et al. 1999; Mahnke 
and Enk 2005), even at their fully matured state (B7high). These Treg cells are marked by 
constitutive expression of CD25 on cellular membrane and intracellular Foxp3, the 
master transcriptional regulator constitutively and exclusively expressed in these cells 
(Hanck, Glatzel et al. 2000). Functionally, Treg cells are characterized by the capacity to 
restrain proliferation and cytotoxic activity of effector T cells. Because of the potential of 
Treg cells to curtail damaging immune responses toward auto- and alloantigens, the 
ability to induce or expand Foxp3-expressing Treg cells has emerged as a key measure of 
the tolerogenic propensity of DCs (Lu, Lee et al. 1999; Thomson 2002).  
   
In the work presented in this chapter, we examined the functional utility of 
PSO10H6-pIL-10 and PLGAO10H6-pIL-10 modified DCs (H-2b) that are immunosuppressive 
in cultures mixed with lymphocyte from MHC-mismatched mice (H-2d). The hypothesis 
is the suppressive functionality of these IL-10 gene-modified DCs is related to the 
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expansion of allogeneic regulatory T cell populations. Other mechanisms including 
alteration of co-stimulatory molecules and Th1 cytokine secretion from DCs may also 
contribute to the suppressive phenotypes of these cells. 
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Methods 
Mixed leukocytes cultures 
In order to explore the immunosuppressive mechanism of IL-10 modified DCs, a 
mixed leukocyte culture between MHC miss matched mice was performed as described 
in the previous chapter. In brief, CD11c+ DCs from C57BL/6 (H-2b) mice were 
transfected with PSO10H6-pIL-10 or PLGAO10H6-pIL-10 particles at day 6 of DC culture. 
After two days, control or pIL-10 transfected DCs were mixed with splenocytes of 
BALB/c mice (H-2d) after passing through nylon mesh (70 mm pores) at a stimulator to 
responder ratio of 5:1.  Expansion of regulatory T cells, secretion of cytokines and 
chemokines in DC-T cell co-cultures were quantified using Foxp3 RT-PCR and 
ELISA/cytokine microarray analysis, respectively. 
 
Flow cytometry analysis of CD80 and CD86 expression on PSO10H6-pIL-10 or 
PLGAO10H6-pIL-10 transfected DCs 
DCs from C57BL/6 (H-2b) mice were transfected with PSO10H6-pIL-10 or 
PLGAO10H6-pIL-10 particles at day 6 of DC culture using the method described in 
Chapter 5. Two days after transfection, DCs were harvested and stained with PE-
conjugated anti-CD80 or PE-conjugated anti-CD86 antibody (BD Pharmingen) on ice 
and analyzed by a Beckman Coulter EPICS XL flow cytometer gated on live cells. 
Student’s t-test was used to evaluate statistical significance.  
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Foxp3 RT-PCR analysis 
Two days after mixing IL-10 modified DCs (H-2b) with splenocytes (H-2d), cells 
were harvested and stained with anti-CD4 magnetic beads (BD BioScience, San Jose, 
California) in PBS. The cell suspension was then washed with separation buffer (PBS, 2 
mM EDTA, 0.5% bovine serum albumin) and CD4+ T cells were selected using an 
IMagTM cell separation system (BD Bioscience, San Jose, CA). Total RNA from the 
CD4+ T cells was then isolated by SV total RNA isolation kit (Promega, Madison, WI). 
0.5 mg of this RNA was amplified using One-Step Eppendorf Master RT plus PCR kit 
(Eppendorf, Hamburg, Germany) in an Eppendorf MasterCycler. Primer pairs specific for 
murine Foxp3 (SuperArray Bioscience, Frederick, MD) and β-actin (R&D Systems, 
Minneapolis, MN) were added to the RNA sample in reverse transcription (50 °C for 50 
min) step, followed by denaturation (94 °C for 4 min). The amplification steps consisted 
of 35 cycles of template denaturation (94 °C for 45 s), primer annealing (55 °C for 45 s) 
and primer elongation (68 °C for 45 s). PCR products were analyzed in 2% agarose gel 
and DNA visualized by ethidium bromide staining.  
 
Cytokines array and ELISA 
The amount of INF-γ and TGF-β produced in DC-T cell co-cultures were 
analyzed by DuoSet Enzyme-Linked ImmunoSorbent Assay (ELISA) kits (R&D 
Systems, Minneapolis, MN) and Emax ImmunoAssay System (Promega, Madison, WI) 
in a 96 well plate according to manufacturers’ protocols, respectively. Expression of 
other cytokines and chemokines (IL-10, G-CSF, M-CSF, IL-1α, IL-2, IL-3, IL-4, IL-5, 
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IL-6, IL-12, IL-13, INF-γ, TNF-α, GM-CSF, VEGF, MIG, Rantes and MCP-1α) were 
analyzed using TranSignalTM mouse cytokine antibody arrays (Panomics, Redwood City, 
CA). Cell culture supernatant was cleared by centrifugation and stored at -80°C until 
analysis. Samples were analyzed following manufacture’s protocol. ELISA assay 
samples were read using a microplate reader at 450 nm in a 96-well plate. Data were 
fitted into a standard curve and concentrations of INF-γ and TGF-β for the samples were 
then calculated based on the standard curve. In cytokine array analysis, 
chemiluminescence signals from each spot on the membrane were captured using a 
Kodak image station and relative signal intensities were quantified using ImageJ 
software.  
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Results 
PSO10H6-pIL-10 or PLGAO10H6-pIL-10 modified DCs induce allogeneic 
regulatory T cell expansion 
 To evaluate the effect of IL-10 modified DCs on allogeneic regulatory T cell 
expansion, BMDCs from C57BL/6 mice (H-2b), transfected with PSO10H6-pIL-10 or 
PLGAO10H6-pIL-10 were mixed with allogeneic splenocytes containing T cells and NK 
cells from BALB/c mice (H-2d). Foxp3 was amplified using RT-PCR method to 
characterize Treg cells population in the DC-T cell co-culture. β-actin was also amplified 
as a control gene for semi-quantitative analysis purpose. Untransfected BMDCs were 
used as a control mode in the mixed lymphocyte culture to evaluate the effect of IL-10 
gene-modification of DCs on Treg cell expansion in the co-culture.  
 
Figure 6.1 and Table 6.1-2 are the results of Foxp3 gene expression in 
allogeneic T cells exposed to PSO10H6-pIL-10 and PLGAO10H6-pIL-10 modified DCs 
(Figure 6.1, Table 6.1-2). Bands shown in those figures were consistent with predicted 
PCR products of Foxp3 (221 bp) and β-actin (302 bp), respectively. The intensity of the 
band reflected the amount of mRNA expressed. The results demonstrated that Foxp3 
expression in allogeneic splenocytes cultured with PSO10H6-pIL-10 modified DCs was up-
regulated compared to T cells exposed to control untransfected DCs (Figure 6.1a, Table 
6.1). Gene expression was semi-quantified by normalizing the intensity of Foxp3 band to 
the corresponding β-actin band (Foxp3/ β-actin) and data obtained from two independent 
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experiments showed a more than one fold increase of Foxp3 expression in allogeneic T 
cells exposed to PSO10H6-pIL-10 modified DCs.  
 
Similarly, allogeneic T cells exposed to PLGAO10H6-pIL-10 modified DCs 
expressed higher levels of Foxp3 compared to these cells cultured with control 
untransfected DCs as shown in the gel electrophoresis analysis of the intensity of final 
RT-PCR products (Figure 6.1b, Table 6.2). Semi-quantitative analysis of Foxp3 gene 
expression from two independent experiments indicated Foxp3 was up-regulated at least 
one fold in allogeneic splenocytes exposed to PLGAO10H6-pIL-10 DCs compared to the 
one mixed with control DCs. 
 
Regulatory T cells are capable of suppressing proliferation and cytotoxic activity 
of effector T cells (CD4 and CD8) through contact dependent or independent manner. 
These results demonstrated that Foxp3, the master transcriptional gene constitutively and 
exclusively expressed in mouse Treg cells, were up-regulated in T cells stimulated with 
PSO10H6-pIL-10 and PLGAO10H6-pIL-10 modified DCs, indicating that these IL-10 gene-
modified DCs can expand allogeneic regulatory T cell population in vitro. This 
mechanism contributes to the immunosuppressive phenotypes of DCs modified with pIL-
10 loaded O10H6 modified polymeric particles. 
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Figure 6.1: Foxp3 mRNA expression in allogeneic T cells stimulated with DCs 
transfected with PSO10H6-pIL-10 (a) and PLGAO10H6-pIL-10 (b). Untransfected DCs were 
used as the control. Bands identified were consistent with predicted PCR products of 
Foxp3 (left two lanes) and β-actin at 221 and 302 bp, respectively. 
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Relative Foxp3 expression  
Mean SEM 
PSO10H6-pIL-10 
transfected DCs  
0.82 0.08 
Control DCs 0.46 0.06 
 
 
Table 6.1: Summary of Foxp3 expression in T cells conditioned by PSO10H6-pIL-10 
transfected and control DCs. Data were obtained from two independent experiments 
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Relative Foxp3 expression  
Mean SEM 
PLGAO10H6-pIL-10 
transfected DCs  
1.03 0.09 
Control DCs 0.48 0.01 
 
Table 6.2: Summary of Foxp3 expression in T cells conditioned by PLGAO10H6-pIL-10 
transfected and control DCs. Data were obtained from two independent experiments 
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Expression of B7 molecules in IL-10 gene-modified DCs 
Co-stimulatory molecules (B7, e.g. CD80, and CD86) which are up-regulated on 
mature DCs trigger the secondary signal between DCs and T cells, which is critical for 
Ag-specific or allogeneic T cell activation (Zhou and Tedder, 1995; Banchereau and 
Steinman, 1998). To evaluate the expression of B7 molecules, DCs were stained with PE-
conjugated anti-CD80 or PE-conjugated anti-CD86 antibody (BD Pharmingen) two days 
after IL-10 transfections with PSO10H6-pIL-10 and PLGAO10H6-pIL-10 particles. The 
frequency of CD80 and CD86 on these cells was analyzed using a Beckman Coulter 
EPICS XL flow cytometer. 
  
Our data indicated no changes in CD80 and CD86 expression when DCs were 
transfected with PSO10H6-pIL-10 (Figure 6.2a-b, solid line) compared to untransfected 
control DCs (Figure 6.2a-b, dashed line) in a representative experiment. Comparison of 
positive fractions from three independent experiments (Figure 6.2c, Table 6.3) using 
student’s t-test (two-tailed, equal variance) showed no significant difference in PSO10H6-
pIL-10 transfected DCs versus control DCs (CD80, p=0.5; CD86, p=0.5). In DC 
transfected with PSO10H6-pIL-10, 71.6% (±1.4) were stained positive for CD80 and 73.8% 
(±2.8) for CD86, while approximately the same fractions of control DCs expressed these 
molecules (CD80 = 70.2 ± 1.5%, CD86 = 72.2 ± 2.9%).  
 
Likewise, DCs transfected with PLGAO10H6-pIL-10 (Figure 6.3a-b, solid line) 
express similar levels of CD80 and CD86 compared to control cells (Figure 6.3a-b, 
dashed line). Comparison of positive fractions of B7 molecules from three independent 
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experiments (Figure 6.3c, Table 6.4) using student’s t-test (two-tailed, equal variance) 
showed no significant difference (CD80, p = 0.7; CD86, p=0.2) in PLGAO10H6-pIL-10 
transfected DCs (CD80 = 54.8 ± 1.4%, CD86 = 54.2 ± 2.0%) versus control DCs (CD80 
= 51.5 ± 3.3%, CD86 = 52.0 ± 5.1%).  
 
These results indicate that PSO10H6-pIL-10 and PLGA O10H6-pIL-10 particles do 
not affect CD80 and CD86 expression in DCs. Thus, the immunosuppression mechanism 
of these IL-10 gene-modified DCs is not related to the modulation of co-stimulatory 
pathways based on the data presented in this section. Additionally, we believe that those 
two polymers can be used as carriers for the delivery of immunosuppressive agents, 
because no up-regulation of B7 was found in DCs exposed to PSO10H6-pIL-10 and PLGA 
O10H6-pIL-10,  
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Figure 6.2: Expression of CD80 (a) and CD86 (b) in DCs transfected with PSO10H6-
pIL-10. Stained control DCs are indicated as dashed line and transfected DCs are 
shown as solid black line. Unstained DCs (grey solid line) were included as baseline; 
(c) and (d) show expression of CD80 and CD86, respectively, in stained control DCs 
(dashed line) and in DCs transfected with PLGAO10H6-pIL-10 (black solid). 
Histograms shown are representative of analysis of three independent DCs cultures. 
Student’s t-test (two-tailed, equal variance) comparison of positive fractions indicates 
no significant difference in PSO10H6-pIL-10/DCs versus control DCs (CD80, p = 0.2; 
CD86, p = 0.5)  
CD80 CD86 
a b 
c  
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Percentage of CD80+ 
DCs 
Percentage of CD86+ 
DCs 
 
Mean SEM Mean SEM 
Control DCs 70.8 1.5 72.2 2.9 
PSO10H6-pIL-10 
transfected DCs 71.6 1.4 73.8 2.8 
 
Table 6.3: CD80 and CD86 expression in control DCs and PSO10H6-pIL-10 transfected 
DCs. Data were obtained from three independent experiments (p=0.2).  
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CD80 CD86 
Figure 6.3: CD80 (a) and CD86 (b) in DCs transfected with PSO10H6-pIL-10. Stained 
control DCs are indicated as dashed line and transfected DCs are shown as solid black 
line. Unstained DCs (grey solid line) were included as baseline; (c) and (d) show 
expression of CD80 and CD86, respectively, in stained control DCs (dashed line) and 
in DCs transfected with PLGAO10H6-pIL-10 (black solid). Histograms shown are 
representative of analysis of three independent DCs cultures. Student’s t-test (two-
tailed, equal variance) comparison of positive fractions indicates no significant 
difference in PLGAO10H6-pIL-10 versus control DCs (CD80, p = 0.7; CD86, p=0.2) 
a b  
c 
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CD80 CD86 
 
Mean SEM Mean SEM 
Control DCs 51.5 3.3 52.0  5.1 
PLGAO10H6-pIL-10 
transfected DCs 54.8 1.4 54.2  2.7 
 
Table 6.4: CD80 and CD86 expression in control DCs and PLGAO10H6-pIL-10 transfected 
DCs. Data were obtained from three independent experiments (p=0.2). 
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Altered cytokine production in allogeneic T cells stimulated with IL-10 gene-
modified DCs 
The cytokine environment in which DCs and T cells interacted reflects the 
dominant immunological drive. To further evaluate the immune suppressive mechanism 
of IL-10 gene-modified DCs, we examined the secretion of cytokines and chemokines in 
the PLGAO10H6-pIL-10 transfected DC (C57BL/6) and allogeneic T cell (BALB/C) co-
culture in which expansion of Foxp3 expression was noted. To profile the expression of 
multiple cytokines and chemokines in the co-culture, an array system (Panomics 
TranSignalTM Arrays, Redwood City, CA) utilizing a membrane spotted with antibodies 
that capture a variety of protein analytes (IL-10, G-CSF, M-CSF, IL-1α, IL-2, IL-3, IL-4, 
IL-5, IL-6, IL-12, IL-13, INF-γ, TNF-α, GM-CSF, VEGF, Monokine Induced by Gamma 
interferon [MIG], Rantes and Macrophage Inflammatory Proteins [MCP-1α]) were used. 
Those cytokines and chemokines play key roles in the maturation of effector cells and 
activation of immune response. Compared with the conventional ELISA essay, the array 
method, which detects the presence of analytes by chemiluminescence, can sensitively 
and accurately characterize multiple cytokines and chemokines in a single experiment.  
 
Data obtained from cultures containing PLGAO10H6-pIL-10 modified DCs were 
compared with those from untransfected DCs to evaluate the effect of IL-10 gene-
modification on DC cytokine secretion. Results from cytokine microarray analysis were 
obtained from two independent experiments and the relative level of cytokine expression 
in the DC: T cell co-culture was indicated as the percentage of positive control signal 
(Figure 6.4a). The result showed no significant changes in the levels of IL-1α, IL-2, IL-3, 
 - 151 - 
IL-4, IL-6, IL-12, IL-13, TNF-α, INF-γ, G-CSF, MIG, and Rantes between the 
supernatants from cultures containing PLGAO10H6-pIL-10 modified DCs and control 
untransfected DCs. IL-1α, IL-2, IL-3, IL-6, IL-12, TNF-α, INF-γ and G-CSF are pro-
inflammatory cytokines whose function includes activating effector T cells, promoting T 
cell differentiation and proliferation, and inducing inflammation. MIG and Rantes are 
chemokines that promote leukocyte trafficking and recruitment to inflammatory sites. IL-
4 and IL-13 are anti-inflammatory cytokines because of their ability to suppress Th1 
response and down-regulate IL-1 and TNF-α. The result showed that IL-10 gene 
modification in DCs does not decrease major pro-inflammatory cytokine and chemokine 
production in DC : T cell co-culture. Additionally, anti-inflammatory cytokines were not 
up-regulated in the co-culture. These results indicated that immunosuppressive function 
of PLGAO10H6-pIL-10 modified DCs was not related to the alteration of the production of 
these pro- and anti-inflammatory cytokines, which affect Th1 response as well as T cell 
trafficking. 
 
 Conversely, we found increase in IL-10 and IL-5 expression, and decrease in 
macrophage colony-stimulating factor (M-CSF) and granulocyte macrophage colony-
stimulating factor (GM-CSF) when T cells were stimulated with PLGAO10H6-pIL-10 
modified DCs (n = 2; Figure 6.4 a-b). IL-10 production was increased when DCs were 
transfected with PLGAO10H6-pIL-10 (p = 0.005). The up-regulation of suppressive 
cytokine IL-10, and down-regulation of pro-inflammatory cytokine M-CSF and GM-CSF 
indicated that the IL-10 gene-modified DCs display a suppressive phenotype in the co-
culture.  
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Given that TGF-β production is an important characteristic of Treg cells (Izcue, 
Coombes et al. 2006), we evaluated the expression of this cytokine using ELISA in the 
DC: T cell co-culture in which expansion of Foxp3 expression was noted. Co-culture 
with  untransfected DCs and T cells were assayed as control group to exam the alteration 
of TGF-β production. The result showed that TGF-β up-regulated four-fold in 
supernatants from T cell culture conditioned by PLGAO10H6-pIL-10 modified DCs 
(1598.23±194.22 pg/mL) compared to control DCs (357.95±102.53 pg/mL) (p = 0.001; 
Figure 6.5a). This result is in agreement with the expansion of Treg cells in mixed 
lymphocyte cultures containing IL-10 gene-modified DCs. 
 
IFN- γ is a major product of Th1 cells and plays a key role in promoting Th1 type 
immune response. Results from the cytokine array experiment showed that amount of 
INF-γ remained unchanged in the co-cultures containing PLGAO10H6-pIL-10 modified 
DCs compared to control untransfected DCs. Herein we confirmed the result of IFN- γ 
secretion in the DC: T cell co-culture using ELISA. The amount of INF-γ remained 
unchanged (p = 0.4; Figure 6.5b) in the co-cultures when PLGAO10H6-pIL-10 modified 
DCs  (423.86±41.38 pg/mL) were used as stimulators compared to control untransfected 
DCs (441.57±37.43 pg/mL). This result is consistent with the one observed in the 
cytokine array experiment, indicating that the suppressive effect of IL-10 gene-modified 
DCs was not mediated by altering the secretion of cytokines that promote Th1 response. 
 
Thus, the inhibitory cytokine TGF-β appears to dominate immune activating 
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cytokines in these cultures. These data confirmed the suppressive phenotype of IL-10 
gene-modified DCs, reconfirmed that their immunosuppressive mechanism is based on 
the expansion of regulatory T cells. 
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a  
 * 
Figure 6.4: Cytokine released in DC- allogeneic T cell co-cultures with PLGAO10H6-pIL-10 
or control DCs using TranSignal™ Arrays (Panomics). a. Cytokine levels in the co-culture 
were presented as percentages of positive control signals. Images intensity was quantified 
using the NIH Image J software. Data were averaged from two independent experiments 
performed. Error bars indicate standard error of mean. b. Images of GM-CSF, M-CSF, IL-
10, and IL-5 detected in a cytokine array membrane in one of the representative 
experiments. Statistical significance was determined using the Student’s t-test (two-tailed, 
paired-samples; *p = 0.005). 
b  
a 
 - 155 - 
TGFβ in DC-T Cell Cultures
0
250
500
750
1000
1250
1500
1750
2000
Control PLGAO10H6-pIL10/DCs
Co
n
c.
 
(pg
/m
l)
#
 
a  
 
INFγ in DC-T Cell Cultures
0
250
500
750
1000
Control PLGAO10H6-pIL10/DCs
Co
n
c.
 
(pg
/m
l)
*
 
b  
Figure 6.5: TGF-β1 (a) and INF-γ (b) ELISA. The cytokine was assayed in DC-
allogeneic T cells co-cultures with PLGAO10H6-pIL-10 transfected DCs or control DCs. 
Data were averaged from three independent experiments performed. Error bars indicate 
standard error of mean. Sensitivity of the assay was 15.6 pg/ml. Background TGF-β1 
signal from sera in culture media was subtracted. Statistical significance was determined 
using the Student’s t-test (two-tailed, paired-samples; #p = 0.001, *p = 0.4). 
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TGF-β (pg/ml) IFN-γ (pg/ml)  
Mean SEM Mean SEM 
Control DCs 357.95 102.53 441.57 37.43 
PLGAO10H6-pIL-10 
transfected DCs 1598.23
#
 194.22 423.86* 41.38 
 
Table 6.5: Summary of data from TGF-β1 and INF-γ ELISA assay. Data were averaged 
from three independent experiments performed. Statistical significance was determined 
using the Student’s t-test (two-tailed, paired-samples; #p = 0.001, *p = 0.4). 
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Discussion 
 
Previous data from our lab has shown that the PSO10H6 particle is an efficient 
vector for oligonucleotide delivery to DCs, capable of introducing NF-κB decoy 
molecules into greater than 50% of primary DC in vitro, down-regulating DC maturation 
and Th1 cytokine IFN-γ production (Kovacs, Zheng et al. 2005). IL-10 gene-modified 
DCs have promising therapeutic potentials (Mahnke, Johnson et al. 2007). We have 
shown that DCs transfected with synthetic vector PSO10H6-pIL-10 suppressed allogeneic T 
cell response in vitro and host cell infiltration into MHC-mismatched graft tissue in vivo. 
Potential immunosuppressive mechanisms of IL-10 gene-modified DCs include down-
regulation B7 co-stimulatory molecule expression, alteration of cytokine secretions, and 
up-regulation of allogeneic or Ag-specific Treg cells. In this chapter, we explored the 
suppressive functional utility of PSO10H6- pIL-10 and PLGAO10H6-pIL-10 transfected DCs 
in a mixed lymphocyte model in which T cell suppression was noted.   
 
We first examined the expansion of regulatory T cells in pIL-10 modified DC: T 
cell mixed lymphocyte cultures because of the potential of Treg cells to suppress 
damaging immune response toward auto and alloantigens. Regulatory T cells are capable 
of restraining proliferation and cytotoxic activity of effector T cells (CD4 and CD8) 
through contact dependent or independent manner. An important measure of T cell-
mediated tolerance is the expansion of Foxp3, the master transcriptional regulator 
constitutively and exclusively expressed in mouse regulatory cells (Hanck, Glatzel et al. 
2000). In our experiments, we observed up-regulation of Foxp3 expression in allogeneic 
T cells co-cultured with PSO10H6-pIL-10 or PLGAO10H6-pIL-10 gene-modified DCs, 
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indicating that both DCs render their suppressive effects through the expanding 
allogeneic regulatory T cells.  
 
Co-stimulatory molecule expression is related to the maturation functions of DCs. 
Interaction between these molecules expressed on the membrane of DCs (CD80 and 
CD86) and the T cell (CD28) is required as the secondary signal to activate Ag-specific T 
cell responses. In the literature, conflicting data are found regarding the effects of IL-10 
on B7 co-stimulatory molecules in DCs. Depending on the model system employed, 
CD80 and CD86 could be up-regulated, unchanged, or down-regulated in IL-10-
conditioned DCs (Enk, Angeloni et al. 1993; Mitra, Judge et al. 1995; Morel, Quaratino 
et al. 1997; Sharma, Stolina et al. 1999; Faulkner, Buchan et al. 2000). In this study, the 
effect of PSO10H6-pIL-10 and PLGAO10H6-pIL-10 particles on CD80 (B7.1) and CD86 
(B7.2) expression on DCs was evaluated using flow cytometry analysis. Results showed 
no significant changes in CD80 and CD86 expression on DCs transfected with PSO10H6-
pIL-10 or PLGAO10H6-pIL-10 compared to control DCs, indicating that the suppressive 
effect of IL-10 gene-modified DCs is not mediated through the changes in DC 
maturation. Additionally, because no up-regulation of B7 was found in DCs exposed to 
PSO10H6-pIL-10 and PLGA O10H6-pIL-10, we believe that those two polymers can be used 
as carriers for the delivery of immunosuppressive agents. 
 
To further evaluate the phenotypes of IL-10 gene-modified DCs, cytokine 
secretion in DC: T cell co-cultured with PLGAO10H6-pIL-10 modified or untranfected 
DCs was analyzed. Cytokines are regulators of host responses to infection, immune 
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responses, and inflammation. Depending on their role in infection and/or inflammation, 
some cytokines clearly promote inflammation and are called pro-inflammatory cytokines, 
whereas other cytokines suppress the activity of pro-inflammatory cytokines and are 
called anti-inflammatory cytokines. IL-1, up-regulated in mature DCs, are pro-
inflammatory cytokines involved in immune defense. IL-1 activates effector T cells, 
increases the expression of adhesion factors on endothelial cells to enable transmigration 
of leukocytes. IL-2 promotes the differentiation and proliferation of T cells. In addition, 
IL-2 is necessary during regulatory T cells development (Thornton and Shevach 1998; 
Thornton, Donovan et al. 2004). IL-3 is secreted by activated T cells to support growth 
and differentiation of T cells in immune response. Tumor necrosis factor-alpha (TNF-α), 
IFN-γ and IL-6 are also classified as pro-inflammatory cytokines because of their role in 
promoting T cell differentiation, NK cell activation, and neutrophil trafficking. IL-12 is a 
cytokine produced by mature dendritic cells. Its pro-inflammatory functionalities include 
promoting the differentiation of naive T cells into Th1 cells and stimulating the 
production of IFN-γ and TNF-α from T cells. MIP, secreted by macrophages, induces the 
synthesis and release of pro-inflammatory cytokines such as IL-1, IL-6 and TNF-α. IL-4 
and IL-13 are anti-inflammatory cytokines owing to their ability to suppress Th1 
response and the expression of pro-inflammatory cytokines such as IL-1, and TNF-α.  
 
Our results showed no changes in most pro-inflammatory cytokines (less than one 
fold) including IL-1α, IL-2, IL-3, IL-6, IL-12, TNF-α, INF-γ, G-CSF, MIP-1α, MIG, and 
Rantes in the supernatants from cultures containing PLGAO10H6-pIL-10 modified DCs 
compared to control DCs. Additionally, expression of IL-4 and IL-13 were also the same 
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between co-cultures containing IL-10 modified DCs and control DCs. 
 
Generally, IL-10 is considered an anti-inflammatory cytokine capable of 
suppressing TNF-α and other pro-inflammatory agents. In some experimental models, 
autocrine IL-10 showed no suppression of pro-inflammatory cytokines, which is in 
agreement with our data (Connor, Harkin et al. 2005). Strle et al.  also found in their 
model, the suppressive effect of IL-10 is not mediated by the down-regulation of 
inflammatory cytokines (TNF-α and IL-6), but rather through the interference of their 
downstream signaling, such as TNF-α-induced phosphorylation of Jun N-terminal kinase 
(Strle, McCusker et al. 2007).  
 
Among all the chemokines tested, MIG, also known as Chemokine (C-X-C motif) 
ligand 9 (CXCL9), contributes to T cell trafficking (Liao, Rabin et al. 1995). Rantes 
(CCL5) promotes the recruitment of leukocytes including T cells, eosinophils, and 
basophils into inflammatory sites. Our results showed that PLGAO10H6-pIL-10 modified 
DCs does not alter the secretion of MIG and Rantes by T cells 2 days post-treatment, 
indicating that the suppressive effect of IL-10 gene-modified DCs is not mediated 
through the interference of these chemokines in our model. Krensky et al. reported that 
CCL5 was not up-regulated in normal T lymphocytes until 3 to 5 days after their 
activation (Krensky and Ahn 2007), suggesting that longer observation period may be 
required in order to observe a change of the level of CCL5 in the co-culture. 
 
Conversely, we detected decreases in M-CSF and GM-CSF when T cells were 
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stimulated with IL-10 gene-modified DCs compared with control DCs (Figure 6.4). 
Members of the CSF cytokine family play important roles in stimulating immune cell 
activation, differentiation, and recruitment. GM-CSF, produced by activated T cells and 
macrophages, promotes Th1 immune response, allergic inflammation, and autoimmunity 
(Fleetwood, Cook et al. 2005; Cao 2007; Eksioglu, Mahmood et al. 2007). M-CSF, also 
named as CSF-1, is known for its role in promoting macrophage and T cell survival and 
proliferation, as well as enhancing functionalities of these cells (Martinez-Moczygemba 
and Huston 2003; Barreda, Hanington et al. 2004; Eksioglu, Mahmood et al. 2007). M-
CSF also up-regulates MHC class II molecule on DCs by promoting its synthesis and 
translocation to the plasma membrane. Previous studies showed that IL-10 inhibits the 
production of GM-CSF and M-CSF by monocytes (de Waal Malefyt, Abrams et al. 
1991). In agreement with this study, our result showed that both M-CSF and GM-CSF 
were suppressed in co-cultures containing PLGAO10H6-pIL-10 modified DCs compared to 
control DCs, indicating that these IL-10-gene modified DCs display a suppressive 
phenotype in the mixed lymphocyte culture.  
 
Additionally, we observed increases in IL-10 and IL-5 when T cells were 
stimulated with IL-10 gene-modified DCs compared with control DCs (Figure 6.4). IL-10 
production increased four-fold when DCs were transfected with PLGAO10H6-pIL-10. 
PLGAO10H6-pIL-10 transfected DCs could contribute to the secretion of IL-10 in the co-
culture. However, because only one in 5 cells in the culture was DCs, a major portion of 
IL-10 could come from Foxp3-expressing Treg cells, as it was demonstrated that Foxp3+ 
Treg cells secrete IL-10 (Izcue, Coombes et al. 2006; Uhlig, Coombes et al. 2006). We 
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cannot rule out, however, that other suppressor T cells (type 1 and type 3) in the system 
which might have contributed to the IL-10 pool (Liston and Rudensky 2007).  IL-5 was 
initially characterized as a Th2 cytokine that promote the growth and differentiation of 
eosinophils. IL-5 could also contributes to counter-regulating the production of Th1 
cytokines, including IFN-γ (Randolph and Fathman 2006). Recent study by Nakagome et 
al. demonstrated that IL-5 suppresses Ag-specific proliferation of CD4+ T cell in vivo 
(Nakagome, Dohi et al. 2007). Further study revealed that IL-5 plays a role in indirectly 
promoting immunosuppressive response through up-regulating TGF-β production. Thus, 
an increase of IL-5 in the co-culture may contribute to the suppressive phenotype of IL-
10 gene-modified DCs.   
 
Our data also show that suppressive cytokine TGF-β appears to dominate 
activating cytokines in these cultures, up-regulated four-fold in T cells conditioned by 
PLGAO10H6-pIL-10 modified DCs compared to control DCs. TGF-β is a pleiotropic 
cytokine with potent immunoregulatory properties and is essential for the maintenance of 
immunological self-tolerance in the CD4+ T-cell compartment (Letterio and Roberts 
1998). Studies showed that TGF-β contributed to CTLA--4-mediated T-cell inhibition 
(Shull, Ormsby et al. 1992) to IL-12-induced JAK2 and TYK2 phosphorylation kinases, 
which is associated with T-cell proliferation and IFN-γ production (Bright and Sriram 
1998).  TGF-β is also a key feature of Treg cells (Enk 2006), playing an important role in 
the conversion of naive CD4+ CD25- T cells into CD4+ CD25+ and Foxp3+ Treg cells. 
Besides, TGF-β signaling is required for the immunosuppressive capacity of CD4+ 
CD25+ Treg cells (Shull, Ormsby et al. 1992).  Thus, our result of TGF-β secretion is 
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consistent with the expansion of Treg cells. 
 
In summary, suppression of co-stimulatory molecules was not observed on IL-10 
modified DCs and among all the pro-inflammatory cytokine tested, only GM-CSF and 
M-CSF secretion were suppressed in the co-culture containing IL-10 gene-modified DCs. 
Nevertheless, emergence of Treg cells in the DC: T cell co-culture was evident in the 
generation of Foxp3-expressing CD4+ cells concomitant with elevated IL-10 and TGF-β 
production, suggesting that the suppressive effect of these IL-10 gene-modified DCs is 
mainly mediated through the expansion of allogeneic regulatory T cells. In general, our 
results establish that PSO10H6-pIL-10 and PLGAO10H6-pIL-10 modulates DCs into 
suppressive phenotypes.  
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CHAPTER 7  
SUMMARY AND ORIGINAL CONTRIBUTIONS 
 
Summary 
In this work, we investigated polystyrene and poly (lactic-co-glycolic acid) 
particles modified with the cationic peptide O10H6 as carriers to introduce a plasmid 
encoding murine interleukin-10 to dendritic cells to modulate immune functions.  
 
The delivery systems were formed by coating O10H6 on PLGA and polystyrene 
fabricated particles and their physical characteristics were evaluated. Results from 
particle size analysis showed that both PLGAO10H6-pIL-10 and PSO10H6-pIL-10 particles 
display unimodal (Gaussian) distributions in the submicron range (mean diameter 
297.2±14nm of PLGAO10H6-pIL-10 and 126.0±8nm of PSO10H6-pIL-10), indicating that 
both systems exist as uniform stable colloidal dispersions, which is preferable for DC 
uptake. Their positive zeta potential (4.7 ±0.5 mv of PLGAO10H6-pIL-10 and 31.26±2.46 
mv of PSO10H6-pIL-10) stabilize the particles in the dispersion. Gel electrophoresis 
analysis revealed that pIL-10 was condensed on the surface of PLGAO10H6 particles via 
electrostatic interaction, as evidenced by the release behavior after the addition of 
excessive amount of negatively charged low molecular weight heparin. Results from the 
serum stability study demonstrated that the O10H6 coated surface on these particles can 
bind and protect plasmid DNA molecules from serum degradation.  
 
Using confocal image analysis and reverse transcription polymerase chain 
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reaction method, we demonstrated that PSO10H6 and PLGAO10H6 particles are effective in 
delivering reporter gene pGFP as well as plasmid IL-10 to DCs. Results showed that IL-
10 gene expression was enhanced by three-fold in both PSO10H6- pIL-10 and PLGAO10H6- 
pIL-10 transfected DCs compared to control DCs.  
 
The suppression of T cell responses by IL-10 gene-modified DCs was evaluated 
using an in vitro mixed leukocyte model containing DCs and allogeneic T cells. The T 
cell response was quantified by the proliferation of allogeneic lymphocytes. Our results 
indicated that DCs transfected with PSO10H6pIL-10 and PLGAO10H6pIL-10 particles elicit 
the weakest proliferation in allogeneic bulk T cells, as well as in CD4+ and CD8+ T cells 
among other transfected DCs. Furthermore, using a cell-embedded Matrigel as a 
surrogate graft, we showed that PSO10H6pIL-10 and PLGAO10H6pIL-10 transfected DCs 
suppress allogeneic host cell infiltration in vivo compared to untransfected DCs. These 
data demonstrated that PSO10H6-pIL10 and PLGAO10H6pIL-10 transfected DCs display a 
suppressive phenotype to down-regulate allogeneic T cell responses. 
 
To further evaluate their immunosuppressive mechanisms, co-stimulatory 
molecule expression, regulatory T cell expansion and cytokine production in co-cultures 
containing IL-10 gene modified DCs and allogeneic T cells were characterized. Results 
showed that co-stimulatory molecule expression was not changed in DCs transfected with 
PSO10H6-pIL10 and PLGAO10H6pIL-10 particles. Data also demonstrated that regulatory T 
cell marker Foxp3 was up-regulated in allogeneic T cells exposed to IL-10 gene-modified 
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DCs. This result was confirmed with the elevation of TGF-β, a cytokine that plays an 
important role in regulatory T cell development.  
 
Taken together, data from this work demonstrated that O10H6 surface-modified 
PS and PLGA
 
particles are effectual vehicles to deliver IL-10 gene to DCs to induce T 
cell tolerance. The expansion of allogeneic regulatory T cells by IL-10 transfected DCs 
may lead to the down-regulation of effector T cell responses in local environments. 
Collectively, these results raise the prospect of using PSO10H6 or PLGAO10H6 as vectors to 
deliver immunosuppressive therapeutics to modulate T cell responses in vivo. 
Biodegradable PLGAO10H6 particles are the choice for treatments that require long-term 
administrations.  
 
Original Contributions 
IL-10 has been investigated in the past as a therapeutic means of attenuating 
damaging immune response. However, using polymeric particles as vectors to genetically 
modified DCs with IL-10 gene to modulate immune functions has not been examined 
extensively. This approach could potentially overcome the limitations of current IL-10 
delivery strategies, namely, short half-life of recombinant IL-10 protein when 
administrated I.V. (Moore, de Waal Malefyt et al. 2001), immunological responses 
toward viral vectors (Sen, Hong et al. 2001; Buonocore, Van Meirvenne et al. 2002), and 
inflammation associated with cationic lipids in liposomal formulations (Stamatatos, 
Leventis et al. 1988; Zelphati and Szoka 1996).   
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This work found that the immunosuppressive mechanisms of IL-10 gene applied 
to DC can be attributed to as alteration of the release of TGF-β (Pestka, Krause et al. 
2004; Kopydlowski, Salkowski et al. 1999; Kubin, Kamoun et al. 1994; Willems, 
Marchant et al. 1994; Tong, Toshiaki et al. 2005) and expansion of regulatory T cells. 
Recent studies have found that Treg cells play a critical role in inducing immune 
tolerance via restraining proliferation and cytotoxic activity of effector T cells. Our data 
emphasize the important role of Treg cells in IL-10 inducing immune tolerance, perhaps 
by increasing the local concentration of TGF-β .  
 
This work demonstrated that PS and PLGA can be used as a component of 
carriers to deliver an immunosuppressive gene to modulate immune functions. Synthetic 
polymeric particles fabricated from polystyrene and PLGA have been tested as vaccine 
carriers in animal models in the past (Fifis, Gamvrellis et al. 2004; Scheerlinck, Gloster et 
al. 2006). Minigo et al. have developed formulations made of PLL-coated polystyrene 
nanoparticles, which condense and deliver DNA vaccines to C57BL/6 mice (Minigo, 
Scholzen et al. 2007). Our work suggested that PLGA copolymers are suitable materials 
in constructing platforms to deliver genes that encoding suppressive cytokines to promote 
immune tolerance. It has been reported in literatures that the adjuvant effect of PLGA 
may hamper their use in tissue engineering or applications that promote immune 
tolerance. Some studies have shown that PLGA particles and films elicit human and 
murine DC maturation (Yoshida and Babensee 2004; Yoshida, Mata et al. 2007), 
implying that the polymer might be pro-inflammatory. Conversely, Fischer et al. have 
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demonstrated that DC phenotypes remain unchanged when exposed to PLGA and 
polyelectrolyte-coated PLGA particles (Fischer, Uetz-von Allmen et al. 2007). Although 
we did not directly address the effects of PLGA itself on DC maturation status in these 
experiments, our data do support the notion that PLGAO10H6-pIL-10 delivers an 
overriding suppressive signal to T cells. Consistent with these observations are results 
reported by Haddadi et al. showing that immunosuppressive effects of rapamycin on DCs 
are enhanced by encapsulating the drug in PLGA nanoparticles (Haddadi, Elamanchili et 
al. 2008).  
 
Several studies have shown that PLGA particles and films elicit human and 
murine DC maturation (Yoshida and Babensee 2004; Yoshida, Mata et al. 2007), 
implying that the polymer might be pro-inflammatory. This effect of polymers may be 
desired in vaccine delivery, but may not be acceptable in tissue engineering or in 
applications that promote immune tolerance. Our results showed no significant changes 
in CD80 and CD86 expression in DCs transfected with PLGAO10H6-pIL-10 as well as 
PSO10H6-pIL-10 particles. Although we did not directly address the effects of PLGA on 
DC maturation, the immune suppression data presented in this dissertation support the 
notion that PLGAO10H6-pIL-10 delivers an overriding suppressive signal to T cells, 
suggesting that PLGA are suitable materials in constructing vectors to deliver 
immunosuppressive modalities to promote immune tolerance.  
 
This work also demonstrated that the polycation O10H6 is effective in modifying 
polymeric particles for DNA binding. Conventionally, DNA can be encapsulated in 
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polymeric particles (Cohen, Levy et al. 2000). However, hydrolysis of PLGA may 
substantially decrease the pH environment in PLGA particles, potentially resulting in 
degradation of DNA (Walter, Moelling et al. 1999; Wang, Robinson et al. 1999). 
Moreover, because plasmid DNA has to diffuse through the polymer matrices, the rate of 
release is often too slow (release lasts for several days/weeks) (Walter, Moelling et al. 
1999; Tinsley-Bown, Fretwell et al. 2000; Zhu, Mallery et al. 2000; Luten, van Steenis et 
al. 2003), leading to less optimal gene expression. Surface loading of nucleic acids with 
polycation allows DNA to be protected and released inside cells without having to diffuse 
through acidic matrices, thereby increases DNA transfection efficiency. Additionally, 
surface loading of nucleic acid allows DNA to be release faster compared to 
encapsulation methods, which will result in more DNA accumulation in cytoplasm and 
more efficient gene transfer.  In this work, we employed polycation O10H6 modified 
polymeric particles loaded with pIL-10 as the delivery vector to DCs. O10H6, a cationic 
peptide that has endosomal escape mechanism, has been shown in our lab to have more 
efficient uptake by DCs and is less toxic than other PLL containing cationic peptides. The 
principal role of O10H6 is to exert a tunable DNA binding surface so that DNA can be 
loaded and protected on the particle, considering that the ionic interaction between the 
DNA and O10H6 peptide is strong enough to bind DNA. One of the potential advantages 
of these particulate vectors is they can be adjusted to achieve different payload of DNA 
by changing the amount of O10H6 peptide added to the particles during fabrication. 
Excessive amount of O10H6 coated on the particles will likely to increase amount of 
positive charge available for DNA binding, thereby increasing DNA loading per particle.  
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A cell transplant model that utilizes Matrigel seeded with ex vivo pIL-10 modified 
DCs from BALB/c (H-2d) mice as a scaffold to establish surrogate ‘‘graft’’ in C57BL/6 
(H-2b) mice. Matrigel has been used extensively as a matrix scaffold for implanting 
tissues in vivo (Shih and Towle 1995; Edamura, Ohgawara et al. 2001; Zimmermann, 
Didie et al. 2002; Zimmermann, Melnychenko et al. 2004; Bharat, Benshoff et al. 2005). 
In this system, the immune response from the recipient can be evaluated by analyzing 
host cell infiltration to the graft after implantation. This Matrigel system embedded with 
ex vivo transfected DCs provides an opportune setting for studying alloreactivity of ex 
vivo-modified DC in vivo. An advantage is the number of donor cells in the implant can 
be controlled, leading to reproducible inflammation. 
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APPENDIX 1 
 
 
Glossary 
 
 
Antigen-presenting cell (APC) : a cell that can break down protein antigens into 
peptides and present the peptides, in conjunction with major histocompatibility complex 
on the cell surface, where they can interact with T cell receptors. Professional APCs 
include dendritic cells, Macrophages, and B cells. 
 
Colloidal dispersion : A system in which particles of colloidal size of any nature (e.g. 
solid, liquid or gas) are dispersed in a continuous phase of a different composition (or 
state). 
 
Cytotoxic T cell (CTL): a sub-group of T lymphocytes with a CD8 marker that 
recognizes antigens on the surface of infected cells or tumor cells. It is capable of 
inducing the death of these infected somatic or tumor cells. 
 
Effector T cell (helper T cell) : a sub-group of lymphocytes that play an important role 
in establishing and maximizing the capabilities of the immune system by activating and 
directing other immune cells. 
 
Enzyme-linked immunosorbent assay (ELISA):. A sensitive immunoassay that uses an 
enzyme linked to an antibody or antigen as a marker for the detection of a specific 
protein. 
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Flow cytometry: a technique for counting, examining, and sorting microscopic particles 
suspended in a stream of fluid. It allows simultaneous multiparametric analysis of the 
physical and/or chemical characteristics of single cells flowing through an optical and/or 
electronic detection apparatus. 
 
Liposome : a spherical vesicle composed of a phospholipid and cholesterol bilayer. 
Liposomes contain a core of aqueous solution.  
 
Major histocompatibility complex (MHC): a group of genes that code for proteins 
found on the surfaces of cells that help the immune system recognize foreign substances. 
The proteins encoded by the MHC display both self and nonself antigens to T cell that 
has the capacity to kill or co-ordinate the killing of pathogens, infected or malfunctioning 
cells. 
 
Regulatory T cell: a specialized subpopulation of T cells that act to suppress activation 
of the immune system and thereby maintain immune system homeostasis and tolerance to 
self-antigens. 
 
Reverse transcription polymerase chain reaction (RT-PCR): a sensitive method for 
the detection of mRNA expression levels. Usually, RNA strand is first reverse transcribed 
into its DNA complement (complementary DNA, or cDNA) using the enzyme reverse 
transcriptase, and the resulting cDNA is then amplified using primers specific for one or 
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more genes. RT-PCR can also be carried out as one-step RT-PCR in which all reaction 
components are mixed in one tube prior to starting the reactions. 
 
Zeta potential: electric potential in the interfacial double layer at the location of the 
slipping plane versus a point in the bulk fluid away from the interface. In other words, 
zeta potential is the potential difference between the dispersion medium and the 
stationary layer of fluid attached to the dispersed particle. 
